euctr_id,title,member_state,trial_status,sponsor_name,sponsor_status,sponsor_country,funder,reg_date
2007-001548-36,"Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler. - bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -",Germany - BfArM,Completed,University of Jena,Non-Commercial,Germany,NA,2009-07-27
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",UK - MHRA,Completed,IPSEN PHARMA S.A.S.,Commercial,France,Ipsen Pharma S.A.S,2006-02-17
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Netherlands - Competent Authority,Completed,"IPSEN Research and Development, BEAUFOUR IPSEN PHARMA",Commercial,France,NA,2006-04-20
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Belgium - FPS Health-DGM,Completed,Ipsen Pharma S.A.S.,Commercial,France,Ipsen Pharma S.A.S.,2006-05-04
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicenter study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Denmark - DHMA,Completed,"IPSEN Research and Development, BEAUFOUR IPSEN PHARMA",Commercial,France,NA,2006-06-29
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Czech Republic - SUKL,Completed,Ipsen Pharma S.A.S,Commercial,France,Ipsen Pharma S.A.S,2006-09-12
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicenter study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Greece - EOF,Completed,"IPSEN Research and Development, BEAUFOUR IPSEN PHARMA",Commercial,France,NA,2006-10-24
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Sweden - MPA,Completed,Ipsen Pharma S.A.S.,Commercial,France,Ipsen Pharma S.A.S.,2006-12-07
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Germany - BfArM,Completed,IPSEN PHARMA S.A.S.,Commercial,France,Ipsen Pharma S.A.S,2007-02-14
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Austria - BASG,Completed,IPSEN PHARMA S.A.S.,,France,NA,2007-03-12
2005-004904-35,"PHASE III, RANDOMISED, DOUBLE BLIND, STRATIFIED COMPARATIVE, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY TO ASSESS THE EFFECT OF DEEP SUBCUTANEOUS INJECTIONS OF LANREOTIDE AUTOGEL 120 MG ADMINISTERED EVERY 28 DAYS ON TUMOUR PROGRESSION FREE SURVIVAL IN PATIENTS WITH NON FUNCTIONING ENTERO-PANCREATIC ENDOCRINE TUMOUR",Italy - Italian Medicines Agency,Completed,BEAUFOUR IPSEN PHARMA,Commercial,France,NA,2007-05-03
2005-004904-35,"Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour.",Slovakia - SIDC (Slovak),Completed,Ipsen Pharma S.A.S,Commercial,France,NA,2008-04-15
2005-004904-35,"Estudio multicéntrico fase III, aleatorizado, doble ciego, estratificado y comparativo, controlado con placebo y de grupos paralelos, para evaluar el efecto de lanreotida Autogel 120 mg, administrado mediante inyección subcutánea profunda cada 28 días, en la supervivencia libre de progresión en pacientes con tumor endocrino entero-pancreático no funcional",Spain - AEMPS,Completed,Ipsen Pharma S.A.S,Commercial,France,NA,2010-03-15
2011-003115-34,A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles after Pelvic Lymphadenectomy in Women with Gynecologic Malignancies: a Randomized Clinical Trial,Austria - BASG,Completed,Medizinische Universität Wien,Non-Commercial,Austria,Nycomed,2012-05-22
2009-012703-25,"A prospective double-blind, randomised concept study of PXL01 versus placebo in flexor tendon surgery.",Sweden - MPA,Completed,Pergamum AB,Commercial,Sweden,Pergamum,2009-09-17
2009-012703-25,"A prospective double-blind, randomised concept study of PXL01 versus placebo in flexor tendon surgery.",Denmark - DHMA,Completed,Pergamum AB,Commercial,Sweden,Pergamum AB,2010-01-11
2009-012703-25,"A prospective double-blind, randomised concept study of PXL01 versus placebo in flexor tendon surgery.",Germany - BfArM,Completed,Pergamum AB,Commercial,Sweden,Pergamum AB,2010-10-19
2006-004865-32,Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study with Bevacizumab plus Erlotinib Or Gemcitabin/Cisplatin plus Bevacizumab,Germany - PEI,Completed,Aktion Bronchialkarzinom e.V.,Non-Commercial,Germany,NA,2007-02-15
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic Goals with Enzyme Replacement Therapy",Netherlands - Competent Authority,Completed,Genzyme Europe B.V.,Commercial,Netherlands,NA,2009-07-01
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic Goals with Enzyme Replacement Therapy",UK - MHRA,Completed,Genzyme Europe B.V.,Commercial,Netherlands,Genzyme Europe B.V.,2009-07-06
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme",France - ANSM,Completed,Genzyme Europe B.V.,Commercial,Netherlands,NA,2009-08-05
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have reached therapeutic goals with enzyme replacement therapy",Germany - BfArM,Completed,Genzyme Europe B.V.,Commercial,Netherlands,Genzyme Europe B.V.,2009-08-11
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme",Spain - AEMPS,Completed,Genzyme Europe B.V.,Commercial,Netherlands,NA,2009-08-17
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic goals with Enzyme Replacement Therapy",Czech Republic - SUKL,Completed,Genzyme Europe B.V.,Commercial,Netherlands,NA,2009-08-21
2008-005223-28,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme",Italy - Italian Medicines Agency,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2009-12-03
2010-022798-32,"DOUBLE-BLIND, RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE ANALGESIC EFFECT OF A SINGLE ORAL ADMINISTRATION OF FOUR DIFFERENT COMBINATION DOSES OF DKP.TRIS WITH TRAM.HCl IN COMPARISON WITH THE SINGLE AGENTS, ON MODERATE TO SEVERE PAIN FOLLOWING IMPACTED THIRD MANDIBULAR MOLAR TOOTH EXTRACTION",UK - MHRA,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,Menarini Ricerche S.p.A.,2010-10-29
2010-022798-32,"DOUBLE-BLIND, RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE ANALGESIC EFFECT OF A SINGLE ORAL ADMINISTRATION OF FOUR DIFFERENT COMBINATION DOSES OF DKP.TRIS WITH TRAM.HCl IN COMPARISON WITH THE SINGLE AGENTS, ON MODERATE TO SEVERE PAIN FOLLOWING IMPACTED THIRD MANDIBULAR MOLAR TOOTH EXTRACTION",Germany - BfArM,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,Menarini Ricerche S.p.A.,2010-11-23
2010-022798-32,"""Estudio doble ciego, aleatorizado, controlado con placebo y con comparador activo, de grupos paralelos, para evaluar el efecto analgésico de una única administración oral de cuatro diferentes combinaciones de dosis de DKP.TRIS con TRAM.HCl, en comparación con los mismos fármacos en monoterapia, sobre el dolor moderado a intenso tras la extracción del tercer molar inferior impactado""",Spain - AEMPS,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-11-25
2010-022798-32,"DOUBLE-BLIND, RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE ANALGESIC EFFECT OF A SINGLE ORAL ADMINISTRATION OF FOUR DIFFERENT COMBINATION DOSES OF DKP.TRIS WITH TRAM.HCl IN COMPARISON WITH THE SINGLE AGENTS, ON MODERATE TO SEVERE PAIN FOLLOWING IMPACTED THIRD MANDIBULAR MOLAR TOOTH EXTRACTION",Hungary - National Institute of Pharmacy,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-11-29
2010-022798-32,"Double-blind, randomised, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single oral administration of four different combination doses of DKP.TRIS with TRAM.HCl in comparison with the single agents, on moderate to severe pain following impacted third mandibular molar tooth extraction",Italy - Italian Medicines Agency,Completed,MENARINI RICERCHE S.P.A.,Commercial,Italy,NA,2010-12-22
2010-022798-32,"DOUBLE-BLIND, RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE ANALGESIC EFFECT OF A SINGLE ORAL ADMINISTRATION OF FOUR DIFFERENT COMBINATION DOSES OF DKP.TRIS WITH TRAM.HCl IN COMPARISON WITH THE SINGLE AGENTS, ON MODERATE TO SEVERE PAIN FOLLOWING IMPACTED THIRD MANDIBULAR MOLAR TOOTH EXTRACTION",Poland - Office for Medicinal Products,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,Menarini Ricerche S.p.A.,2011-05-10
2011-002901-31,"A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain",UK - MHRA,Completed,Mundipharma Research GmbH & Co. KG,Commercial,Germany,Mundipharma Research GmbH & Co. KG,2011-09-21
2011-002901-31,"A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain",Spain - AEMPS,Completed,Mundipharma Research GmbH & Co. KG,Commercial,Germany,Mundipharma Research GmbH & Co. KG,2011-10-05
2011-002901-31,"A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain",Germany - BfArM,Completed,Mundipharma Research GmbH & Co. KG,Commercial,Germany,Mundipharma Research GmbH & Co. KG,2011-10-06
2011-002901-31,"A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain",Czech Republic - SUKL,Completed,Mundipharma Research GmbH & Co. KG,Commercial,Germany,Mundipharma Research GmbH & Co. KG,2011-10-10
2011-002901-31,"A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain",Hungary - National Institute of Pharmacy,Completed,Mundipharma Research GmbH & Co. KG,Commercial,Germany,Mundipharma Research GmbH & Co. KG,2011-10-13
2008-004968-40,"A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age",Germany - BfArM,Completed,Technische Universität Dresden,Non-Commercial,Germany,Dresden University of Technology,2008-11-13
2005-005362-36,"A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",Finland - Fimea,Completed,Regensburg University Hospital,Non-Commercial,Germany,NA,2006-04-07
2005-005362-36,"A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",UK - MHRA,Completed,Regensburg University Hospital,Non-Commercial,Germany,NA,2006-04-20
2005-005362-36,"A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",Sweden - MPA,Completed,Regensburg University Hospital,Non-Commercial,Germany,NA,2006-04-21
2005-005362-36,"A prospective randomised, open-labelled, trial comparing sirolimus- containing versus mTor-Inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.",Belgium - FPS Health-DGM,Completed,Regensburg University Medical Center,Non-Commercial,Germany,NA,2006-04-24
2005-005362-36,"A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",Norway - NOMA,Completed,Regensburg University Hospital,Non-Commercial,Germany,NA,2006-05-03
2005-005362-36,"A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",Austria - BASG,Completed,Regensburg University Hospital,Non-Commercial,Germany,NA,2006-05-08
2005-005362-36,"ENSAYO PROSPECTIVO, ALEATORIZADO Y ABIERTO QUE COMPARA LA INMUNOSUPRESIÓN CON SIROLIMUS FRENTE A LA INMUNOSUPRESIÓN SIN INHIBIDORES DEL mTOR EN PACIENTES QUE SE SOMEN A TRASPLANTE DE HIGADO DEBIDO A UN CARCINOMA HEPATOCELULAR",Spain - AEMPS,Completed,Regensburg University Medical Center,Non-Commercial,Germany,NA,2006-05-25
2005-005362-36,"A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS MTOR-INHIBITOR-FREE IMMUNOSUPPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",Italy - Italian Medicines Agency,Completed,REGENSBURG UNIVERSITY MEDICAL CENTRE,Non-Commercial,Germany,NA,2007-02-22
2012-004555-36,A prospective randomized controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (CSC).,France - ANSM,Completed,Centre Hospitalier Intercommunal de Créteil,Non-Commercial,France,Centre Hospitalier de CRETEIL,2015-06-18
2010-021414-32,"A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE",Hungary - National Institute of Pharmacy,Prematurely Ended,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,Pfizer Ltd,2010-09-17
2010-021414-32,"A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE",Germany - BfArM,Prematurely Ended,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,Pfizer Ltd,2010-10-12
2010-021414-32,"A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE",Bulgarian Drug Agency,Prematurely Ended,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,Pfizer Ltd,2011-01-04
2010-021414-32,"A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE",Czech Republic - SUKL,Prematurely Ended,Pfizer Limited,Commercial,United Kingdom,Pfizer Ltd,2012-01-30
2012-000108-13,A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,Bayer Vital GmbH,2012-11-09
2012-000108-13,A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,Bayer Vital GmbH,2012-11-09
2006-002061-39,"A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant and Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 and QS-21 Adjuvant in Subjects with Mild to Moderate Alzheimer’s Disease",Germany - PEI,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",2006-08-18
2006-002061-39,"Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 with QS-21 adjuvant in Subjects with Mild to Moderate Alzheimer’s Disease",France - ANSM,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2006-10-30
2006-002061-39,"A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 with QS-21 Adjuvant in Subjects with Mild to Moderate Alzheimer’s Disease",Spain - AEMPS,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2010-03-11
2007-005994-79,"Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes con enfermedad de Alzheimer de grado leve a moderado que no son portadores de la apolipoproteína E (ApoE) e4",Spain - AEMPS,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-02-25
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Ireland - HPRA,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-04
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",UK - MHRA,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-07
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Belgium - FPS Health-DGM,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-14
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Germany - PEI,Prematurely Ended,"Wyeth, a Pfizer company",Commercial,United States,"Wyeth Research Pharmaceuticals Inc., acting throught its division Wyeth Research, a Pfizer company",2008-03-25
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",France - ANSM,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-27
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Finland - Fimea,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-01
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Sweden - MPA,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-03
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E &#949;4 Non-Carriers",Italy - Italian Medicines Agency,Prematurely Ended,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-04-23
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Slovakia - SIDC (Slovak),Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-24
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Portugal - INFARMED,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-24
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Austria - BASG,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-05-08
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Netherlands - Competent Authority,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-06-02
2007-005994-79,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-carriers",Denmark - DHMA,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-07-31
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",UK - MHRA,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-02-22
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Ireland - HPRA,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-05
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Belgium - FPS Health-DGM,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-14
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Germany - PEI,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-25
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",France - ANSM,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-27
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Finland - Fimea,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-31
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Sweden - MPA,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-03
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E &#949;4 Carriers",Italy - Italian Medicines Agency,Prematurely Ended,"Wyeth Research Division, Wyeth Pharmeceuticals Inc.",Commercial,United States,NA,2008-04-22
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Portugal - INFARMED,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-24
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Austria - BASG,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-05-07
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Netherlands - Competent Authority,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-06-02
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Denmark - DHMA,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-07-30
2007-005995-14,"Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes con enfermedad de Alzheimer de grado leve a moderado que son portadores de la apolipoproteína E (ApoE) e4",Spain - AEMPS,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2010-03-08
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Slovakia - SIDC (Slovak),Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2010-04-15
2011-004168-30,A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,GlaxoSmithKline,2012-06-04
2011-004168-30,A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,Belgium - FPS Health-DGM,Completed,Hannover Medical School,Non-Commercial,Germany,GlaxoSmithKline,2014-02-03
2010-019866-96,"A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma",Belgium - FPS Health-DGM,Prematurely Ended,ZIOPHARM Oncology Inc,Commercial,United States,ZIOPHARM Oncology Inc,2010-05-19
2010-019866-96,"A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma",UK - MHRA,Prematurely Ended,ZIOPHARM Oncology Inc,Commercial,United States,NA,2010-06-17
2010-019866-96,"Estudio de fase III, internacional, multicéntrico, aleatorizado, doble ciego, controlado con placebo de doxorrubicina más palifosfamida-tris comparado con doxorrubicina más placebo en pacientes con sarcoma de tejido blando metastásico en primera línea.",Spain - AEMPS,Ongoing,ZIOPHARM Oncology Inc,Commercial,United States,NA,2010-10-26
2010-019866-96,"A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma",Italy - Italian Medicines Agency,Prematurely Ended,ZIOPHARM Oncology Inc,Commercial,United States,NA,2010-11-30
2009-010738-23,Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage,Germany - BfArM,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,Celgene GmbH,2009-09-09
2012-002716-10,"An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgaris are treated with s.c. methotrexate using an optimized treatment schedule",Germany - BfArM,Completed,Prof. Dr. Kristian Reich,Non-Commercial,Germany,medac GmbH,2012-11-02
2012-002716-10,"An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgaris are treated with s.c. methotrexate using an optimized treatment schedule",UK - MHRA,Completed,Prof. Dr. Kristian Reich,Non-Commercial,Germany,medac GmbH,2012-11-08
2012-002716-10,"An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgaris are treated with s.c. methotrexate using an optimized treatment schedule",Netherlands - Competent Authority,Completed,Prof. Dr. Kristian Reich,Non-Commercial,Germany,medac GmbH,2012-11-19
2011-005615-87,"A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",Germany - PEI,Completed,"Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin",Non-Commercial,Germany,Novartis Pharma,2012-07-24
2011-003746-41,"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",Germany - PEI,Prematurely Ended,"Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin",Non-Commercial,Germany,Novartis Pharma,2011-11-28
2008-001405-41,A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX),Germany - BfArM,Completed,GMIHO mbH,Non-Commercial,Germany,NA,2008-08-28
2009-009998-10,"Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial",Germany - BfArM,Completed,"Centre for Ophthalmology, University of Tuebingen",Non-Commercial,Germany,NA,2009-12-02
2011-005471-17,Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors,Germany - BfArM,Completed,Klinikum der Universität München-Großhadern,Non-Commercial,Germany,LMU München,2012-01-03
2012-003362-41,"Randomized, double-blind, multicentre study to compare the efficacy and safety of two different dosages of a novel budesonide suppository versus a mesalazine suppository versus a combination therapy of budesonide/mesalazine suppositories in patients with acute ulcerative proctitis",Germany - BfArM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2013-04-16
2006-001641-33,Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas),Germany - BfArM,Completed,Universitätsklinikum Essen,Non-Commercial,Germany,Deutsche Krebshilfe,2007-04-25
2010-021790-37,"Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",Germany - BfArM,Completed,"Universitätsklinikum Schleswig-Holstein, Campus Lübeck",Non-Commercial,Germany,German Federal Ministry of Education and Resarch,2011-08-10
2012-004383-22,"Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain. Prospective, open, monocentric study to investigate perioperative tissue concentrations of antibiotics and regional analgesics using microdialysis in obese and non-obese patients.",Germany - BfArM,Completed,University of Leipzig,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2013-01-15
2015-002726-39,"A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults",Germany - BfArM,Completed,Pfizer Inc.,Commercial,United States,Pfizer Inc.,2015-12-09
2015-002726-39,"A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults",Spain - AEMPS,Completed,AstraZeneca AB,Commercial,Sweden,AstraZeneca AB,2016-02-03
2010-020606-15,"An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer",Germany - PEI,Prematurely Ended,AIO-Studien-gGmbH,Non-Commercial,Germany,Amgen GmbH,2011-12-02
2010-020606-15,"An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer",Belgium - FPS Health-DGM,Completed,AIO-Studien-gGmbH,Non-Commercial,Germany,Amgen GmbH,2012-10-29
2010-020606-15,"An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer",Austria - BASG,Prematurely Ended,AIO-Studien-gGmbH,Non-Commercial,Germany,Amgen GmbH,2012-11-28
2010-020606-15,"An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer",Spain - AEMPS,Prematurely Ended,AIO-Studien-gGmbH,Non-Commercial,Germany,Amgen GmbH,2013-02-04
2009-013099-38,"Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab - Capecitabine/FUFA plus Bevacizumab versus Capecitabine/FUFA plus Irinotecan plus Bevacizumab as first-line therapy in metastatic colorectal cancer -",Germany - PEI,Completed,"Klinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand",Non-Commercial,Germany,NA,2010-06-04
2004-002501-72,Studie zur neoadjuvanten Therapie bei Hochrisikopatienten mit Weichteilsarkom (STS) im Erwachsenenalter,Germany - BfArM,Ongoing,NA,NA,NA,NA,2004-10-20
2004-002501-72,Studie zur neoadjuvanten Therapie bei Hochrisikopatienten mit Weichteilsarkom (STS) im Erwachsenenalter,Germany - BfArM,Ongoing,NA,NA,NA,NA,2004-10-20
2008-008527-14,"A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control After Total Hip Replacement and the Untoward Effects of Combined Morphine and Oxycodone vs. Morphine Alone",Germany - BfArM,Ongoing,University of Witten/Herdecke,Non-Commercial,Germany,NA,2009-02-17
2007-002808-18,A double-blind placebo controlled dose-response study for evaluation of safety and efficacy of immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense) adsorbed onto aluminium hydroxide in patients with IgE-mediated allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma,Germany - PEI,Completed,ALLERGOPHARMA JOACHIM GANZER KG,Commercial,Germany,NA,2007-07-10
2007-007146-34,The Anti-Interleukin-1 in Diabetes Action trial,Denmark - DHMA,Completed,Steno Diabetes Center,Non-Commercial,Denmark,NA,2008-07-21
2007-007146-34,The Anti-Interleukin-1 in Diabetes Action trial,Germany - BfArM,Completed,Steno Diabetes Center,Non-Commercial,Denmark,NA,2008-08-25
2007-007146-34,"Estudio aleatorizado del efecto del antagonista del receptor de interleucina 1 (anakinra, Kineret®) sobre la producción de insulina en pacientes con diabetes tipo 1 - The Anti-Interleukin-1 in Diabetes Action trial",Spain - AEMPS,Prematurely Ended,Steno Diabetes Center,Non-Commercial,Denmark,NA,2009-03-11
2007-007146-34,The Anti-Interleukin-1 in Diabetes Action trial,Denmark - DHMA,Completed,Steno Diabetes Center,Non-Commercial,Denmark,NA,2008-07-21
2007-007146-34,The Anti-Interleukin-1 in Diabetes Action trial,Germany - BfArM,Completed,Steno Diabetes Center,Non-Commercial,Denmark,NA,2008-08-25
2007-007146-34,"Estudio aleatorizado del efecto del antagonista del receptor de interleucina 1 (anakinra, Kineret®) sobre la producción de insulina en pacientes con diabetes tipo 1 - The Anti-Interleukin-1 in Diabetes Action trial",Spain - AEMPS,Prematurely Ended,Steno Diabetes Center,Non-Commercial,Denmark,NA,2009-03-11
2010-023942-63,The safety and feasibility of delivering xenon to patients before and after coronary artery bypass graft implantation: a pilot study,Germany - BfArM,Completed,"Clinical Trials Center Aachen, University of Aachen",Non-Commercial,Germany,NA,2010-12-06
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Germany - PEI,Prematurely Ended,Merck KGaA,Commercial,Germany,Merck KGaA,2008-01-14
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Czech Republic - SUKL,Completed,Merck KGaA,Commercial,Germany,NA,2008-02-01
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Belgium - FPS Health-DGM,Prematurely Ended,Merck KGaA,Commercial,Germany,Merck KGaA,2008-03-05
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Hungary - National Institute of Pharmacy,Completed,Merck KGaA,Commercial,Germany,Merck KGaA,2008-03-18
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",France - ANSM,Completed,Merck KGaA,Commercial,Germany,NA,2008-03-18
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Austria - BASG,Completed,Merck KGaA,Commercial,Germany,NA,2008-04-22
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Spain - AEMPS,Prematurely Ended,Merck KGaA,Commercial,Germany,NA,2008-05-13
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Netherlands - Competent Authority,Completed,Merck KGaA,Commercial,Germany,NA,2008-06-02
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Portugal - INFARMED,Prematurely Ended,Merck KGaA,Commercial,Germany,NA,2008-06-24
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction",Italy - Italian Medicines Agency,Prematurely Ended,Merck KGaA,Commercial,Germany,NA,2008-07-10
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",UK - MHRA,Prematurely Ended,Merck KGaA,Commercial,Germany,Merck KGaA,2008-10-17
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Bulgarian Drug Agency,Prematurely Ended,Merck KGaA,Commercial,Germany,NA,2008-11-20
2007-004219-75,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.",Greece - EOF,Prematurely Ended,Merck KGaA,Commercial,Germany,NA,2009-02-20
2005-003870-88,"Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients",Germany - BfArM,Completed,Mukoviszidose Institut gGmbH i. G.,Non-Commercial,Germany,NA,2006-08-28
2009-012748-17,"A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disease who are apolipoprotein Eε4 non-carriers.",Germany - PEI,Completed,Janssen Alzheimer Immunotherapy,Commercial,Ireland,Janssen Alzheimer Immunotherapy,2009-06-19
2009-012748-17,"A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disease who are apolipoprotein Eε4 non-carriers.",Austria - BASG,Completed,Janssen Alzheimer Immunotherapy,Commercial,Ireland,Janssen Alzheimer Immunotherapy,2009-07-24
2006-005328-18,"Etude prospective, randomisée, en double aveugle versus placebo, internationale, groupe parallèle, évaluant l'efficacité et la sécurité d'un bolus I.V de tenecteplase en comparaison avec un traitement standard chez des patients normotensifs ayant une embolie pulmonaire aigue.",France - ANSM,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,NA,2007-03-27
2006-005328-18,"A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction. Thrombolysis in Acute Pulmonary Embolism",Germany - BfArM,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,Assistance Publique - Hopitaux de Paris (AP-HP),2007-06-18
2006-005328-18,"PEITHO Pulmonary Embolism Thrombolysis Study A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction.",Italy - Italian Medicines Agency,Completed,ASSISTANCE PUBLIQUE HÃ”PITAUX DE PARIS/ DE`LE`GATION A` LA RECHERCHE CLINIQUE ET AU DE`VELOPPEMENT,Non-Commercial,France,Assistance Publique des Hopitaux de Paris,2007-08-29
2006-005328-18,"PEITHO Pulmonary Embolism THrOmbolysis Study A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction. Thrombolysis in Acute Pulmonary Embolism",Portugal - INFARMED,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),2007-09-10
2006-005328-18,"A prospective, randomized, double-blind, placebo-controlled, international, multicenter, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase as compared with standard treatment in normotensive patients with acute pulmonary embolism and with echographic and laboratory evidence of right ventricular dysfunction.",Austria - BASG,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,NA,2008-01-14
2006-005328-18,"A prospective, randomized, double-blind, placebo-controlled, international, multicenter, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic and laboratory evidence of right ventricular dysfunction.",Greece - EOF,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,NA,2009-03-19
2006-005328-18,"Ensayo clínico prospectivo, aleatorizado, doble ciego, controlado con placebo, internacional, multicéntrico, de grupos paralelos, que evaluará la eficacia y seguridad de la administración de un bolo intravenoso de tecneplasa más tratamiento anticoagulante convencional comparado con el tratamiento anticoagulante convencional en pacientes normotensos con tromboembolia de pulmón aguda y evidencia ecocardiográfica (o TAC en espiral) y bioquímica de disfunción del ventrículo derecho.",Spain - AEMPS,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,NA,2009-04-29
2006-005328-18,"PEITHO Pulmonary EmbolIsm THrOmbolysis Study. A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction.",Belgium - FPS Health-DGM,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,NA,2009-08-20
2006-005328-18,"A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction.",Hungary - National Institute of Pharmacy,Completed,Assistance Publique - Hôpitaux de Paris (AP-HP),Non-Commercial,France,NA,2010-05-18
2011-005305-73,"Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomised, prospective study.",Germany - BfArM,Prematurely Ended,University Medical Center of the Johannes Gutenberg-University Mainz,Non-Commercial,Germany,nap,2012-04-03
2008-002985-70,"Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.",Germany - BfArM,Completed,University of Magdeburg,,Germany,NA,2008-12-17
2009-012815-16,Dosis-Wirkungsstudie von Rocuronium unter Propofol-Anästhesie (Rocuronium Dose Finding Study after single shot or steady state propofol anesthesia),Germany - BfArM,Completed,Technische Universität München,Non-Commercial,Germany,NA,2009-09-24
2008-003967-37,Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease,Germany - PEI,Completed,CureVac GmbH,Commercial,Germany,NA,2008-07-21
2007-007637-39,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,Germany - BfArM,Completed,Charité - Campus Mitte,Non-Commercial,Germany,NA,2008-04-15
2009-012088-32,Prospektive und randomisierte Multicenter-Studie (Phase III-Studie) zur Verbesserung der Funktion des Nervus facialis und des Nervus vestibulocochlearis nach der Resektion von Akustikusneurinomen durch die prophylaktische Gabe von vasoaktiven Medikamenten,Germany - BfArM,Completed,Martin-Luther-Universität Halle-Wittenberg,Non-Commercial,Germany,NA,2009-10-21
2009-018161-12,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder",UK - MHRA,Completed,Shire Development Inc,Commercial,United Kingdom,Shire Development Inc,2010-08-26
2009-018161-12,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder",Germany - BfArM,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2010-10-13
2009-018161-12,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder",Netherlands - Competent Authority,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2010-11-10
2009-018161-12,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder Estudio de Fase 3, doble ciego, controlado con placebo, multicéntrico, de mantenimiento a largo plazo y retirada aleatorizada, de la eficacia y seguridad de Clorhidrato de Guanfacina de liberación prolongada en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con Hiperactividad",Spain - AEMPS,Completed,Shire Development Inc,Commercial,United Kingdom,NA,2010-11-24
2009-018161-12,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder",Sweden - MPA,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2010-12-28
2009-018161-12,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder",Belgium - FPS Health-DGM,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2011-04-22
2009-018161-12,"A phase 3, double-blind, placebo-controlled, multicentre, randomised-withdrawal, long-term maintenance of efficacy and safety study of extended-release Guanfacine Hydrochloride in children and adolescents aged 6-17 with Attention-deficit/Hyperactivity Disorder",Italy - Italian Medicines Agency,Completed,Shire Development Inc.,Commercial,United States,NA,2011-12-28
2014-000973-38,Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers,Germany - BfArM,Prematurely Ended,RWTH Aachen vertreten durch das CTC-A,Non-Commercial,Germany,University Hospital Aachen,2014-03-31
2008-004132-20,This protocol describes a total of three studies that are intrinsically linked. It does therefore have three titels. 1. The effect of xenon and sevoflurane on depth of hypnosis monitors when titrated to standard anaesthesia parameter. 2. The efficacy of dexamethasone for prevention of PONV after xenon or sevoflurane. 3. Ondansetron as rescue for the treatment of established PONV after xenon or sevoflurane.,Germany - BfArM,Ongoing,Air Liquide Santé International,Non-Commercial,France,NA,2008-09-10
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Germany - PEI,Completed,ALK-Abelló A/S,Commercial,Denmark,ALK-Abelló A/S,2010-05-04
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Denmark - DHMA,Completed,ALK-Abelló A/S,Commercial,Denmark,ALK-abello,2010-05-20
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Slovakia - SIDC (Slovak),Completed,ALK-Abelló A/S,Commercial,Denmark,NA,2010-05-26
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Lithuania - SMCA,Completed,ALK-Abelló A/S,Commercial,Denmark,ALK-abello,2010-06-02
2010-018621-19,Eficacia del liofilizado oral ALK de ácaros en sujetos con asma inducido por ácaros del polvo doméstico. Ensayo MITRA.,Spain - AEMPS,Completed,ALK-Abelló A/S,Commercial,Denmark,NA,2010-06-15
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma.,UK - MHRA,Completed,ALK-Abello A/S,Commercial,Denmark,NA,2010-06-18
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Austria - BASG,Completed,ALK-Abelló A/S,Commercial,Denmark,ALK-Abelló A/S,2010-06-23
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Netherlands - Competent Authority,Completed,ALK-Abelló A/S,Commercial,Denmark,ALK-abello,2011-06-22
2010-018621-19,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.,Latvia - SAM,Completed,ALK-Abelló A/S,Commercial,Denmark,ALK-Abello A/S,2011-11-22
2009-010966-47,"Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia",Germany - BfArM,Completed,Universität Bremen,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung (BMBF),2009-10-14
2009-010966-47,"Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia",Germany - BfArM,Completed,Universität Bremen,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung (BMBF),2009-10-14
2008-005653-37,"Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",Germany - PEI,Suspended by CA,Universityhospital of Heidelberg,Non-Commercial,Germany,NA,2009-01-14
2008-005653-37,"Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",Denmark - DHMA,Prematurely Ended,Universityhospital of Heidelberg,Non-Commercial,Germany,Octapharma AG,2013-03-21
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Germany - PEI,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2011-08-09
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",UK - MHRA,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2011-09-06
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Finland - Fimea,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2011-09-23
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Italy - Italian Medicines Agency,Completed,CSL BEHRING GMBH,Commercial,Germany,CSL Behring GmbH,2011-12-28
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Austria - BASG,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2012-03-14
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Czech Republic - SUKL,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2013-04-25
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Poland - Office for Medicinal Products,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2013-05-17
2011-002685-20,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in complex cardiovascular surgery",Denmark - DHMA,Completed,CSL Behring GmbH,Commercial,Germany,CSL Behring GmbH,2013-09-02
2008-008513-19,"Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen. English title: A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering from Advanced, Metastatic Soft Tisssue Sarcoma.",Germany - BfArM,Completed,University Hospital Heidelberg,Non-Commercial,Germany,NA,2009-06-23
2011-003201-14,"Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/neu Expressing (1+/SISH positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy",Germany - PEI,Prematurely Ended,Krankenhaus Nordwest GmbH,Non-Commercial,Germany,TRION Pharma,2011-10-26
2012-000055-13,"A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis",Germany - BfArM,Completed,Almirall S.A.,Commercial,Spain,Almirall S.A.,2012-08-24
2012-000055-13,"A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis",Austria - BASG,Completed,Almirall S.A.,Commercial,Spain,Almirall S.A.,2012-09-11
2012-000055-13,"A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis",Netherlands - Competent Authority,Completed,Almirall S.A.,Commercial,Spain,Almirall S.A.,2012-10-03
2012-000055-13,"A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis",Poland - Office for Medicinal Products,Completed,Almirall S.A.,Commercial,Spain,Almirall S.A.,2012-12-05
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Austria - BASG,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-05-02
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Germany - BfArM,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-05-06
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,UK - MHRA,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-05-27
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Italy - Italian Medicines Agency,Completed,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Non-Commercial,Belgium,NA,2005-06-07
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Denmark - DHMA,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-06-30
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Belgium - FPS Health-DGM,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-07-04
2004-002714-11,"Estudio de fase III para evaluar la quimioterapia primaria con temozolomida frente a la radioterapia en pacientes con gliomas de bajo grado, con estratificación por pérdida del 1p",Spain - AEMPS,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-10-10
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Portugal - INFARMED,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-11-09
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Hungary - National Institute of Pharmacy,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-12-30
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Sweden - MPA,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2006-01-12
2004-002714-11,Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study,Greece - EOF,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2006-07-27
2009-017324-11,"Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlung bei Bedarf",Germany - PEI,Completed,Universitätsmedizin Göttingen,Non-Commercial,Germany,Novartis Pharma GmbH,2010-01-18
2012-003390-26,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Latvia - SAM,Completed,Birken AG,Commercial,Germany,Birken AG,2012-10-31
2012-003390-26,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Greece - EOF,Completed,Birken AG,Commercial,Germany,Birken AG,2012-11-28
2012-003390-26,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Spain - AEMPS,Completed,Birken AG,Commercial,Germany,Birken AG,2012-11-29
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Germany - BfArM,Completed,Birken AG,Commercial,Germany,Birken AG,2012-04-11
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Czech Republic - SUKL,Completed,Birken AG,Commercial,Germany,Birken AG,2012-06-06
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Finland - Fimea,Completed,Birken AG,Commercial,Germany,Birken AG,2012-06-26
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Austria - BASG,Completed,Birken AG,Commercial,Germany,Birken AG,2013-03-26
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Bulgarian Drug Agency,Completed,Birken AG,Commercial,Germany,Birken AG,2013-04-16
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Poland - Office for Medicinal Products,Completed,Birken AG,Commercial,Germany,Birken AG,2013-04-30
2010-019945-24,"Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epithelialization of Skin lesions of Patients with Epidermolysis bullosa hereditaria",Germany - BfArM,Completed,Birken GmbH,Commercial,Germany,NA,2010-07-13
2013-001636-22,"A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",Germany - BfArM,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Roche Diagnostics International AG,2013-06-25
2013-001636-22,"A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",Hungary - National Institute of Pharmacy,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Roche Diagnostics International AG,2013-11-07
2013-001636-22,"A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",Austria - BASG,Completed,Klinikum der Universität München,Non-Commercial,Germany,Roche Diagnostics International AG,2014-01-15
2013-001636-22,"A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",Poland - Office for Medicinal Products,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Roche Diagnostics International AG,2015-03-11
2009-017010-68,A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure,Germany - BfArM,Completed,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,Non-Commercial,Germany,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,2010-04-01
2007-000338-38,"A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREAMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER",Germany - PEI,Completed,Oncoscience AG,Commercial,Germany,NA,2007-04-23
2013-002539-13,Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) in infants with retinopathy of prematurity (ROP),Germany - PEI,Restarted,University Medical Center Freiburg,Non-Commercial,Germany,University Medical Center Freiburg,2013-12-30
2009-017153-35,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery.",France - ANSM,Completed,AIR LIQUIDE SANTE INTERNATIONAL,Commercial,France,NA,2010-02-18
2009-017153-35,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery.",Germany - BfArM,Completed,AIR LIQUIDE SANTE INTERNATIONAL,Commercial,France,AIR LIQUIDE SANTE INTERNATIONAL,2010-03-08
2009-017153-35,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery.",UK - MHRA,Completed,AIR LIQUIDE SANTE INTERNATIONAL,Commercial,France,AIR LIQUIDE MEDICAL SYSTEM,2010-03-17
2009-017153-35,"Ensayo internacional, multicéntrico, aleatorizado, controlado, para evaluar el efecto del xenón en el delirio postoperatorio en pacientes ancianos que se someten a cirugía de fractura de cadera.",Spain - AEMPS,Completed,AIR LIQUIDE SANTE INTERNATIONAL,Commercial,France,NA,2010-04-06
2009-017153-35,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on postoperative delirium in elderly patients undergoing hip fracture surgery.",Italy - Italian Medicines Agency,Completed,AIR LIQUIDE SANTE` INTERNATIONAL,Commercial,France,NA,2010-08-23
2009-017153-35,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery.",Belgium - FPS Health-DGM,Completed,AIR LIQUIDE SANTE INTERNATIONAL,Commercial,France,AIR LIQUIDE MEDICAL SYSTEM,2012-12-13
2008-008280-96,Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.,Germany - BfArM,Completed,"Department of Psychiatry and Psychotherapy, University of Mainz",Non-Commercial,Germany,Ministry of Education and Research,2009-07-14
2014-003810-96,Emergence times and airway reactions in general laryngeal mask airway anesthesia: a randomized multicenter controlled trial,Germany - BfArM,Completed,"RWTH Aachen University for the Medical Falculty, represented by Clinical Trial Center Aachen (CTC-A)",Non-Commercial,Germany,"University Hospital Aachen, Department of Anesthesia",2014-11-24
2014-002186-30,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus a Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using a Day Before-Only Dosing Regimen in Adults",UK - MHRA,Completed,Norgine Ltd,Commercial,United Kingdom,Norgine Ltd,2014-08-12
2014-002186-30,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus a Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using a Day Before-Only Dosing Regimen in Adults",Germany - BfArM,Completed,Norgine Ltd,Commercial,United Kingdom,Norgine Ltd,2014-08-15
2014-002186-30,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus a Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using a Day Before-Only Dosing Regimen in Adults",Netherlands - Competent Authority,Completed,Norgine Ltd,Commercial,United Kingdom,Norgine Ltd,2014-10-07
2014-002186-30,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus a Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using a Day Before-Only Dosing Regimen in Adults",Spain - AEMPS,Completed,Norgine Ltd,Commercial,United Kingdom,Norgine Ltd,2014-10-16
2014-002186-30,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus a Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using a Day Before-Only Dosing Regimen in Adults",Poland - Office for Medicinal Products,Completed,Norgine Ltd,Commercial,United Kingdom,Norgine Ltd,2014-10-17
2013-004529-99,"A double-blind, controlled, parallel-group, randomized, multicenter clinical trial to assess the efficacy and safety of a herbal drug containing centaury, lovage root, and rosemary leaf (CLR) in comparison to fosfomycin trometamol for the treatment of acute lower uncomplicated urinary tract infections (uUTIs) in women",Germany - BfArM,Completed,Bionorica SE,Commercial,Germany,Bionorica SE,2015-08-17
2009-016966-97,"Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Using Eculizumab",Germany - PEI,Completed,Universitätsklinikum Essen,Non-Commercial,Germany,NA,2010-02-08
2012-001650-26,"A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock",Germany - BfArM,Completed,"Ruprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D",Non-Commercial,Germany,Dr. Franz Köhler Chemie GmbH,2012-08-14
2011-005603-32,Use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms,Germany - BfArM,Completed,German Cancer Research Center (DKFZ),Non-Commercial,Germany,DKTK,2012-05-30
2011-001024-38,,Germany - BfArM,Completed,AIO-Studien-gGmbH,Non-Commercial,Germany,AIO-Studien-gGmbH,2011-06-09
2012-000845-11,"A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)",Germany - BfArM,Completed,ApoPharma Inc.,Commercial,Canada,European Commission (Main monetary support),2012-03-30
2012-000845-11,"A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)",Italy - Italian Medicines Agency,Completed,ApoPharma Inc.,Commercial,Canada,European Commission (Main monetary support),2013-07-31
2012-000845-11,"A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)",UK - MHRA,Completed,ApoPharma Inc,Commercial,Canada,European Commission (main monetary support),2013-09-19
2012-000928-18,"Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)",Germany - BfArM,Completed,Hospital of the Ludwig-Maximilians-University of Munich,Non-Commercial,Germany,Deutsche Parkinson Vereinigung (DZNE),2013-06-28
2008-002356-18,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.,Germany - BfArM,Completed,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,medac Gesellschaft für klinische Spezialpräparate mbH,2008-06-27
2008-002356-18,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens,Italy - Italian Medicines Agency,Completed,MEDAC RESEARCH,Commercial,Germany,NA,2008-11-19
2008-002356-18,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.,Poland - Office for Medicinal Products,Completed,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,medac Gesellschaft für klinische Spezialpräparate mbH,2009-05-08
2008-002356-18,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.,Finland - Fimea,Prematurely Ended,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,medac Gesellschaft für klinische Spezialpräparate mbH,2009-08-20
2008-002356-18,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.,France - ANSM,Completed,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,NA,2009-09-07
2008-002356-18,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.,Hungary - National Institute of Pharmacy,Completed,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,medac Gesellschaft für klinische Spezialpräparate mbH,2009-09-17
2011-004463-69,Investigation of Radiation Retinopathy (RadiRet Study),Germany - PEI,Prematurely Ended,Charité – University Medicine Berlin,Non-Commercial,Germany,Novartis Pharma,2012-08-03
2011-004787-30,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,Germany - BfArM,Prematurely Ended,Charite Universitaetsmedizin Berlin,Non-Commercial,Germany,Charite Universitaetsmedizin Berlin,2012-07-13
2014-000599-24,"Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative inoperable (locally advanced or metastatic) breast cancer with prior exposure to antihormonal therapy",Germany - BfArM,Completed,"Universitätsklinikum Essen, Westdeutsches Tumorzentrum",Non-Commercial,Germany,Novartis Pharma GmbH,2014-09-02
2005-005592-14,"Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT)",Germany - BfArM,Completed,"IFSgGmbH, Institute for clinical research",Non-Commercial,Germany,NA,2006-05-12
2011-002544-27,"Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment An open-label, non-randomized, multicenter phase IIIb clinical trial",Germany - BfArM,Completed,Technische Universitaet Muenchen Fakultaet fuer Medizin,Non-Commercial,Germany,Novartis Pharma GmbH,2011-09-06
2005-003854-80,Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central,Germany - BfArM,Prematurely Ended,"Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University",Non-Commercial,Germany,NA,2006-01-04
2011-003934-16,"A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature after Total Hip Arthroplasty",Germany - PEI,Ongoing,Pluristem Ltd.,Commercial,Israel,Pluristem Ltd.,2012-02-14
2008-005828-84,Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.,Germany - BfArM,Completed,"ENT Hospital, Johannes-Gutenberg University, Mainz",Non-Commercial,Germany,NA,2009-01-28
2005-002716-16,A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS,Italy - Italian Medicines Agency,Completed,PHILOGEN S.P.A.,Non-Commercial,Italy,NA,2006-02-07
2005-002716-16,A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS,Italy - Italian Medicines Agency,Completed,PHILOGEN S.P.A.,Non-Commercial,Italy,NA,2006-02-07
2007-001609-81,Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer,Germany - PEI,Prematurely Ended,Philogen S.pA.,Commercial,Italy,NA,2007-06-18
2007-001609-81,Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer,Germany - PEI,Prematurely Ended,Philogen S.pA.,Commercial,Italy,NA,2007-06-18
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Italy - Italian Medicines Agency,Prematurely Ended,PHILOGEN S.P.A.,Commercial,Italy,NA,2007-12-17
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Germany - PEI,Prematurely Ended,Philogen S.p.A.,Commercial,Italy,NA,2008-02-04
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Austria - BASG,Prematurely Ended,Philogen S.p.A.,Commercial,Italy,NA,2011-03-03
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Italy - Italian Medicines Agency,Prematurely Ended,PHILOGEN S.P.A.,Commercial,Italy,NA,2007-12-17
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Germany - PEI,Prematurely Ended,Philogen S.p.A.,Commercial,Italy,NA,2008-02-04
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Austria - BASG,Prematurely Ended,Philogen S.p.A.,Commercial,Italy,NA,2011-03-03
2009-015383-33,"Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie",Germany - BfArM,Completed,"Freistaat Bayern, vertreten durch die Universität Regensburg",Non-Commercial,Germany,NA,2010-06-14
2011-001779-38,"Prospective, randomized, double-blind, placebo-controlled, parallel-group, 3-stage dose-finding study to identify a safe and effective dose of NT 201 for unilateral injection into the soft palate for treatment of habitual snoring",Germany - BfArM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,Merz Pharmaceuticals GmbH,2011-08-31
2010-020441-27,"Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of of the efficacy, safety, and tolerability of repeated intravitreal administration of ranibizumab combined with selective laser photocoagulation of non-perfused retinal areas in subjects with macular edema secondary to central retinal vein occlusion (CRVO)",Germany - PEI,Completed,"University of Leipzig Ritterstr. 26, 04109 Leipzig",Non-Commercial,Germany,Novartis Pharma,2011-02-23
2007-002824-13,"Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20% for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CPAP-Therapy.",Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,NA,2008-09-11
2010-022223-29,"Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy",Hungary - National Institute of Pharmacy,Completed,Helsinn Healthcare SA,Commercial,Switzerland,NA,2011-02-21
2010-022223-29,"Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy",Germany - BfArM,Completed,Helsinn Healthcare SA,Commercial,Switzerland,HELSINN HEALTHCARE SA,2011-03-02
2010-022223-29,"Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy",Poland - Office for Medicinal Products,Completed,Helsinn Healthcare SA,Commercial,Switzerland,HELSINN HEALTHCARE SA,2011-04-06
2010-022223-29,"Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy.",Italy - Italian Medicines Agency,Completed,Helsinn Healthcare SA,Commercial,Switzerland,NA,2011-05-09
2010-022223-29,"Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy",Bulgarian Drug Agency,Completed,Helsinn Healthcare SA,Commercial,Switzerland,HELSINN HEALTHCARE SA,2011-06-14
2007-005063-96,Prospective trial of intravenous levetiracetam in patients with primary brain tumors and at least one symptomatic seizure who undergo biopsy or cytoreductive surgery.,Germany - BfArM,Completed,University Hospital Tübingen,Non-Commercial,Germany,NA,2007-10-01
2013-002708-14,Phase II study to assess bacterial count reduction of three Octenidine mouthwash concentrations in comparison to a placebo in patients with mild gingivitis,Germany - BfArM,Completed,Schülke & Mayr GmbH,Commercial,Germany,Schülke & Mayr GmbH,2013-07-23
2009-011454-17,Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia,Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2009-11-17
2009-011454-17,Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies.,France - ANSM,Completed,Hôpital Universitaire de Münster,Non-Commercial,Germany,NA,2010-03-22
2009-011454-17,Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia - A European paediatric oncology off-patent medicines consortium protocol.,UK - MHRA,Completed,Universitatsklinikum Munster,Non-Commercial,Germany,NA,2010-06-29
2004-004403-37,"Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie",Germany - BfArM,Prematurely Ended,Universitätsklinikum Heidelberg,Non-Commercial,Germany,NA,2005-10-28
2011-002539-24,Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis,Germany - BfArM,Prematurely Ended,Hospital of the University of Munich,Non-Commercial,Germany,Genzyme Corporation,2012-02-13
2016-001921-15,"Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acute ulcerative proctitis",Germany - BfArM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2016-12-09
2016-001921-15,"Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acute ulcerative proctitis",Latvia - SAM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2017-01-03
2016-001921-15,"Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acute ulcerative proctitis",Hungary - National Institute of Pharmacy,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2017-01-06
2016-001921-15,"Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acute ulcerative proctitis",Slovakia - SIDC (Slovak),Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2017-01-12
2016-001921-15,"Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acute ulcerative proctitis",Poland - Office for Medicinal Products,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2017-03-17
2009-014040-11,"Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from wild type K-ras colon cancer: A prospective multicenter phase II study.",Germany - BfArM,Completed,University of Regensburg,Non-Commercial,Germany,Merck Pharma GmbH,2010-07-01
2006-006404-11,"INTRAMYOCARDIAL TRANSPLANTATION OF BONE MARROW STEM CELLS FOR IMPROVEMENT OF POST-INFARCT MYOCARDIAL REGENERATION IN ADDITION TO CABG SURGERY: a controlled prospective, randomized, double blinded multicenter trial",Germany - PEI,Temporarily Halted,Miltenyi Biotec GmbH,Commercial,Germany,German Federal Ministry of Education and Research,2007-08-30
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder",UK - MHRA,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,Shire Pharmaceuticals Development Ltd,2010-10-08
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder",Germany - BfArM,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2010-10-15
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6 17 years with Attention-Deficit/Hyperactivity Disorder",Netherlands - Competent Authority,Prematurely Ended,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2010-11-16
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6 17 years with Attention-Deficit/Hyperactivity Disorder",France - ANSM,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2010-11-16
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6 17 years with Attention-Deficit/Hyperactivity Disorder Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, en grupos paralelos, con referencia activa y placebo, de la eficacia y seguridad de la optimización de dosis de clorhidrato de guanfacina de liberación prolongada en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con Hiperactividad",Spain - AEMPS,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2010-12-03
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6 17 years with Attention-Deficit/Hyperactivity Disorder",Sweden - MPA,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2010-12-28
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder",Ireland - HPRA,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,Shire Pharmaceuticals Development Ltd,2011-05-10
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder",Austria - BASG,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2011-05-16
2010-018579-12,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder",Bulgarian Drug Agency,,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2011-11-04
2010-018579-12,"A phase 3, randomised, double-blind, multicentre, parallel-group, placebo- and active-reference, dose-optimisation efficacy and safety study of extended-release Guanfacine Hydrochloride in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder",Italy - Italian Medicines Agency,Completed,Shire Pharmaceutical Development ltd,Commercial,United Kingdom,NA,2011-12-28
2011-002789-18,"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION",Germany - BfArM,Completed,Menarini Ricerche S.p.A,Commercial,Italy,Menarini Ricerche S.p.A,2011-08-08
2011-002789-18,"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION",Spain - AEMPS,Completed,MENARINI RICERCHE S.P.A,Commercial,Italy,MENARINI RICERCHE S.P.A.,2011-09-19
2011-002789-18,"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION",UK - MHRA,Completed,Menarini Ricerche S.p.A,Commercial,Italy,Menarini Ricerche S.p.A,2012-02-14
2011-002789-18,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Dose-Ranging Phase II Study Assessing Ranolazine in the Maintenance of Sinus Rhythm after Electrical Cardioversion in Patients with Non-Permanent Atrial Fibrillation",Italy - Italian Medicines Agency,Completed,MENARINI RICERCHE S.P.A.,Commercial,Italy,Menarini Ricerche S.p.A.,2012-03-01
2016-002860-15,"A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris",Germany - BfArM,Completed,Galderma R&D SNC,Commercial,France,Galderma R&D SNC,2016-10-20
2016-002860-15,"A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris",Czech Republic - SUKL,Completed,Galderma R&D SNC,Commercial,France,Galderma R&D SNC,2017-05-11
2010-020063-21,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",Germany - PEI,Completed,Charité-Universitätsmedizin,Non-Commercial,Germany,NA,2010-05-21
2009-014580-39,A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch,Germany - PEI,Completed,ALK-Abelló Arzneimittel GmbH,Commercial,Germany,NA,2009-10-12
2012-000442-35,"PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",Germany - PEI,Completed,Biomay AG,Commercial,Austria,Biomay AG,2012-02-21
2012-000442-35,"PHASE IIB STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",Slovenia - JAZMP,Completed,Biomay AG,Commercial,Austria,Biomay AG,2012-02-27
2012-000442-35,"PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",Austria - BASG,Completed,Biomay AG,Commercial,Austria,Biomay AG,2012-02-28
2012-000442-35,"PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",Belgium - FPS Health-DGM,Completed,Biomay AG,Commercial,Austria,Biomay AG,2012-03-07
2012-000442-35,"PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",Denmark - DHMA,Completed,Biomay AG,Commercial,Austria,Biomay AG,2012-04-20
2012-000442-35,"PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",Netherlands - Competent Authority,Completed,Biomay AG,Commercial,Austria,Biomay AG,2016-10-04
2011-001398-19,D-cycloserine augmented exposure therapy in patients with agoraphobia,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2011-05-30
2009-017168-17,"A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction",Germany - BfArM,Completed,"Gilead Sciences, Inc.",Commercial,United States,NA,2010-01-21
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Germany - BfArM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-05-11
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Austria - BASG,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-06-05
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Netherlands - Competent Authority,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-06-13
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Lithuania - SMCA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-06-21
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Norway - NOMA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-06-28
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Sweden - MPA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-07-09
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",UK - MHRA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-07-16
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Spain - AEMPS,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-07-19
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Finland - Fimea,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-08-02
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Hungary - National Institute of Pharmacy,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-08-14
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Denmark - DHMA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2012-08-17
2011-002754-31,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",Belgium - FPS Health-DGM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2014-07-04
2011-003648-31,"Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction with intraoperatively administered Sufentanil for elective cardiac surgery",Germany - BfArM,Completed,Universitätsklinikum Erlangen,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2011-08-18
2007-004612-31,Efficacy and safety of Haemocomplettan® P in patients experiencing acute bleeding while undergoing aortic replacement surgery,Germany - PEI,Completed,CSL Behring GmbH,Commercial,Germany,NA,2008-02-14
2012-002358-22,"NEUPRO DB, efficacy profile of Neurexan in an experimental acute stress setting – an explorative double blind study in healthy probands",Germany - BfArM,Completed,Biologische Heilmittel Heel GmbH,Commercial,Germany,Biologische Heilmittel Heel GmbH,2012-07-30
2012-002358-22,"NEUPRO DB, efficacy profile of Neurexan in an experimental acute stress setting – an explorative double blind study in healthy probands",Germany - BfArM,Completed,Biologische Heilmittel Heel GmbH,Commercial,Germany,Biologische Heilmittel Heel GmbH,2012-07-30
2008-008896-32,"Memory, Ageing, and the Cholinergic System a combined fMRI and PET study",Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,NA,2009-07-21
2011-000572-33,Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of PArvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme,Germany - PEI,Completed,Oryx GmbH und Co. KG,Commercial,Germany,Oryx GmbH und Co. KG,2011-03-16
2009-011252-22,Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG),Germany - BfArM,Completed,"Medical Faculty, University of Bonn",Non-Commercial,Germany,NA,2010-05-03
2008-000952-28,"An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma",Germany - BfArM,Completed,Janssen-Cilag International NV (JCI),Commercial,Belgium,NA,2008-04-16
2008-000952-28,"An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma",Belgium - FPS Health-DGM,Completed,Janssen-Cilag International NV (JCI),Commercial,Belgium,NA,2008-04-25
2008-000952-28,"An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma",France - ANSM,Completed,Janssen-Cilag International NV (JCI),Commercial,Belgium,NA,2008-07-21
2008-000952-28,"An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma",UK - MHRA,Completed,Janssen-Cilag International NV (JCI),Commercial,Belgium,NA,2008-11-27
2007-003986-42,"Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia",Germany - BfArM,Completed,University Hospital of Tübingen,Non-Commercial,Germany,NA,2007-10-19
2008-005560-13,A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II),Germany - BfArM,Completed,Medizinische Hochschule Hannover,Non-Commercial,Germany,Roche Pharma AG,2009-06-05
2008-005560-13,A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II),Greece - EOF,Completed,Medizinische Hochschule Hannover,Non-Commercial,Germany,NA,2009-10-20
2006-002938-38,EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION,Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,NA,2006-09-07
2008-008238-35,"Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML)",Germany - BfArM,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,Universitätsklinikum Ulm,2009-03-23
2008-008238-35,"Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Mye-loid Leukemia (AML) - AMLSG 11-08",Austria - BASG,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,NA,2010-04-07
2009-016142-44,Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,Germany - BfArM,Completed,University Hospital Ulm,Non-Commercial,Germany,University Hospital Ulm,2010-07-06
2009-016142-44,Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,Austria - BASG,Completed,University Hospital Ulm,Non-Commercial,Germany,NA,2010-08-23
2009-011889-28,Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation,Germany - PEI,Completed,University of Ulm,Non-Commercial,Germany,Else-Kröner Frisenius Stiftung (P80/08 // A65/08),2009-05-27
2009-011889-28,Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation,Austria - BASG,Completed,University of Ulm,Non-Commercial,Germany,Else-Kröner Frisenius Stiftung (P80/08 // A65/08),2010-10-06
2012-002154-23,Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML) when no intensive treatment is possible,Germany - BfArM,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,Deutsche Krebshilfe,2014-04-11
2013-003678-29,"Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and dexamethasonE in RelapSed myeloma Plus rEsponse adapted Cyclophosphamide as a Tailored InnoVativE strategy",Germany - BfArM,Completed,Universitätsklinikum Tübingen,Non-Commercial,Germany,Celgene GmbH,2014-01-23
2011-002291-16,Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,Germany - BfArM,Temporarily Halted,"Universitätsklinikum Schleswig-Holstein, Campus Kiel",Non-Commercial,Germany,BmBf,2012-04-23
2012-000447-27,Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,Germany - BfArM,Temporarily Halted,"Universitätsklinikum Schleswig-Holstein, Campus Kiel",Non-Commercial,Germany,BmBf,2012-04-23
2012-003696-18,Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk.,Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,University of Cologne,2013-03-01
2005-004866-17,"An Open-label, single arm Phase II Trial of Photodynamic Therapy using Foscan for non-curatively-resectable bile duct carcinoma",Germany - BfArM,Completed,"Dept Medicine I, Paracelsus Med. Univ. Landeskrankenanstalten Salzburg / SALK",Non-Commercial,Austria,NA,2005-11-22
2005-004866-17,"An Open-label, single arm Phase II Trial of Photodynamic Therapy using Foscan for non-curatively-resectable bile duct carcinoma",Austria - BASG,Completed,Paracelsus Medical University,Non-Commercial,Austria,NA,2005-11-23
2007-001014-17,"A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease",France - ANSM,Completed,Alfa Wassermann S.p.A.,Commercial,Italy,NA,2007-06-01
2007-001014-17,"A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease",Hungary - National Institute of Pharmacy,Completed,Alfa Wassermann S.p.A.,Commercial,Italy,NA,2007-06-19
2007-001014-17,"A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohns disease",Italy - Italian Medicines Agency,Completed,ALFA WASSERMANN,Commercial,Italy,NA,2007-10-24
2007-001014-17,"A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease",Germany - BfArM,Completed,Alfa Wassermann S.p.A.,Commercial,Italy,NA,2008-03-03
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Germany - BfArM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2009-11-04
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Hungary - National Institute of Pharmacy,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,NA,2010-05-19
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Sweden - MPA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-05-26
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Belgium - FPS Health-DGM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-06-01
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Denmark - DHMA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-06-18
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Czech Republic - SUKL,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-06-25
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Lithuania - SMCA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2013-11-25
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Spain - AEMPS,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2013-12-27
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Netherlands - Competent Authority,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2014-03-05
2008-005994-36,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in patients with lymphocytic colitis",Italy - Italian Medicines Agency,Completed,DR. FALK PHARMA GMBH,Commercial,Germany,DR FALK PHARMA GmbH,2018-11-30
2008-001764-36,Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.,Italy - Italian Medicines Agency,Ongoing,Azienda Ospedaliero Universitaria ''San Luigi Gonzaga'',Non-Commercial,Italy,NA,2008-10-01
2008-001764-36,Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.,Germany - BfArM,Ongoing,"University of Turin, Dept of Clinical & Biological Sciences",Non-Commercial,Italy,University of Torino,2008-10-02
2009-012449-48,„Sympathetic neural outflow during Xenon anesthesia in humans“,Germany - BfArM,Completed,Air Liquide Santé International,Commercial,France,NA,2009-09-03
2011-004267-71,"Randomised, double-blind, placebo-controlled, dose-ranging Phase II study of APD421 (amisulpride for IV injection) for the prevention of post-operative nausea and vomiting",Germany - BfArM,Completed,Acacia Pharma Ltd,Commercial,United Kingdom,Acacia Pharma Ltd,2011-10-24
2006-000720-13,"Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease",Germany - BfArM,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-01-29
2006-000720-13,"Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease",Austria - BASG,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-03-03
2006-000720-13,"Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease",Denmark - DHMA,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-03-17
2006-000720-13,"Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease",Czech Republic - SUKL,Completed,Dr. Falk Pharma GmbH,Commercial,Germany,Dr. Falk Pharma GmbH,2010-06-30
2010-020793-42,The effect of vitamin D on all-cause mortality in congestive heart failure patients,Germany - BfArM,Completed,"Clinic for Thoracic and Cardiovascular Surgery, Heart Centre North Rhine-Westfalia",Non-Commercial,Germany,NA,2010-06-07
2008-008239-27,Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade),Germany - BfArM,Completed,Technische Universität München,Non-Commercial,Germany,NA,2008-12-30
2011-003648-31,"Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction with intraoperatively administered Sufentanil for elective cardiac surgery",Germany - BfArM,Completed,Universitätsklinikum Erlangen,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2011-08-18
2012-001989-15,"A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease.",Germany - BfArM,Ongoing,Universität des Saarlandes,Non-Commercial,Germany,Servier Deutschland GmbH,2012-05-18
2011-005807-33,,Germany - PEI,Completed,Medizinische Fakultät der Universität Bonn,Non-Commercial,Germany,Novartis,2012-09-20
2008-000245-55,Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors,Germany - BfArM,Completed,GYN Research GmbH,Non-Commercial,Germany,NA,2008-04-16
2012-004079-38,"Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study",Germany - BfArM,Ongoing,"Central Institute of Mental Health, Department of Psychiatry and Psychotherapy",Non-Commercial,Germany,"Central Institute of Mental Health, Research Group Molecular Schizophrenia Research",2012-12-27
2009-013648-35,"KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18).",Ireland - HPRA,Completed,PENTA Foundation,Non-Commercial,Italy,NA,2010-03-12
2009-013648-35,"KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18).",Netherlands - Competent Authority,,PENTA Foundation,Non-Commercial,Italy,NA,2010-07-29
2009-013648-35,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18)",France - ANSM,Completed,Paediatric European Network for Treatment of AIDS (PENTA) Foundation,Non-Commercial,Italy,NA,2010-07-29
2009-013648-35,"KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18).",UK - MHRA,Completed,PENTA Foundation,Non-Commercial,Italy,NA,2010-08-03
2009-013648-35,"KONCERT. Estudio sobre la farmacocinética, seguridad y eficacia de lopinavir/ritonavir comprimidos dos veces al día o una vez al día con la dosis ajustada en función del peso como parte de un tratamiento antirretroviral combinado en niños infectados por el VIH-1 (PENTA 18).",Spain - AEMPS,Completed,Fundación Penta,Non-Commercial,Spain,NA,2010-08-30
2009-013648-35,"KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twicedaily versus oncedaily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18)",Portugal - INFARMED,Completed,PENTA Foundation,Non-Commercial,Italy,NA,2011-01-17
2009-013648-35,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-dailyversus once-daily Iopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected chiidren (PENTA 18)",Belgium - FPS Health-DGM,Completed,PENTA FOUNDATION,Non-Commercial,Italy,PENTA FOUNDATION,2011-01-24
2009-013648-35,"KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18).",Germany - BfArM,Completed,PENTA Foundation,Non-Commercial,Italy,PENTA Foundation,2011-05-13
2010-022570-13,"Gadovit-Studie Intraindividueller Vergleich der diagnostischen Wertigkeit von delayed-enhancement imaging mit Gadobutrol (Gadovist®) versus Gadobenat Dimeglumin (Multihance®) mittels einer MRT Bildgebung bei einem Myorkardinfarkt. Monozentrische, randomisierte, einfach verblindete, cross-over Studie. EUDRACT-Nr.: 2010-022570-13 Prüfplancode: GAD-1140-WIL-0020-I",Germany - BfArM,Completed,Medizinsiche Fakultät der Technischen Universität München,Non-Commercial,Germany,NA,2010-09-28
2010-021333-31,Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation (Tacrolimus-Organ-Perfusion TOP-Studie),Germany - BfArM,Prematurely Ended,Klinikum der Universität München,Non-Commercial,Germany,Klinikum der Universität München,2011-06-14
2010-021275-92,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",Germany - BfArM,Completed,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-10-01
2008-002632-15,"Randomized, multicenter, double blind study to compare the efficacy and tolerability of Oleogel-S-10 for 3 months versus placebo only in patients with mild to moderate ac-tinic keratoses located at the face and head",Germany - BfArM,Completed,Birken GmbH,Commercial,Germany,NA,2008-07-16
2010-021719-18,Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,Genzyme Europe BV,2011-10-05
2014-002265-30,"A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency.",Germany - BfArM,Completed,Diurnal Limited,Commercial,United Kingdom,European Commission (TAIN-Project No: 281654),2014-12-23
2010-022058-18,A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY),Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,NA,2011-01-03
2008-003392-40,Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN1A,Germany - BfArM,Completed,Universität Marburg,Non-Commercial,Germany,NA,2009-01-20
2005-003324-19,"STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: A multicentre, double-blind, randomized, phase IV clinical trial comparing the safety, tolerability and efficacy of levetiracetam versus lamotrigine and carbamazepine in the oral antiepileptic therapy of newly diagnosed elderly patients with focal epilepsy.",Germany - BfArM,Completed,University of Mainz,Non-Commercial,Germany,NA,2006-09-14
2005-003324-19,"STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: A multicentre, double-blind, randomized, phase IV clinical trial comparing the safety, tolerability and efficacy of levetiracetam versus lamotrigine and carbamazepine in the oral antiepileptic therapy of newly diagnosed elderly patients with focal epilepsy.",Austria - BASG,Completed,University of Mainz,Non-Commercial,Germany,NA,2007-08-10
2004-002761-21,"RANDOMIZED, MULTICENTRE OPEN LABEL STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF SOLARAZE® FOR 3 MONTHS VERSUS 6 MONTHS IN PATIENTS WITH MILD TO MODERATE ACTINIC KERATOSIS LOCATED AT THE FACE AND HEAD",Germany - BfArM,Ongoing,University Medical Center,Non-Commercial,Germany,NA,2005-11-28
2006-001367-36,Benefit of adjunctive systemic postsurgical doxycycline in regenerative periodontal surgery,Germany - BfArM,Completed,Prof. Dr. Peter Eickholz,Non-Commercial,Germany,NA,2006-08-29
2006-006478-79,"Study of Radioembolization (RE) with SIR-Spheres® versus Transarterial Chemoembolisation (TACE) in patients with unresectable primary Hepatocellular Carcinoma. A comparative, prospective, randomised, open, pilot trial to evaluate health-related quality of life, pharmaco-economic parameters, and efficacy.",Germany - BfArM,Completed,SIRTEX Medical Europe,Commercial,Germany,NA,2007-05-16
2006-001936-30,A phase II dose escalation study of caspofungin in patients with invasive aspergillosis,Germany - BfArM,Completed,Universität zu Köln,Non-Commercial,Germany,NA,2006-10-24
2006-005249-13,Influence of the OATP1B1 genotype on the hepatic uptake of Primovist® in healthy volunteers and in patients with liver disease,Germany - BfArM,Completed,"Department of Clinical Pharmacology, University of Greifswald",Non-Commercial,Germany,NA,2007-01-25
2015-002752-27,Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match - N²M² (NOA-20),Germany - PEI,Completed,University Hospital Heidelberg,Non-Commercial,Germany,German Cancer Research Center (DKFZ),2017-04-04
2008-002673-13,Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo,Germany - BfArM,Completed,PSKS,Non-Commercial,Germany,NA,2008-08-27
2005-005638-10,Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease,Germany - BfArM,Completed,University of Münster,Non-Commercial,Germany,NA,2006-09-25
2007-006914-41,Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma,Germany - BfArM,Ongoing,"Dept. of Psychiaty, University of Freiburg",Non-Commercial,Germany,NA,2009-08-03
2009-016043-19,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,Germany - BfArM,Completed,Charité – University Medicine Berlin,Non-Commercial,Germany,NA,2010-02-09
2010-023645-29,"Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study",Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2011-01-11
2011-002785-20,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2011-08-11
2007-000902-55,"Prospective Phase II study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin",UK - MHRA,Completed,EBMT (European group for Blood and Marrow Transplantation),Non-Commercial,Netherlands,NA,2007-06-26
2007-000902-55,"Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin",France - ANSM,Completed,EBMT (European group for Blood and Marrow Transplantation),Non-Commercial,United Kingdom,NA,2007-10-04
2007-000902-55,"Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin: a Study from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party",Germany - PEI,Completed,EBMT (European Group for Blood and Marrow Transplantation),Non-Commercial,Netherlands,NA,2009-09-29
2010-022660-12,"A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation",Germany - BfArM,Prematurely Ended,Friedrich Schiller University,Non-Commercial,Germany,BAYER Vital GmbH,2010-11-22
2012-005698-30,Impact of Xenon-anaesthesia on the renal function after partial nephrectomy - PaNeX: Partial Nephrectomy under Xenon,Germany - BfArM,Prematurely Ended,Clinical Trial Center Aachen,Non-Commercial,Germany,University Hospital Aachen,2013-01-29
2006-006573-24,"Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicenter study",Germany - BfArM,Prematurely Ended,University Hospital of Heidelberg,Non-Commercial,Germany,NA,2007-02-01
2015-001820-51,"BMC2012, Cell based therapy by implanted bone marrow-derived mononuclear cells (BMC) for bone augmentation of plate-stabilized proximal humeral fractures - a randomized, open, multicentric study - phase IIa",Germany - PEI,Completed,"Dekan der medizinischen Fakultät, Universitätsklinikum Frankfurt, Goethe-Universität",Non-Commercial,Germany,Hessisches Ministerium für Wissenschaft und Kunst,2015-10-15
2011-000843-26,,Germany - BfArM,Completed,University Medical Center Goettingen,Non-Commercial,Germany,Pfizer Pharma GmbH,2011-06-28
2006-003122-28,Argatroban versus Lepirudin in Critically Ill Patients,Germany - BfArM,Completed,Heinrich-Heine-Universität Düsseldorf,Non-Commercial,Germany,NA,2008-08-22
2005-000490-21,"Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial",Germany - BfArM,Ongoing,1. Frauenklinik der LMU- Innenstadt,Non-Commercial,Germany,NA,2005-04-07
2014-001882-28,Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SSc-APAH),Germany - BfArM,Completed,Thoraxklinik-Heidelberg gGmbH,Non-Commercial,Germany,GlaxoSmithKline GmbH,2014-08-07
2009-009916-33,Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy,Germany - BfArM,Completed,University Medical Center Freiburg,Non-Commercial,Germany,federal ministry of education and research,2010-10-11
2004-004956-38,"Randomised, placebo controlled, single-center, double-blind clinical trial to investigate efficacy and safety of Aprepitant combined with Kevatril and Dexamethasone versus Placebo combined with Kevatril and Dexamethasone in prevention of acute and delayed high-dose chemotherapy-induced nausea and vomiting in subjects with multiple myeloma receiving an autologous peripheral blood stemcell transplantation.",Germany - BfArM,Completed,"Gerlinde Egerer (MD); Internal Medicine, Department V",Non-Commercial,Germany,NA,2005-09-22
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Netherlands - Competent Authority,Completed,Beaufour Ipsen Pharma,Commercial,France,NA,2008-02-01
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",France - ANSM,Completed,Beaufour Ipsen Pharma,Commercial,France,NA,2008-02-21
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA. Estudio en fase IIIb, multicéntrico, abierto, de un solo brazo, para evaluar la seguridad y eficacia de Lanreotida Autogel 120 mg, administrado cada 28 días, como tratamiento médico principal en pacientes acromegálicos con macroadenoma",Spain - AEMPS,Prematurely Ended,Beaufour Ipsen Pharma,Commercial,France,NA,2008-03-06
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Sweden - MPA,Completed,Ipsen Pharma SAS,Commercial,France,Ipsen Pharma SAS,2008-03-07
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",UK - MHRA,Completed,Ipsen Pharma SAS,Commercial,France,NA,2008-03-07
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Belgium - FPS Health-DGM,Completed,Ipsen Pharma SAS,Commercial,France,NA,2008-03-11
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Czech Republic - SUKL,Completed,Ipsen Pharma SAS,Commercial,France,NA,2008-03-11
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Finland - Fimea,Completed,Ipsen Pharma SAS,Commercial,France,NA,2008-03-11
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Germany - BfArM,Completed,Ipsen Pharma SAS,Commercial,France,NA,2008-04-15
2007-000155-34,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA.",Italy - Italian Medicines Agency,Completed,BEAUFOUR IPSEN PHARMA,Commercial,France,NA,2009-03-20
2009-011881-27,Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study.,Germany - BfArM,Completed,University Medical Center of the Johannes Gutenberg-University Mainz,Non-Commercial,Germany,University Medical Center of the Johannes Gutenberg-University Mainz,2010-01-20
2010-024613-31,"A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Formulation 2011/2012, when Administered to adult and elderly subjects.",Germany - PEI,Completed,Novartis Vaccines and Diagnostics GmbH,Commercial,Germany,Novartis Vaccines and Diagnostics Srl,2011-05-03
2009-017458-11,"Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",Germany - BfArM,Prematurely Ended,"Institute for Social Medicine, Epidemiology, and Health Economics, Charité Berlin",Non-Commercial,Germany,NA,2010-03-24
2007-001094-29,"Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment SUCCESS B-Trial",Germany - BfArM,Completed,Klinikum der LMU,Non-Commercial,Germany,NA,2007-12-06
2011-002687-25,Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency (PHYSCA-Trial),Germany - BfArM,Completed,University Hospital of Wuerzburg,Non-Commercial,Germany,University Hospital Wuerzburg,2011-10-06
2010-021777-37,"""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month""",Germany - PEI,Completed,Universitätsklinikum Schleswig-Holstein (UK-SH),Non-Commercial,Germany,NA,2010-08-09
2004-005244-28,Pilotstudie zur Therapieoptimierungsstudie für den Morbus Hodgkin bei Kindern und Jugendlichen,Germany - BfArM,Completed,Universität Leipzig,Non-Commercial,Germany,NA,2005-02-01
2014-005440-17,"Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain",Germany - BfArM,Prematurely Ended,Private Universität Witten/Herdecke gGmbH,Non-Commercial,Germany,Private Universität Witten/Herdecke gGmbH,2015-03-11
2004-003701-24,"A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.",Italy - Italian Medicines Agency,Completed,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Non-Commercial,Belgium,NA,2005-08-01
2004-003701-24,"A randomised, open-label phase III trial to evaluate the efficacy and safety of Bexarotene (TargretinTM) capsules combined with PUVA, compared to PUVA treatment alone in patients with Mycosis Fungoides.",Denmark - DHMA,Completed,European Organisation for Research and Treatment of Cancer (EORTC),Non-Commercial,Belgium,NA,2006-12-15
2004-001746-32,"Phase II clinical trial with Caelyx mono-chemotherapy in patients with advanced Mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy",Germany - BfArM,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2005-01-19
2004-000149-39,"'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocytic Leukemia'",Italy - Italian Medicines Agency,Completed,Genzyme Corporation,Commercial,United Kingdom,NA,2007-02-15
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",UK - MHRA,Completed,"Orion Corporation, ORION PHARMA, Finland",Commercial,United Kingdom,NA,2005-03-22
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Sweden - MPA,Completed,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland",Commercial,United Kingdom,NA,2005-05-02
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Denmark - DHMA,Completed,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland",Commercial,United Kingdom,NA,2005-05-31
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Finland - Fimea,Completed,"Orion Corporation, ORION PHARMA",Commercial,Finland,NA,2005-06-03
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Ireland - HPRA,Completed,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland",Commercial,United Kingdom,NA,2005-08-16
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Germany - BfArM,Completed,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland",Commercial,United Kingdom,NA,2005-12-02
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Lithuania - SMCA,Completed,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland",Commercial,United Kingdom,NA,2006-03-24
2004-005234-39,"Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",Latvia - SAM,Completed,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland",Commercial,United Kingdom,NA,2006-09-29
2007-001831-73,REducing Deaths due to OXidative Stress The REDOXS© Study A 2×2 factorial randomized trial of glutamine and antioxidant supplementation in critically ill patients,Germany - BfArM,Completed,"Kingston General Hospital, Queen's University of Kingston",Non-Commercial,Canada,NA,2008-10-13
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Hungary - National Institute of Pharmacy,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2005-02-10
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",UK - MHRA,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2005-02-23
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Germany - BfArM,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2005-03-01
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Czech Republic - SUKL,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2005-04-11
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Spain - AEMPS,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2006-04-03
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Sweden - MPA,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2007-09-27
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Denmark - DHMA,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2007-10-10
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Portugal - INFARMED,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2007-10-11
2004-004184-29,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis.",Netherlands - Competent Authority,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2007-10-17
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,Germany - BfArM,Completed,"Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA",2005-11-24
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosome Positive Leukemias,Spain - AEMPS,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2006-01-20
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,Hungary - National Institute of Pharmacy,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2007-01-11
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosome Positive Leukemias,Austria - BASG,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., a Pfizer Company",Commercial,United States,NA,2007-02-06
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,Finland - Fimea,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2007-03-28
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,Sweden - MPA,Completed,"Wyeth Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA",2007-06-12
2005-004230-40,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,UK - MHRA,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2007-10-15
2004-000592-33,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",Sweden - MPA,Completed,Gentium S.p.A,Commercial,Italy,NA,2006-01-05
2004-000592-33,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",Ireland - HPRA,Completed,Gentium S.p.A,Commercial,Italy,NA,2006-01-10
2004-000592-33,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",UK - MHRA,Completed,Gentium S.p.A,Commercial,Italy,NA,2006-01-20
2004-000592-33,"Prospektive Studie über Inzidenz und Verlauf der Venenverschlusskrankheit bei prophylaktischem Einsatz von Defibrotide (DF, Gentium, Italien) im Rahmen der Stammzelltransplantation bei Kindern",Austria - BASG,Completed,EBMT,Non-Commercial,United Kingdom,NA,2006-04-12
2004-000592-33,"Prospective study of the incidence and outcome of Veno-occlusive disease (VOD)with the prophylactic use of Defibrotide (DF, Gentium, Italy) in pediatric stem cell transplantation",Italy - Italian Medicines Agency,Completed,GENTIUM,Commercial,Italy,NA,2007-03-08
2004-000592-33,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",Czech Republic - SUKL,Completed,Gentium S.p.A,Commercial,Italy,NA,2007-11-08
2005-003018-14,"Randomized phase III trial comparing early treatment with fludarabine, cyclophosphamide + rituximab versus deferred treatment in untreated Binet stage A patients with high risk of progression CLL 7 protocol of the GCLLSG and FCGCLL",Austria - BASG,Completed,AKH Vienna,Non-Commercial,Austria,NA,2006-01-26
2005-003018-14,"Randomized phase III trial comparing early treatment with fludarabine, cyclophosphamide + rituximab versus deferred treatment in untreated Binet Stage A patients with high risk of progression.",Czech Republic - SUKL,Prematurely Ended,"Deutsche CLL-Studiengruppe, Klinik fur Innere Medizin",Non-Commercial,Germany,NA,2007-12-28
2005-000968-33,"Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK",Germany - PEI,Completed,"Medizinische Klinik III, Kardiologie, Universität Frankfurt",Non-Commercial,Germany,NA,2005-03-16
2005-006178-86,A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease,Germany - BfArM,Prematurely Ended,European group for Blood and Marrow Transplantation,Non-Commercial,United Kingdom,NA,2007-02-01
2005-006178-86,A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease,Netherlands - Competent Authority,Prematurely Ended,European group for Blood and Marrow Transplantation,Non-Commercial,United Kingdom,NA,2007-03-02
2005-006178-86,"Ensayo clínico aleatorizado, doble ciego y controlado con placebo de comparación de ciclosporina y esteroides con y sin Myfortic® como tratamiento de la enfermedad injerto contra huésped crónica extensa",Spain - AEMPS,Ongoing,European group for Blood and Marrow Transplantation,Non-Commercial,United Kingdom,NA,2007-06-01
2005-006178-86,A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease,Sweden - MPA,Prematurely Ended,European group for Blood and Marrow Transplantation,Non-Commercial,United Kingdom,NA,2007-07-19
2005-001113-18,Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO,Germany - BfArM,Prematurely Ended,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2005-12-21
2008-001043-19,"Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens",Germany - BfArM,Completed,Genzyme Europe BV,Commercial,United Kingdom,NA,2008-07-18
2008-001043-19,"Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens",France - ANSM,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2008-08-22
2008-001043-19,"A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens",Italy - Italian Medicines Agency,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2009-02-09
2005-001967-70,"An open-label, long-term, safety, and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who completed FUTURE 1",UK - MHRA,Completed,Actelion Pharmaceuticals Ltd.,Commercial,Switzerland,NA,2005-08-25
2005-001967-70,"An open-label, long-term, safety, and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who completed FUTURE 1",Germany - BfArM,Completed,Actelion Pharmaceuticals Ltd.,Commercial,Switzerland,NA,2005-08-30
2005-001967-70,An open label long term safety and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who completed FUTURE 1,Italy - Italian Medicines Agency,Completed,Actelion Pharmaceuticals Ltd,Commercial,Switzerland,NA,2007-01-19
2006-001464-23,"A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 years and above, with pulmonary arterial hypertension (PAH)",Czech Republic - SUKL,Completed,"Pfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ",Commercial,,NA,2006-04-21
2006-001464-23,"A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 years and above, with pulmonary arterial hypertension (PAH)",Germany - BfArM,Completed,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,Germany,Pfizer Ltd,2006-05-05
2006-001464-23,"A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects, aged 18 years and above, with pulmonary arterial hypertension (PAH)",UK - MHRA,Completed,Pfizer Ltd,Commercial,United Kingdom,NA,2006-06-11
2006-001464-23,"A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS AND ABOVE, WITH PULMONARY ARTERIAL HYPERTENSION PAH",Italy - Italian Medicines Agency,Completed,PFIZER,Commercial,Italy,NA,2007-02-19
2006-001464-23,"A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 years and above, with pulmonary arterial hypertension (PAH)",Greece - EOF,Completed,"Pfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ",Commercial,,NA,2009-01-30
2005-005709-50,Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells in patients with chronic ischemic heart disease,Germany - PEI,Completed,"Cardiology, University of Frankfurt",Non-Commercial,Germany,NA,2006-01-09
2006-000445-19,Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial,Germany - BfArM,Ongoing,Swiss group for clinical cancer research,Non-Commercial,Switzerland,NA,2007-03-29
2006-000445-19,Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial,Belgium - FPS Health-DGM,Completed,Swiss Group for Clinical Cancer Research,Non-Commercial,Switzerland,NA,2008-12-16
2006-001732-53,"Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie",Germany - PEI,Prematurely Ended,University Hospital of Heidelberg,Non-Commercial,Germany,NA,2006-06-13
2005-004840-30,"ADJUVANT CHEMOTHERAPY WITH PEMETREXED AND CISPLATIN vs. VINORELBINE AND CISPLATIN IN NSCLC IB, IIA, IIB, T3N1: A RANDOMIZED PHASE II STUDY",Germany - BfArM,Completed,Thoraxklinik Heidelberg,Non-Commercial,Germany,Thoraxklinik Heidelberg,2006-04-04
2005-004840-30,"ADJUVANT CHEMOTHERAPY WITH PEMETREXED AND CISPLATIN vs. VINORELBINE AND CISPLATIN IN NSCLC IB, IIA, IIB, T3N1: A RANDOMIZED PHASE II STUDY",Belgium - FPS Health-DGM,Completed,Thoraxklinik Heidelberg,Non-Commercial,Germany,Eli Lilly Benelux,2006-05-04
2006-000358-38,Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of the initial concentration and the initial decline of the HCV RNA,Germany - BfArM,Completed,Klinikum der J. W. Goethe-Universität Frankfurt - Medizinische Klinik I,Non-Commercial,Germany,NA,2006-03-23
2009-017454-12,"INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL A phase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase®/Actilyse®) alone when initiated within three hours of acute ischemic stroke onset.",Germany - BfArM,Prematurely Ended,University of Cincinnati - Academic Medical Center -Department of Neurology,Non-Commercial,United States,"National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Health (NIH), United States",2010-11-09
2009-017454-12,"INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL A phase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase®/Actilyse®) alone when initiated within three hours of acute ischemic stroke onset.",Netherlands - Competent Authority,Prematurely Ended,University of Cincinnati - Academic Medical Center -Department of Neurology,Non-Commercial,United States,"National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Health (NIH)",2010-12-15
2009-017454-12,PROTOCOLO DEL ENSAYO CLÍNICO DE TRATAMIENTO INTERVENCIONISTA DEL ICTUS (INTERVENTIONAL MANAGEMENT OF STROKE),Spain - AEMPS,Temporarily Halted,University of Cincinnati - Academic Medical Center -Department of Neurology,Non-Commercial,United States,NA,2011-01-21
2005-004067-30,"A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis",Austria - BASG,Prematurely Ended,"Department of Rheumatology, Internal Medicine III, Medical University of Vienna",Non-Commercial,Austria,NA,2006-03-31
2005-004067-30,"A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis",Netherlands - Competent Authority,Prematurely Ended,"Department of Rheumatology, Internal Medicine III, Medical University of Vienna",Non-Commercial,Austria,NA,2006-04-20
2005-004067-30,"A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis",Germany - PEI,Prematurely Ended,"Department of Rheumatology, Internal Medicine III, Medical University of Vienna",Non-Commercial,Austria,NA,2006-05-11
2005-005966-35,"A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML",Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2006-02-08
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Belgium - FPS Health-DGM,Completed,"OSI Pharmaceuticals, LLC",Commercial,United States,NA,2006-09-06
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Hungary - National Institute of Pharmacy,Completed,"OSI Pharmaceuticals, LLC",Commercial,United States,NA,2006-09-14
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Germany - BfArM,Prematurely Ended,"OSI Pharmaceuticals, LLC",Commercial,United States,NA,2006-09-18
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Austria - BASG,Completed,"OSI Pharmaceuticals, LLC",Commercial,United States,NA,2006-10-02
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Czech Republic - SUKL,Prematurely Ended,"OSI Pharmaceuticals, LLC",Commercial,United States,NA,2006-10-25
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",France - ANSM,Completed,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2006-12-29
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Greece - EOF,Prematurely Ended,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2007-05-02
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",Italy - Italian Medicines Agency,Prematurely Ended,"OSI PHARMACEUTICALS, LLC",Commercial,United States,"OSI Pharnaceutical, LLC",2007-06-14
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors",UK - MHRA,Prematurely Ended,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2007-12-17
2005-001747-29,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.",Spain - AEMPS,Prematurely Ended,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2010-03-15
2006-000176-32,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation,Germany - BfArM,Completed,Stragen France,Commercial,France,NA,2006-03-31
2006-000176-32,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation,UK - MHRA,Completed,Stragen France,Commercial,France,NA,2006-09-29
2006-000176-32,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation,Hungary - National Institute of Pharmacy,Completed,Stragen France,Commercial,France,NA,2007-05-22
2006-000176-32,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation,Italy - Italian Medicines Agency,Completed,STRAGEN FRANCE SAS,Commercial,France,NA,2009-03-17
2006-003834-14,"Safety and Efficacy of Novel Modified Release Formulation of Oxacarbazepine (OXC MR) vs an Immediate Release Oxacarbazepine (OXC IR) Product in Patients with Partial Epilepsy. Open-Labelled, Controlled, Parallel Group, Flexible Dose, Multicentre Study",Germany - BfArM,Prematurely Ended,Desitin Arzneimittel GmbH,Commercial,Germany,NA,2006-08-11
2005-005168-94,Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer,Germany - PEI,Completed,Philipps-University of Marburg,Non-Commercial,Germany,NA,2006-01-31
2006-001984-53,Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,Germany - BfArM,Completed,Friedrich-Schiller-Universität Jena,Non-Commercial,Germany,NA,2007-01-19
2006-001984-53,Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,Austria - BASG,Completed,Friedrich-Schiller-Universität Jena,Non-Commercial,Germany,NA,2008-09-09
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Netherlands - Competent Authority,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-02
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Belgium - FPS Health-DGM,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-07
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",France - ANSM,Completed,Celgene International Sàrl,Commercial,Switzerland,NA,2006-11-08
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Germany - BfArM,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-09
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Ireland - HPRA,Completed,Celgene International Sàrl,Commercial,Switzerland,NA,2006-11-09
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Czech Republic - SUKL,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-14
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Austria - BASG,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-20
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",UK - MHRA,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-23
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Denmark - DHMA,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-11-23
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Sweden - MPA,Completed,Celgene International Sàrl,Commercial,Switzerland,Celgene International Sàrl,2006-12-05
2006-001865-41,"A phase III, Multicentre, Randomised, Double-Blind, Placebo controlled study to determine the efficacy and safety of lenalidomide (Revlimid in combination with Melphalan and Prednisone versus placebo plus melphalan and prednisone in subjects with newly diagnosed multiple myeloma who are 65 years of age or older",Italy - Italian Medicines Agency,Completed,Celgene,Commercial,Switzerland,NA,2007-05-09
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Greece - EOF,Completed,Celgene International Sàrl,Commercial,Switzerland,NA,2007-05-14
2006-001865-41,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older",Spain - AEMPS,Completed,Celgene International Sàrl,Commercial,Switzerland,NA,2010-03-11
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other filamentous fungi.",Belgium - FPS Health-DGM,Completed,"Astellas Global Pharma Development, Inc.",Commercial,United States,NA,2006-11-13
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi.",Germany - BfArM,Completed,"Astellas Pharma Global Development, Inc",Commercial,United States,Astellas Global Pharma Development Inc.,2006-11-16
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi.",Hungary - National Institute of Pharmacy,Completed,"Astellas Pharma Global Development, Inc",Commercial,United States,Astellas Global Pharma Development Inc.,2007-01-22
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other filamentous fungi. Estudio de fase III, doble ciego y aleatorizado para evaluar la seguridad y eficacia de BAL8557 frente a voriconazol en el tratamiento primario de enfermedades fúngicas invasivas, causadas por especies de Aspergillus u otros hongos filamentosos.",Spain - AEMPS,Completed,Basilea Pharmaceutica Ltd,Commercial,Switzerland,NA,2007-02-07
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other filamentous fungi.",Netherlands - Competent Authority,Completed,Basilea Pharmaceutica Ltd,Commercial,Switzerland,NA,2007-03-02
2006-003868-59,"A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filamentous fungi",Italy - Italian Medicines Agency,Completed,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.",Commercial,United States,Astellas,2007-05-15
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi.",UK - MHRA,Completed,"Astellas Pharma Global Development, Inc",Commercial,United States,Astellas Global Pharma Development Inc.,2007-06-14
2006-003868-59,"A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other filamentous fungi.",Czech Republic - SUKL,Prematurely Ended,Basilea Pharmaceutica Ltd,Commercial,Switzerland,NA,2007-07-09
2006-002801-30,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPY",Belgium - FPS Health-DGM,Completed,MENARINI RICERCHE S.p.A,Commercial,Italy,NA,2006-10-02
2006-002801-30,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPY",Czech Republic - SUKL,Completed,MENARINI RICERCHE S.p.A,Commercial,Italy,NA,2006-11-09
2006-002801-30,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPY",Hungary - National Institute of Pharmacy,Completed,MENARINI RICERCHE S.p.A,Commercial,Italy,NA,2006-11-20
2006-002801-30,"A RANDOMIZED,DOUBLE BLIND,PLACEBO CONTROLLED,MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPY",Germany - PEI,Prematurely Ended,MENARINI RICERCHE S.p.A,Commercial,Italy,NA,2006-12-18
2006-002801-30,"A randomized, double blind, placebo controlled, multicentre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapy.",Italy - Italian Medicines Agency,Completed,MENARINI RICERCHE S.P.A.,Commercial,Italy,NA,2007-04-02
2006-002801-30,"""Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo del tratamiento de mantenimiento con ABAGOVOMAB en pacientes con cáncer epitelial de ovario después de una respuesta completa a la quimioterapia de primera línea""",Spain - AEMPS,Completed,MENARINI RICERCHE S.p.A,Commercial,Italy,NA,2010-03-10
2006-001040-31,"Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation ""RELAZA""",Germany - BfArM,Completed,University of Technology Dresden,Non-Commercial,Germany,NA,2006-07-14
2005-003587-34,"A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with haematological malignancies",Greece - EOF,Ongoing,MolMed,Commercial,Italy,NA,2007-04-12
2006-001097-24,Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.,Germany - PEI,Completed,"Technische Universitaet Muenchen, Medizinische Fakultaet",Non-Commercial,Germany,Merck Serono GmbH,2006-05-22
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Ireland - HPRA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-03-08
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",UK - MHRA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-03-09
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Belgium - FPS Health-DGM,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-03-14
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Czech Republic - SUKL,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-03-15
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Germany - BfArM,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-03-15
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Portugal - INFARMED,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-03-28
2006-004306-50,ENSAYO MULTICENTRICO Y ABIERTO DE ACCESO EXPANDIDO A MARAVIROC.,Spain - AEMPS,Completed,"PFIZER, S.A.",Commercial,Spain,NA,2007-04-02
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Netherlands - Competent Authority,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-04-04
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Austria - BASG,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-05-21
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Greece - EOF,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-05-25
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Italy - Italian Medicines Agency,Completed,PFIZER,Commercial,Italy,NA,2007-06-05
2006-004306-50,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",Denmark - DHMA,Prematurely Ended,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2007-06-18
2006-002768-24,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease",Denmark - DHMA,Completed,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Commercial,United States,NA,2006-11-29
2006-002768-24,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease",Belgium - FPS Health-DGM,Completed,Otsuka Pharmaceutical Development & Commercialization. Inc.,Commercial,United States,NA,2006-12-05
2006-002768-24,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease",UK - MHRA,Completed,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Commercial,United States,NA,2006-12-07
2006-002768-24,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease",Germany - BfArM,Completed,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Commercial,United States,NA,2006-12-15
2006-002768-24,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease",France - ANSM,Completed,"Otsuka Maryland Research Institute, Inc.",Commercial,United States,NA,2006-12-29
2006-002768-24,"Phase III multicenter, double blind,placebo controlled, parallel arm trial to determine long-term safety and efficacy of oral tolvaptan tablet regimen in adult subjects with autosomal dominant polycystic kidney disease",Italy - Italian Medicines Agency,Completed,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,Non-Commercial,United States,Otsuka Pharmaceutical Development,2007-07-23
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group,Germany - BfArM,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,NA,2006-09-05
2006-000995-33,First International Inter-Group Study for classical Hodgkin´s Lymfoma in Children and Adolescents,Czech Republic - SUKL,Completed,"Martin Luther University of Halle/Wittenberg, Medizinische Fakultät, Prodekanat Forschung",Non-Commercial,Germany,NA,2007-07-26
2006-000995-33,First International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,UK - MHRA,Completed,Martin Luther University of Hallle/Wittenburg,Non-Commercial,Germany,NA,2007-10-10
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group,Sweden - MPA,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,NA,2007-11-08
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents,Austria - BASG,Completed,Martin Luther University of Halle/Wittenberg,Non-Commercial,Germany,Deutsche Krebshilfe,2007-12-14
2006-000995-33,EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,France - ANSM,Completed,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Non-Commercial,France,NA,2008-05-13
2006-000995-33,First International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,Ireland - HPRA,Completed,Our Lady's Children's Hospital,Non-Commercial,Ireland,NA,2008-05-21
2006-000995-33,Primer Estudio Internacional Inter-Grupo del linfoma de Hodgkin clásico en niños y adolescentes,Spain - AEMPS,Completed,Martin Luther University of Halle-Wittemberg,Non-Commercial,Germany,NA,2008-08-14
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group,Denmark - DHMA,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,NA,2008-09-03
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group,Poland - Office for Medicinal Products,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,NA,2010-01-19
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group,Belgium - FPS Health-DGM,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,NA,2010-09-07
2006-000995-33,EuroNet-Paediatric Hodgkin�s Lymphoma Group,Netherlands - Competent Authority,Completed,Martin-Luther-University Halle-Wittenberg,Non-Commercial,Germany,NA,2010-09-20
2006-000995-33,EuroNet-Paediatric Hodgkin’s Lymphoma Group:First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents,Slovenia - JAZMP,Completed,Martin Luther University of Halle/Wittenberg,Non-Commercial,Germany,NA,2011-10-17
2006-003667-31,Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,Germany - BfArM,Prematurely Ended,"Medical Faculty, TU Dresden",Non-Commercial,Germany,NA,2007-04-23
2006-003667-31,Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,Austria - BASG,Prematurely Ended,"Medical Faculty, TU Dresden",Non-Commercial,Germany,NA,2007-08-14
2006-002056-14,Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie) (Acute cholecystitis – early laparoscopic surgery versus antibiotic therapy and delayed elective cholecystectomy = ACDC-study),Germany - BfArM,Completed,Universitätsklinikum Heidelberg,Non-Commercial,Germany,NA,2006-06-13
2006-006913-34,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy",Hungary - National Institute of Pharmacy,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2007-02-15
2006-006913-34,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy",Netherlands - Competent Authority,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2007-04-06
2006-006913-34,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy",Germany - BfArM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2007-05-07
2006-006913-34,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.",Czech Republic - SUKL,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2007-05-10
2006-006913-34,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy",UK - MHRA,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2011-08-15
2006-004350-25,Crystalloids or colloids in patients with severe sepsis: effects on hemodynamics and tolerability of enteral nutrition,France - ANSM,Completed,Fresenius Kabi Deutschland GmbH,Commercial,Germany,NA,2006-12-29
2006-004350-25,Crystalloids or colloids in patients with severe sepsis: effects on hemodynamics and tolerability of enteral nutrition,Germany - BfArM,Completed,Fresenius Kabi Deutschland GmbH,Commercial,Germany,NA,2008-11-14
2006-002727-16,"Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after neoadjuvant chemotherapy and intended curative resection",Germany - PEI,Completed,Fresenius Biotech GmbH,Commercial,Germany,Fresenius Biotech GmbH,2006-11-01
2006-002727-16,"Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after neoadjuvant chemotherapy and intended curative resection",Austria - BASG,Completed,Fresenius Biotech GmbH,Commercial,Germany,NA,2007-03-08
2006-002727-16,"Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after neoadjuvant chemotherapy and intended curative resection",UK - MHRA,Completed,Fresenius Biotech GmbH,Commercial,Germany,NA,2007-03-09
2006-006030-17,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",Finland - Fimea,Completed,Orion Corporation Orion Pharma,Commercial,Finland,NA,2007-03-26
2006-006030-17,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",UK - MHRA,Completed,Orion Corporation Orion Pharma,Commercial,United Kingdom,NA,2007-03-28
2006-006030-17,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",Belgium - FPS Health-DGM,Completed,Orion Corporation Orion Pharma,Commercial,United Kingdom,NA,2007-04-12
2006-006030-17,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",Germany - BfArM,Completed,Orion Corporation Orion Pharma,Commercial,United Kingdom,NA,2007-06-13
2006-006030-17,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",Netherlands - Competent Authority,Completed,Orion Corporation Orion Pharma,Commercial,United Kingdom,NA,2007-09-06
2006-006233-40,"Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every month over a period of one year) in type 2 idiopathic macular telangiectasia",Germany - PEI,Completed,"Department of Ophthalmology, Bonn University",Non-Commercial,Germany,NA,2007-03-06
2006-001212-72,Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherapy-Trial/ MIR),Germany - PEI,Completed,University Hospital of Heidelberg,Non-Commercial,Germany,NA,2007-05-09
2007-001335-54,"SAFETY AND EFFICACY OF CIMICOXIB, A SELECTIVE COX-2 INHIBITOR, IN COMBINATION WITH SERTRALINE COMPARED TO SERTRALINE COMBINED WITH PLACEBO IN TREATMENT OF MAJOR DEPRESSION",Germany - BfArM,Completed,Affectis Pharmaceuticals AG,Commercial,Germany,NA,2007-06-18
2007-001335-54,"SAFETY AND EFFICACY OF CIMICOXIB, A SELECTIVE COX-2 INHIBITOR, IN COMBINATION WITH SERTRALINE COMPARED TO SERTRALINE COMBINED WITH PLACEBO IN TREATMENT OF MAJOR DEPRESSION",Czech Republic - SUKL,Completed,Affectis Pharmaceuticals AG,Commercial,Germany,NA,2008-05-15
2007-001335-54,"SAFETY AND EFFICACY OF CIMICOXIB, A SELECTIVE COX-2 INHIBITOR, IN COMBINATION WITH SERTRALINE COMPARED TO SERTRALINE COMBINED WITH PLACEBO IN TREATMENT OF MAJOR DEPRESSION",Austria - BASG,Completed,Affectis Pharmaceuticals AG,Commercial,Germany,NA,2008-07-11
2006-005342-36,"A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201, free of complexing proteins, in the treatment of glabellar frown lines",Germany - BfArM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2007-03-21
2006-006166-42,"Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -",Germany - BfArM,Ongoing,University of Tuebingen,Non-Commercial,Germany,NA,2007-01-02
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Germany - PEI,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-03-01
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Slovakia - SIDC (Slovak),Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-04-03
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",UK - MHRA,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-05-15
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Austria - BASG,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-05-24
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Hungary - National Institute of Pharmacy,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-06-20
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.",Spain - AEMPS,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-08-24
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Bulgarian Drug Agency,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-02-12
2006-006323-39,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,Germany - BfArM,Completed,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-03-05
2007-001161-14,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris.",UK - MHRA,Completed,Genzyme Corporation,Commercial,United States,NA,2007-08-01
2007-001161-14,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris.",Germany - PEI,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2007-08-23
2007-001161-14,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Sclerosis.",Czech Republic - SUKL,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2007-09-11
2007-001161-14,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris.",Sweden - MPA,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2007-12-18
2007-001161-14,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris.",France - ANSM,Completed,Genzyme Corporation,Commercial,United States,NA,2008-01-08
2007-001161-14,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris.",Poland - Office for Medicinal Products,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2008-05-12
2005-001938-32,"EFFICACY, SAFETY, AND QUALITY OF LIFE OF A LONG-TERM HOME PARENTERAL NUTRITION REGIMEN WITH EITHER LIPIDEM® OR LIPOFUNDIN® MCT A MONO-CENTER, RANDOMIZED, DOUBLE BLIND STUDY",Germany - BfArM,Completed,B.Braun Melsungen AG,Commercial,Germany,B. Braun Melsungen AG,2007-04-23
2005-002822-78,Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III?,Germany - BfArM,Completed,Klinik Neuropädiatrie und Muskelkrankheiten,Non-Commercial,Germany,NA,2005-11-21
2006-006984-21,"prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function of patients with severe sepsis and septic shock",Germany - BfArM,Completed,Friedrich-Schiller-University of Jena,Non-Commercial,Germany,NA,2007-02-02
2007-002142-37,"SUNITINIB (SUTENT, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiforme An Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies",Austria - BASG,Completed,Medizinische Universität Innsbruck,Non-Commercial,Austria,NA,2007-07-18
2007-002142-37,"SUTENT (SUNITINIB, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiforme An Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies",Germany - BfArM,Completed,Medizinische Universität Innsbruck,Non-Commercial,Austria,NA,2008-04-21
2006-000934-11,A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of house dust mite (Dermatophagoides pteronyssinus) in patients with rhinitis/rhinoconjunctivitis and/or allergic asthma bronchiale,Germany - PEI,Completed,Alllergopharma Joachim Ganzer KG,Commercial,Germany,NA,2006-05-10
2007-002532-28,A Phase II Study of Efficacy of Rabbit Antithymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome,Germany - PEI,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2007-07-31
2007-002532-28,A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome,UK - MHRA,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2007-07-31
2007-002532-28,A Phase II Study of Efficacy of Rabbit Antithymoglobulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome,France - ANSM,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2007-08-29
2007-002532-28,A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome,Netherlands - Competent Authority,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-01-22
2007-002841-19,"""Estudio aleatorizado, multicéntrico para evaluar la eficacia y seguridad de bevacizumab en combinación con letrozol comparado con letrozol solo, en mujeres postmenopáusicas con cáncer de mama localmente recurrente o metastásico con indicación de hormonoterapia como tratamiento de primera línea"".",Spain - AEMPS,Completed,Grupo Español de Investigación en Cáncer de Mama (GEICAM),Non-Commercial,Spain,NA,2007-07-12
2007-002841-19,"MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH ENDOCRINE TREATMENT COMPARED TO ENDOCRINE TREATMENT ALONE, IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC CANCER WITH INDICATION OF HORMONOTHERAPY AS FIRST-LINE TREATMENT",Germany - PEI,Completed,Grupo Español de Investigación en Cáncer de Mama (GEICAM),Non-Commercial,Spain,NA,2008-04-16
2007-004896-20,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis",Netherlands - Competent Authority,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,Shire Pharmaceuticals,2008-02-01
2007-004896-20,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis",Finland - Fimea,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,Shire Pharmaceuticals,2008-02-11
2007-004896-20,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis",Germany - BfArM,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2008-02-18
2007-004896-20,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis.",Italy - Italian Medicines Agency,Completed,Shire Pharmaceuticals Development Ltd,Commercial,United Kingdom,NA,2008-07-03
2007-004896-20,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis",Hungary - National Institute of Pharmacy,Completed,Shire Pharmaceutical Development Ltd,Commercial,United Kingdom,NA,2009-02-23
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",UK - MHRA,Completed,Genzyme Corporation,Commercial,United States,NA,2007-10-04
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Netherlands - Competent Authority,Completed,Genzyme Corporation,Commercial,United States,NA,2007-12-19
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Sweden - MPA,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2007-12-28
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Germany - PEI,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2008-01-02
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",France - ANSM,Completed,Genzyme Corporation,Commercial,United States,NA,2008-01-08
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Belgium - FPS Health-DGM,Completed,Genzyme Corporation,Commercial,United States,NA,2008-01-22
2007-001162-32,Estudio aleatorio ciego para el evaluador y de dosis ciega de fase 3 que compara dos ciclos anuales intravenosos de dosis baja y alta de alemtuzumab con interferón beta-1a (Rebif®) subcutáneo tres veces a la semana en pacientes con esclerosis múltiple de recaída-remisión que han recaído durante el tratamiento,Spain - AEMPS,Completed,Genzyme Corporation,Commercial,United States,NA,2008-02-14
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Czech Republic - SUKL,Completed,Genzyme Corporation,Commercial,United States,NA,2008-03-31
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Austria - BASG,Completed,Genzyme Corporation,Commercial,United States,NA,2008-07-14
2007-001162-32,"A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High- Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy",Italy - Italian Medicines Agency,Completed,Genzyme Corporation,Commercial,United States,NA,2008-07-14
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Denmark - DHMA,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2008-07-25
2007-001162-32,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy",Poland - Office for Medicinal Products,Completed,Genzyme Corporation,Commercial,United States,Genzyme Corporation,2008-10-24
2007-000124-41,"Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer",Germany - BfArM,Completed,GBG Forschungs GmbH,Commercial,Germany,NA,2007-03-12
2010-022515-20,PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF PD 0332991 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA,Czech Republic - SUKL,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA",Commercial,United States,Pfizer Inc.,2010-11-23
2010-022515-20,PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF PD 0332991 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA,Germany - BfArM,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA",Commercial,United States,Pfizer Inc.,2010-11-29
2007-005891-15,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease",Hungary - National Institute of Pharmacy,Prematurely Ended,"Cogentus Pharmaceuticals, Inc.",Commercial,United States,NA,2008-02-13
2007-005891-15,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease",Germany - BfArM,Temporarily Halted,"Cogentus Pharmaceuticals, Inc.",Commercial,United States,NA,2008-03-10
2007-005891-15,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease",Czech Republic - SUKL,Prematurely Ended,"Cogentus Pharmaceuticals, Inc.",Commercial,United States,NA,2008-03-17
2007-005891-15,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease",Slovakia - SIDC (Slovak),Completed,"Cogentus Pharmaceuticals, Inc.",Commercial,United States,NA,2008-04-09
2007-005891-15,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease",Italy - Italian Medicines Agency,Prematurely Ended,COGENTUS PHARMACEUTICALS INTERNATIONAL LIMITED,Commercial,United Kingdom,NA,2008-05-16
2007-005891-15,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease",Bulgarian Drug Agency,Prematurely Ended,"Cogentus Pharmaceuticals, Inc.",Commercial,United States,NA,2008-08-04
2007-002765-12,Influence of the angiotensin receptor blocker Telmisartan on the red blood cell function and the microcirculatory perfusion (ITEM),Germany - BfArM,Completed,RWTH Aachen University,Non-Commercial,Germany,NA,2007-07-06
2006-003567-31,Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,Germany - BfArM,Ongoing,"Med. Klinik II, Grosshadern, Klinikum der Universität München",Non-Commercial,Germany,NA,2007-03-29
2006-006520-19,"An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of positive B-precursor acute lymphoblastic leukemia (ALL)",Germany - PEI,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2007-06-19
2007-003461-41,Cardiac imaging under dobutamine stress for early assessment of right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation,Germany - BfArM,Prematurely Ended,"Deutsche Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler",,Germany,NA,2007-09-10
2006-005834-19,"A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer",Germany - PEI,Completed,GBG Forschungs GmbH,Commercial,Germany,NA,2007-02-09
2006-006390-24,"Prospektive, randomized, controlled, multicentre, partly double blind study to compare Disci/Rhus toxicodendron comp., placebo and waiting list in patients with chronic low back pain.",Germany - BfArM,Completed,WALA Heilmittel GmbH,Commercial,Germany,NA,2007-01-24
2005-005393-73,A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to Associate PET Findings with Molecular Markers,Germany - BfArM,Completed,University Cologne,Non-Commercial,Germany,NA,2007-12-14
2007-002663-26,"Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors",Germany - BfArM,Completed,AEterna Zentaris GmbH,Commercial,Germany,NA,2007-08-29
2007-002663-26,"Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors",Bulgarian Drug Agency,Completed,AEterna Zentaris GmbH,Commercial,Germany,NA,2008-02-27
2007-001424-12,A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis,UK - MHRA,Completed,Intercept Pharmaceuticals,Commercial,United States,Intercept Pharmaceuticals,2007-09-03
2007-001424-12,A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis,France - ANSM,Completed,Intercept Pharmaceuticals,Commercial,United States,NA,2008-05-16
2007-001424-12,Estudio de la monoterapia INT-747 (6-ECDCA) en pacientes con cirrosis biliar primaria,Spain - AEMPS,Completed,Intercept Pharmaceuticals,Commercial,United States,NA,2008-05-22
2007-001424-12,A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis,Austria - BASG,Completed,Intercept Pharmaceuticals,Commercial,United States,NA,2008-09-09
2007-001424-12,A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis,Germany - BfArM,Completed,Intercept Pharmaceuticals,Commercial,United States,NA,2008-10-23
2007-000224-41,"A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferase type 2) in patients with pulmonary tuberculosis",Germany - BfArM,Prematurely Ended,University of Cologne,Non-Commercial,Germany,NA,2007-07-12
2007-000224-41,"A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferase type 2) in patients with pulmonary tuberculosis",Bulgarian Drug Agency,Prematurely Ended,University of Cologne,Non-Commercial,Germany,NA,2009-11-24
2007-002015-38,"""ENSAYO CLÍNICO MULTICÉNTRICO, FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO INTRAINDIVIDUALMENTE CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE P144 EN EL TRATAMIENTO TÓPICO DE LA FIBROSIS CUTÁNEA DE PACIENTES CON ESCLEROSIS SISTÉMICA""",Spain - AEMPS,Ongoing,ISDIN,Commercial,Spain,NA,2007-07-02
2007-002015-38,"Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis.",Hungary - National Institute of Pharmacy,Completed,ISDIN,Commercial,Spain,NA,2007-07-09
2007-002015-38,"PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, INTRAINDIVIDUALLY PLACEBO CONTROLLED CLINICAL TRIAL, TO EVALUATE EFFICACY AND SAFETY OF P144 TOPICAL ADMINISTRATION FOR SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS.",UK - MHRA,Completed,ISDIN,Commercial,Spain,NA,2007-07-31
2007-002015-38,"PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, INTRAINDIVIDUALLY PLACEBO CONTROLLED CLINICAL TRIAL, TO EVALUATE EFFICACY AND SAFETY OF P144 TOPICAL ADMINISTRATION FOR SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS.",Germany - BfArM,Completed,ISDIN,Commercial,Spain,NA,2007-08-03
2007-002015-38,"Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis.",Italy - Italian Medicines Agency,Ongoing,ISDIN S.A.,Commercial,Spain,NA,2009-06-19
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Germany - BfArM,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,France,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",2008-01-07
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Hungary - National Institute of Pharmacy,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",2008-01-16
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",UK - MHRA,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",2008-02-08
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Belgium - FPS Health-DGM,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",2008-02-14
2007-003780-50,"Estudio de fase 3, abierto y aleatorizado, de bosutinib comparado con imatinib en sujetos con leucemia mieloide crónica cromosoma Filadelfia positiva en fase crónica, de diagnóstico reciente",Spain - AEMPS,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-02-21
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Latvia - SAM,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. (A Pfizer Company),Commercial,United States,NA,2008-02-26
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Lithuania - SMCA,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",2008-03-18
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",France - ANSM,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-05-05
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Italy - Italian Medicines Agency,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc.,",Commercial,United States,NA,2008-06-03
2007-003780-50,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",Slovenia - JAZMP,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-12-10
2007-003998-55,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.",Finland - Fimea,Completed,AstraZeneca AB,Commercial,Sweden,NA,2007-10-05
2007-003998-55,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.",Netherlands - Competent Authority,Completed,AstraZeneca AB,Commercial,Sweden,NA,2007-10-26
2007-003998-55,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.",Hungary - National Institute of Pharmacy,Completed,AstraZeneca AB,Commercial,Sweden,NA,2007-11-05
2007-003998-55,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.",Slovakia - SIDC (Slovak),Completed,AstraZeneca AB,Commercial,Sweden,NA,2008-04-09
2007-003998-55,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.",Germany - BfArM,Completed,AstraZeneca AB,Commercial,Sweden,NA,2009-02-16
2007-003998-55,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.",UK - MHRA,Completed,AstraZeneca AB,Commercial,Sweden,NA,2010-10-18
2007-002999-34,"A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.",UK - MHRA,Prematurely Ended,Ipsen Limited,Commercial,United Kingdom,NA,2007-10-11
2007-002999-34,"A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.",Germany - BfArM,Prematurely Ended,Ipsen Limited,Commercial,United Kingdom,NA,2007-10-15
2007-002999-34,"A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.",Netherlands - Competent Authority,Prematurely Ended,Ipsen Limited,Commercial,United Kingdom,NA,2007-10-24
2007-002999-34,"A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.",Belgium - FPS Health-DGM,Completed,Ipsen Limited,Commercial,United Kingdom,NA,2007-11-09
2007-002999-34,"A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.",France - ANSM,Completed,Ipsen Limited,Commercial,United Kingdom,NA,2007-11-12
2007-002999-34,"A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one injection cycle with either botulinum toxin Type-A (Dysport® 125, 250 or 500 Units) or placebo followed by an optional 6-month extension phase in the symptomatic treatment of micturition urgency and frequency in continent female subjects suffering from idiopathic overative bladder.",Czech Republic - SUKL,Completed,Ipsen Limited,Commercial,United Kingdom,NA,2007-12-12
2007-002999-34,"A PHASE II, INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED, 12-WEEK, PRINCEPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF A ONE INJECTION CYCLE WITH EITHER BOTULINUM TOXIN TYPE-A (DYSPORT 125, 250 OR 500 UNITS) OR PLACEBO FOLLOWED BY AN OPTIONAL 6-MONTH EXTENSION PHASE IN THE SYMPTOMATIC TREATMENT OF MICTURITION URGENCY AND FREQUENCY IN CONTINENT FEMALE SUBJECTS SUFFERING FROM IDIOPATHIC OVERACTIVE BLADDER",Italy - Italian Medicines Agency,Prematurely Ended,IPSEN LIMITED,Commercial,United Kingdom,NA,2008-01-07
2007-002999-34,"“Estudio princeps de fase II, internacional, multicéntrico, prospectivo, aleatorizado, de grupos paralelos, doble ciego, de variación de la dosis, controlado por placebo, de 12 semanas para evaluar la eficacia y la seguridad de un ciclo de inyecciones o bien con toxina botulínica tipo a (dysport® 125, 250 o 500 unidades) o bien con placebo, seguido por una fase de ampliación opcional de 6 meses, en el tratamiento sintomático del tenesmo vesical y la frecuencia de micción en mujeres continentes que padecen vejiga hiperactiva idiopática”",Spain - AEMPS,Completed,Ipsen Limited,Commercial,United Kingdom,NA,2010-03-09
2005-000743-29,"Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, second and third amendment).",Belgium - FPS Health-DGM,Ongoing,Heads Study Group,Non-Commercial,Germany,NA,2009-06-09
2007-005478-29,A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,France - ANSM,Completed,"PTC Therapeutics, Inc.",Commercial,United States,NA,2008-01-24
2007-005478-29,A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,Germany - BfArM,Completed,"PTC Therapeutics, Inc.",Commercial,United States,NA,2008-01-28
2007-005478-29,A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,Sweden - MPA,Completed,"PTC Therapeutics, Inc.",Commercial,United States,NA,2008-02-22
2007-005478-29,A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,UK - MHRA,Completed,"PTC Therapeutics, Inc.",Commercial,United States,NA,2008-02-22
2007-005478-29,A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,Belgium - FPS Health-DGM,Completed,"PTC Therapeutics, Inc.",Commercial,United States,NA,2008-02-27
2007-005478-29,Estudio de fase 2b sobre la eficacia y la seguridad de PTC124 en pacientes con distrofia muscular de Duchenne y Becker mediada por mutación terminadora,Spain - AEMPS,Completed,"PTC Therapeutics, Inc.",Commercial,United States,NA,2008-03-10
2007-005478-29,A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,Italy - Italian Medicines Agency,Completed,"PTC THERAPEUTICS, INC.",Commercial,United States,NA,2008-07-14
2006-003686-13,"An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",Germany - BfArM,Completed,"Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin",Non-Commercial,Germany,NA,2007-03-29
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Finland - Fimea,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2007-10-18
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Czech Republic - SUKL,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2007-10-30
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Spain - AEMPS,Completed,Merck Serono International S.A.,Commercial,Switzerland,NA,2007-11-16
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinsons Disease treated with a stable dose of a single dopamine agonist.",Italy - Italian Medicines Agency,Completed,MERCK SERONO INTERNATIONAL SA,Commercial,Italy,NA,2008-01-04
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Slovakia - SIDC (Slovak),Completed,Merck Serono S.A. - Geneva,Commercial,Switzerland,NA,2008-04-16
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson?s Disease treated with a stable dose of a single dopamine agonist.",Portugal - INFARMED,Completed,Merck Serono S.A-Geneva,Commercial,Switzerland,NA,2009-01-07
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Poland - Office for Medicinal Products,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A - Geneva,2009-02-27
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Bulgarian Drug Agency,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2009-05-21
2007-002963-28,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.",Germany - BfArM,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2009-12-22
2007-003262-17,Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation,Germany - BfArM,Prematurely Ended,University Hospital Magdeburg,Non-Commercial,Germany,NA,2008-07-08
2007-001918-16,"Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study SoraPeg Trial",Germany - BfArM,Completed,"Universitätsklinikum Schleswig-Holstein, Campus Kiel",Non-Commercial,Germany,NA,2009-04-14
2006-005262-39,Flupirtin as Oral Treatment in MS,Germany - BfArM,Completed,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-03-09
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",Sweden - MPA,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,.,2007-10-17
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",Czech Republic - SUKL,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,NA,2007-11-05
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",Belgium - FPS Health-DGM,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,NA,2007-11-23
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN).",Spain - AEMPS,Completed,"Pfizer, S.A.",Commercial,Spain,NA,2007-11-26
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",Austria - BASG,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,NA,2007-12-11
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",UK - MHRA,Completed,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,NA,2008-01-18
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",France - ANSM,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK",Commercial,United Kingdom,NA,2008-02-26
2007-003949-32,"A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN)",Italy - Italian Medicines Agency,Completed,PFIZER,Commercial,Italy,NA,2008-03-17
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",Germany - BfArM,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,Pfizer Inc.,2009-05-14
2007-003949-32,"A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)",Netherlands - Competent Authority,Completed,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",Commercial,United Kingdom,NA,2009-12-23
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Belgium - FPS Health-DGM,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2007-09-04
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Finland - Fimea,Prematurely Ended,Merck Serono International S.A.,Commercial,Switzerland,NA,2007-10-18
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",France - ANSM,Completed,Merck Serono S.A. - Geneva,Commercial,Switzerland,NA,2007-11-12
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Hungary - National Institute of Pharmacy,Completed,Merck Serono S.A.-Geneva,Commercial,Switzerland,NA,2007-11-15
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Spain - AEMPS,Completed,Merck Serono International S.A.,Commercial,Switzerland,NA,2007-11-30
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Netherlands - Competent Authority,Completed,Merck Serono International S.A.,Commercial,Switzerland,NA,2007-12-11
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Estonia - SAM,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2008-01-02
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Austria - BASG,Completed,Newron Pharmaceuticals SpA,Commercial,Italy,Merck Serono S.A. - Geneva,2008-02-13
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Slovakia - SIDC (Slovak),Completed,Merck Serono S.A. - Geneva,Commercial,Switzerland,NA,2008-04-16
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Germany - BfArM,Completed,Merck Serono S.A. - Geneva,Commercial,Switzerland,NA,2008-12-17
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",UK - MHRA,Completed,Merck Serono S.A - Geneva,Commercial,Switzerland,NA,2009-01-14
2007-002964-90,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.",Czech Republic - SUKL,Completed,Merck Serono S.A. - Geneva,Commercial,Switzerland,NA,2010-08-27
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Hungary - National Institute of Pharmacy,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-03-18
2007-003793-26,"Estudio de fase 3b, aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacientes con carcinoma de células renales avanzado",Spain - AEMPS,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-03-27
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",France - ANSM,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-04-22
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Belgium - FPS Health-DGM,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc",2008-04-23
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Portugal - INFARMED,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-05-19
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Czech Republic - SUKL,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc",2008-06-18
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Germany - BfArM,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidary of Pfizer Inc.",2008-07-10
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Slovakia - SIDC (Slovak),Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc",2008-07-18
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",Netherlands - Competent Authority,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-07-31
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs. Bevacizumab (Avastin) + Interferon-alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma",Italy - Italian Medicines Agency,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Commercial,United States,NA,2008-12-10
2007-003793-26,"Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma",UK - MHRA,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc",2010-09-10
2006-005710-12,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-06-18
2007-003512-57,"Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)",France - ANSM,Completed,Bioprojet,Commercial,France,NA,2007-07-23
2007-003786-41,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines in unprimed healthy subjects aged between 6 and up to 72 months.",Germany - PEI,Prematurely Ended,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,NA,2007-07-31
2007-003786-41,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines in unprimed healthy subjects aged between 6 and up to 72 months.",Finland - Fimea,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,NA,2008-05-06
2007-003786-41,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines in unprimed healthy subjects aged 6 to <72 months.",Italy - Italian Medicines Agency,Completed,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,Commercial,Italy,NA,2009-08-12
2007-003786-41,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines in unprimed healthy subjects aged between 6 and up to 72 months.",Hungary - National Institute of Pharmacy,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,NA,2009-08-18
2007-003786-41,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines in unprimed healthy subjects aged between 6 and up to 72 months.",Belgium - FPS Health-DGM,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,NA,2009-09-03
2007-002119-17,EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion / [EPLERAF-Study: Eplerenone in the prevention of atrial fibrillation recurrences after cardioversion],Germany - BfArM,Ongoing,Universität des Saarlandes,Non-Commercial,Germany,NA,2007-08-22
2007-003508-36,"A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis",Hungary - National Institute of Pharmacy,Completed,Nitec Pharma AG,Commercial,Switzerland,NA,2008-02-18
2007-003508-36,"A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis",UK - MHRA,Completed,Nitec Pharma AG,Commercial,Switzerland,NA,2008-02-29
2007-003508-36,"A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis",Germany - BfArM,Completed,Nitec Pharma AG,Commercial,Switzerland,NA,2008-03-28
2007-005983-28,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al tratamiento con erlotinib o gefitinib",Spain - AEMPS,Completed,"Boehringer Ingelheim España, S.A.",Commercial,Spain,NA,2008-02-26
2007-005983-28,"Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non small cell lung cancer patients failing erlotinib or gefitinib",UK - MHRA,Completed,Boehringer Ingelheim Limited,Commercial,United Kingdom,NA,2008-02-29
2007-005983-28,"Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non small cell lung cancer patients failing erlotinib or gefitinib",Belgium - FPS Health-DGM,Completed,SCS Boehringer Ingelheim Comm.V,Commercial,Belgium,NA,2008-03-06
2007-005983-28,"Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non small cell lung cancer patients failing erlotinib or gefitinib",Netherlands - Competent Authority,Completed,Boehringer Ingelheim bv,Commercial,Netherlands,NA,2008-03-06
2007-005983-28,"Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non small cell lung cancer patients failing erlotinib or gefitinib",Germany - BfArM,Completed,Boehringer Ingelheim Pharma GmbH & Co.KG,Commercial,Germany,NA,2008-04-17
2007-005983-28,"Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non small cell lung cancer patients failing erlotinib or gefitinib",France - ANSM,Completed,Boehringer Ingelheim France,Commercial,France,NA,2008-05-05
2007-005983-28,"Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing erlotinib or gefitinib",Italy - Italian Medicines Agency,Completed,BOEHRINGER ING.,Commercial,Italy,NA,2008-09-15
2007-000427-17,A phase II multicenter study to test progression- free and overall survival of CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after antineoplastic treatment failure,Germany - BfArM,Completed,CYTAVIS BioPharma GmbH,Commercial,Germany,NA,2007-06-18
2007-006302-13,"A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART",Germany - PEI,Completed,Bionor Immuno AS,Commercial,Norway,NA,2008-01-17
2007-006302-13,"A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART",UK - MHRA,Completed,Bionor Immuno AS,Commercial,Norway,NA,2008-01-18
2007-006302-13,"Estudio multicéntrico, randomizado, doble ciego en fase II, sobre la inmunogeneicidad de la vacuna -4x frente a placebo en pacientes infectados por VIH-1, que han mantenido una respuesta adecuada a TAR",Spain - AEMPS,Completed,Bionor Immuno AS,Commercial,Norway,NA,2008-02-20
2007-006302-13,"A Phase II, Randomized,Double-blind,Multicenter,Immunogenecity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART",Italy - Italian Medicines Agency,Completed,BIONOR IMMUNO AS,Commercial,Norway,NA,2008-05-19
2007-006302-13,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART",Germany - PEI,Completed,Bionor Immuno AS,Commercial,Norway,Bionor Immuno AS,2012-08-06
2007-006302-13,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART",UK - MHRA,Completed,Bionor Immuno AS,Commercial,Norway,Bionor Immuno AS,2012-08-06
2007-006302-13,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART",Spain - AEMPS,Ongoing,Bionor Immuno AS,Commercial,Norway,Bionor Immuno AS,2012-08-23
2007-006302-13,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART.",Italy - Italian Medicines Agency,Completed,BIONOR IMMUNO AS,Commercial,Norway,Bionor Immuno AS,2012-11-23
2007-004401-10,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic shock in patients with severe sepsis",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Federal Ministry of Education and Research,2008-02-28
2007-002223-32,"A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",Germany - BfArM,Completed,Charité Universitaetsmedizin,Non-Commercial,Germany,NA,2008-02-07
2007-002223-32,"A multicentre, double-blind, randomised controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",Ireland - HPRA,Prematurely Ended,Charité Universitaetsmedizin,Non-Commercial,Germany,NA,2009-03-26
2007-005022-71,Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer,Germany - BfArM,Completed,CESAR Central European Society for Anticancer Drug Research – EWIV,Non-Commercial,Austria,NA,2008-03-03
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",UK - MHRA,Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-02-22
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Ireland - HPRA,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-05
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Belgium - FPS Health-DGM,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-14
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Germany - PEI,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-25
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",France - ANSM,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-03-27
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Finland - Fimea,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-03-31
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Sweden - MPA,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-03
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E &#949;4 Carriers",Italy - Italian Medicines Agency,Prematurely Ended,"Wyeth Research Division, Wyeth Pharmeceuticals Inc.",Commercial,United States,NA,2008-04-22
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Portugal - INFARMED,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-04-24
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Austria - BASG,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-05-07
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Netherlands - Competent Authority,Prematurely Ended,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2008-06-02
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Denmark - DHMA,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2008-07-30
2007-005995-14,"Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes con enfermedad de Alzheimer de grado leve a moderado que son portadores de la apolipoproteína E (ApoE) e4",Spain - AEMPS,Prematurely Ended,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",Commercial,United States,NA,2010-03-08
2007-005995-14,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers",Slovakia - SIDC (Slovak),Completed,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA",Commercial,United States,"Wyeth, a Pfizer company",2010-04-15
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Sweden - MPA,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,NA,2008-05-21
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL Axitinib (AG 013736) como tratamiento de segunda línea del cáncer de células renales metastático: Ensayo Axis,Spain - AEMPS,Completed,"Pfizer, S.A.",Commercial,Spain,NA,2008-05-26
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Austria - BASG,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,NA,2008-06-23
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,France - ANSM,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,NA,2008-06-27
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,UK - MHRA,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",2008-06-27
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Ireland - HPRA,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,NA,2008-07-09
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Germany - BfArM,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017 US",Commercial,United States,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",2008-07-11
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Italy - Italian Medicines Agency,Completed,PFIZER INC.,Commercial,United States,Pfizer,2008-07-30
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Poland - Office for Medicinal Products,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",2008-09-08
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Greece - EOF,Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,NA,2009-02-27
2008-001451-21,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,Slovakia - SIDC (Slovak),Completed,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",Commercial,United States,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",2009-09-11
2006-005410-13,"EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).",Germany - BfArM,Prematurely Ended,University Hospital of Ulm,Non-Commercial,Germany,NA,2008-01-21
2005-004236-40,Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer,Germany - BfArM,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,Sanofi-Aventis Deutschland GmbH,2007-10-08
2007-000710-37,A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN),Germany - PEI,Completed,CSL Behring AG,Commercial,Switzerland,NA,2007-09-10
2007-000710-37,A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN),Italy - Italian Medicines Agency,Completed,CSL Behring AG,Commercial,Switzerland,NA,2008-02-12
2007-000710-37,A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN),UK - MHRA,Completed,CSL Behring AG,Commercial,Switzerland,NA,2008-02-15
2007-004225-26,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.",Germany - BfArM,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Incorporated,2008-06-26
2007-004225-26,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.",UK - MHRA,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Inc,2008-06-27
2007-004225-26,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.",Netherlands - Competent Authority,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2008-07-03
2007-004225-26,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.",Belgium - FPS Health-DGM,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2008-07-04
2007-004225-26,"Estudio doble ciego, con doble agente ficticio, multicéntrico, aleatorizado en fase 3 de la seguridad y la eficacia de elvitegravir reforzado con ritonavir (EVG/r) en comparación con raltegravir (RAL) cada uno administrado con un régimen de fondo en sujetos adultos infectados por VIH-1 que han recibido tratamiento antirretroviral.",Spain - AEMPS,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2008-07-04
2007-004225-26,"A multicenter, randomised, double-blind, double-dummy, phase III study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) each administered with a background regimen in HIV-1 infected, antiretroviral treatment-experienced adults.",Italy - Italian Medicines Agency,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2008-07-21
2007-004225-26,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.",Portugal - INFARMED,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2008-08-13
2007-004225-26,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults.",France - ANSM,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2008-08-21
2007-004746-33,"A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central nervous system (CNS)",Germany - BfArM,Completed,Bayer HealthCare Pharmaceuticals INC,Commercial,United States,NA,2008-04-21
2007-004746-33,"A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central nervous system (CNS)",Austria - BASG,Completed,Bayer HealthCare Pharmaceuticals INC,Commercial,United States,NA,2009-08-04
2007-001955-20,"A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTIRETROVIRAL ACTIVITY OF DERMAVIR (LC002) PATCH IN TREATMENT-NAÏVE HIV-1-INFECTED PATIENTS",Germany - PEI,Ongoing,Genetic Immunity Kft.,Commercial,Hungary,NA,2007-08-23
2007-006014-41,Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery Disease,Germany - BfArM,Prematurely Ended,"University Heidelberg, University Hospital Mannheim",Non-Commercial,Germany,NA,2008-02-07
2007-006014-41,Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery Disease,Netherlands - Competent Authority,Prematurely Ended,"University Heidelberg, University Hospital Mannheim",Non-Commercial,Germany,NA,2008-07-17
2007-006081-15,"A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects",Germany - PEI,Completed,Symphogen A/S,Commercial,Denmark,NA,2008-02-07
2007-006081-15,"A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects. ""Estudio abierto, multicéntrico, única dosis intravenosa, de búsqueda de dosis para determinar la seguridad y eficacia de Sym001 en el tratamiento de la púrpura trombocitopénica inmune (PTI) en pacientes no esplenectomizados y RhD positivos""",Spain - AEMPS,Ongoing,Symphogen A/S,Commercial,Denmark,NA,2008-03-04
2007-006081-15,"A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects",Belgium - FPS Health-DGM,Ongoing,Symphogen A/S,Commercial,Denmark,NA,2008-04-09
2007-006081-15,"A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects",UK - MHRA,Completed,Symphogen A/S,Commercial,Denmark,Symphogen AS,2010-08-26
2007-006516-31,"Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-Study)",Germany - BfArM,Completed,"University Hospital Freiburg, represented by the Executive Medical Director (LÄD)",Non-Commercial,Germany,NA,2008-03-17
2007-005116-12,"Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy New title since Protocol Version 4.0 Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy",Germany - BfArM,Prematurely Ended,Technical University of Munich,Non-Commercial,Germany,Novartis Pharma GmbH,2007-11-05
2007-003511-31,"Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity and Efficacy (following Helicobacter pylori infectious challenge) of Novartis’ Investigational H. pylori Vaccine in H. pylori-Negative Adults",Germany - PEI,Completed,Novartis Vaccines and Diagnostics GmbH & Co. KG,Commercial,Germany,NA,2008-04-04
2008-005448-18,An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma,Germany - PEI,Completed,"Morphotek, Inc.",Commercial,United States,"Morphotek, Inc.",2009-02-25
2008-005448-18,Ensayo clínico abierto de MORAb-009 en combinación con pemetrexed y cisplatino en pacientes con mesotelioma,Spain - AEMPS,Completed,"Morphotek, Inc.",Commercial,United States,NA,2009-02-26
2008-005448-18,An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma,Netherlands - Competent Authority,Completed,"Morphotek, Inc.",Commercial,United States,NA,2009-06-05
2007-007835-16,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",Austria - BASG,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-06-10
2007-007835-16,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",Germany - BfArM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-07-10
2007-007835-16,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",UK - MHRA,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-08-21
2007-007835-16,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",Portugal - INFARMED,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-08-22
2007-007835-16,"Evaluación clínica, controlada con placebo, doble ciego, aleatorizada de la eficacia, seguridad y tolerabilidad de Neramexano en pacientes con acúfenos subjetivos",Spain - AEMPS,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-08-22
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma,Germany - BfArM,Completed,Mundipharma Research Limited,Commercial,United Kingdom,NA,2008-08-21
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma,France - ANSM,Completed,Mundipharma Research Limited,Commercial,United Kingdom,NA,2008-08-22
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma,Austria - BASG,Prematurely Ended,Mundipharma Research Limited,Commercial,United Kingdom,NA,2008-10-13
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma,UK - MHRA,Prematurely Ended,Mundipharma Research Limited,Commercial,United Kingdom,NA,2008-10-13
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma,Netherlands - Competent Authority,Prematurely Ended,Mundipharma Research Limited,Commercial,United Kingdom,NA,2008-11-25
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkins Lymphoma,Italy - Italian Medicines Agency,Prematurely Ended,MUNDIPHARMA RESEARCH LIMITED,Commercial,United Kingdom,NA,2009-05-08
2008-002219-42,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s Lymphoma,Czech Republic - SUKL,Prematurely Ended,Mundipharma Research Limited,Commercial,United Kingdom,NA,2009-11-13
2005-002618-40,"HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymomas in children and adolescents Parts of the study:P-HIT-REZ 2005 - a non-randomised trial for the treatment of relapsed PNETs, E-HIT-REZ 2005: Phase II study: oral therapy with temozolomide - a nonrandomised trial for the treatment of relapsed ependymomas, Phase II study - intraventricular therapy with etoposide in neoplastic meningitis",Germany - BfArM,Completed,"Rheinische Friedrich-Wilhelms-University of Bonn, University Hospital",Non-Commercial,Germany,German Children's Cancer Foundation,2006-01-09
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",UK - MHRA,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-05-16
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Germany - BfArM,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-05-20
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",France - ANSM,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-05-26
2008-000679-90,"Estudio en Fase III, aleatorizado, doble ciego, multicéntrico, de grupos paralelos, controlado con placebo y con fármaco activo sobre la seguridad y eficacia de la optimización de dosis de Lisdexanfetamina Dimesilato (LDX) en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con Hiperactividad (TDAH).",Spain - AEMPS,Completed,Shire Pharmaceutical Development Limited,Non-Commercial,United Kingdom,NA,2008-05-29
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Netherlands - Competent Authority,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-06-13
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Sweden - MPA,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-06-18
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Belgium - FPS Health-DGM,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-06-18
2008-000679-90,"A phase III, randomized, double blind, multicenter, parallel group, placebo and active controlled, dose optimization safety and efficacy study of Lisdexamfetamine Dimesylate (LDX) in children and adolescent aged 6-17 with attention-deficit/hyperactivity disorder (ADHD)",Italy - Italian Medicines Agency,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2009-03-20
2008-000679-90,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Hungary - National Institute of Pharmacy,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2009-11-04
2008-002263-13,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use",Austria - BASG,Completed,Bayer HealthCare AG,Commercial,Germany,NA,2008-10-21
2008-002263-13,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use",Germany - BfArM,Completed,Bayer HealthCare AG,Commercial,Germany,NA,2008-10-27
2008-002263-13,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use",Belgium - FPS Health-DGM,Completed,Bayer HealthCare AG,Commercial,Germany,NA,2008-11-12
2008-002263-13,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use",Spain - AEMPS,Completed,Bayer HealthCare AG,Commercial,Germany,NA,2008-11-27
2008-002263-13,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest, SH T00658ID, compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use .",Italy - Italian Medicines Agency,Completed,BAYER HEALTHCARE AG,Commercial,Germany,NA,2009-01-20
2006-006532-21,Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6),Belgium - FPS Health-DGM,Completed,EORTC,Non-Commercial,Belgium,Roche,2008-04-23
2006-006532-21,Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6),UK - MHRA,Completed,European Organization for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2008-04-25
2006-006532-21,Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6),France - ANSM,Completed,EORTC,Non-Commercial,Belgium,NA,2008-05-05
2006-006532-21,Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6),Germany - BfArM,Completed,EORTC,Non-Commercial,Belgium,Universitätsklinikum Halle/Saale,2008-11-17
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,Germany - PEI,Completed,"Charité-Universitätsmedizin Berlin, Germany",Non-Commercial,Germany,NA,2007-01-05
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III-IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease.,Sweden - MPA,Ongoing,Charite-Universitätsmedizin Berlin Germany,Non-Commercial,Germany,NA,2007-04-13
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,Austria - BASG,Completed,"Charité-Universitätsmedizin Berlin, Germany",Non-Commercial,Germany,NA,2007-04-25
2005-005434-12,"Randomized, multicenter cross-over study investigating the effect of bicarbonate-based solutions (Physioneal 35 vs. 40) on protein metabolism in children and adolescents on chronic peritoneal dialysis",Germany - BfArM,Prematurely Ended,Universitaetsklinikum Erlangen,Non-Commercial,Germany,NA,2008-05-28
2007-004884-24,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA),France - ANSM,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,NA,2008-06-20
2007-004884-24,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA),Austria - BASG,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,MEDA Pharma GmbH & Co. KG,2008-06-24
2007-004884-24,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA),Germany - BfArM,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,MEDA Pharma GmbH & Co. KG,2008-06-26
2008-001686-28,Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,Germany - BfArM,Prematurely Ended,Universität Wuerzburg,Non-Commercial,Germany,NA,2008-04-02
2008-001686-28,Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,Austria - BASG,Prematurely Ended,Universität Wuerzburg,Non-Commercial,Germany,NA,2010-10-13
2008-001265-28,"“Estudio abierto de extensión con P144 para la ampliación del tratamiento tópico de la fibrosis cutánea de pacientes con esclerosis sistémica previamente tratados en el ensayo ISD002-P144-07""",Spain - AEMPS,Ongoing,ISDIN,Commercial,Spain,NA,2008-04-08
2008-001265-28,OFFENE (UNVERBLINDETE) VERLÄNGERUNGSTUDIE FÜR PATIENTEN AUS DER ISD002-P144-07 STUDIE MIT TOPISCH AUFGETRAGENEM P144 AUF HAUTFIBROSEN BEI PATIENTEN MIT SYSTEMISCHER SKLEROSE,Germany - BfArM,Completed,ISDIN,Commercial,Spain,NA,2008-05-19
2008-001265-28,Open Label Extension (OLE) for the patients treated in the ISD002-P144-07 study with P144 topical administration for skin fibrosis in patients with systemic sclerosis.,Hungary - National Institute of Pharmacy,Prematurely Ended,ISDIN,Commercial,Spain,NA,2008-08-05
2008-001265-28, Open Label Extension (OLE) for the patients treated in the ISD002-P144-07 study with P144 topical administration for skin fibrosis in patients with systemic sclerosis,UK - MHRA,Completed,ISDIN,Commercial,Spain,NA,2008-08-19
2008-001265-28,Open Label Extension (OLE) for the patients treated in the ISD002-P144-07 study with P144 topical administration for skin fibrosis in patients with systemic sclerosis,Italy - Italian Medicines Agency,Completed,ISDIN S.A.,Commercial,Spain,NA,2009-12-07
2008-000720-10,"A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Germany - BfArM,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-05-19
2008-000720-10,"A Phase III, Open-Label, Extension, Multicentre, Safety Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",France - ANSM,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-05-23
2008-000720-10,"A Phase III, Open-Label, Extension, Multicentre, Safety Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Netherlands - Competent Authority,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-06-13
2008-000720-10,"A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Sweden - MPA,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-06-18
2008-000720-10,"A Phase III, Double-Blind, Placebo-Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Belgium - FPS Health-DGM,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2008-06-18
2008-000720-10,"A Phase III, Double-Blind, Placebo-Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",UK - MHRA,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2008-06-30
2008-000720-10,"A phase III, open label, extension, multicenter, safety study of Lisdexanfetamine Dimesilate (LDX)in children and adolescent aged 6-17 with attention-deficit/hyperactivity disorder (ADHD)",Italy - Italian Medicines Agency,Completed,Shire UK,Commercial,United Kingdom,NA,2009-03-20
2008-000720-10,"A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)",Hungary - National Institute of Pharmacy,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,NA,2009-11-04
2008-005306-39,Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification,Germany - BfArM,Prematurely Ended,"RWTH Aachen University, represented by the rector, himself represented by Clinical Trial Center Aachen (CTC-A)",Non-Commercial,Germany,RWTH Aachen University,2008-11-19
2007-005666-12,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapy",Germany - PEI,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-12-07
2007-005666-12,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapy",Hungary - National Institute of Pharmacy,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-01-07
2007-005666-12,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapy",Belgium - FPS Health-DGM,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-01-18
2007-005666-12,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapy",UK - MHRA,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-02-07
2007-005666-12,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapy",Latvia - SAM,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-04-02
2007-005666-12,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapy",Bulgarian Drug Agency,Prematurely Ended,immatics biotechnologies GmbH,Commercial,Germany,NA,2009-04-13
2007-005365-35,"Multicentric, parallel, controlled, randomized, single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with continous ambulatory or automated peritoneal dialysis.",Sweden - MPA,Completed,Fresenius Medical Care Deutschland GmbH,Commercial,Germany,Fresenius Medical Care Deutschland GmbH,2008-05-22
2007-005365-35,"Multicenter, parallel, controlled, randomized, single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or automated peritoneal dialysis.",Germany - BfArM,Completed,Fresenius Medical Care Deutschland GmbH,Commercial,Germany,NA,2008-08-06
2007-005365-35,"Multicenter, parallel, controlled, randomized, single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with continous ambulatory or automated peritoneal dialysis.",France - ANSM,Completed,Gambro Lundia AB,Commercial,France,NA,2008-08-21
2007-005365-35,"Multicentric, parallel, controlled, randomized, single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with continous ambulatory or automated peritoneal dialysis.",Denmark - DHMA,Completed,Fresenius Medical Care Deutschland GmbH,Commercial,Germany,Fresenius Medical Care Deutschland GmbH,2009-10-27
2007-005365-35,"Multicenter, parallel, controlled, randimized, single-blind clinical evaluation of new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or automated peritoneal dialysis",UK - MHRA,Completed,Fresenius Medcial Care Deutschland GmbH,Commercial,Germany,NA,2012-05-15
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,Germany - BfArM,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2009-01-05
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,Netherlands - Competent Authority,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2009-01-29
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,Spain - AEMPS,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2009-02-20
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,France - ANSM,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2009-03-17
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome.,Italy - Italian Medicines Agency,Completed,NPS PHARMACEUTICALS,Commercial,United Kingdom,NA,2009-04-15
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,UK - MHRA,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2009-05-22
2008-006193-15,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,Denmark - DHMA,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2009-05-26
2008-003931-19,"An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Netherlands - Competent Authority,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-07-17
2008-003931-19,"An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",France - ANSM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-07-25
2008-003931-19,"Ensayo abierto, multicéntrico y no controlado para investigar la pauta de administración de degarelix una vez al mes como privación intermitente de andrógenos durante un ciclo de tratamiento en pacientes con cáncer de próstata que requieren tratamiento de privación androgénica.",Spain - AEMPS,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-09-18
2008-003931-19,"An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Belgium - FPS Health-DGM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,Ferring Pharmaceuticals A/S,2008-10-03
2008-003931-19,"An open-label, multi-centre, uncontrolled, trial investigating Degarelix one-month dosing regimenadministered as Intermittent Androgen Deprivation (IAD) for one cycle in patients with prostate cancer requiring androgen deprivation therapy.",Italy - Italian Medicines Agency,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-11-26
2008-000132-40,"Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study",Germany - BfArM,Completed,Auris Medical AG,Commercial,Switzerland,NA,2008-09-22
2008-000132-40,"Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study",Czech Republic - SUKL,Completed,Auris Medical AG,Commercial,Switzerland,NA,2010-12-30
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,Sweden - MPA,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2008-12-17
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,Netherlands - Competent Authority,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2009-02-05
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,Belgium - FPS Health-DGM,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2009-02-20
2008-003924-52,Estudio de fase 3 sobre la eficacia y la seguridad de PTC124 como tratamiento oral para la fibrosis quística mediada por mutación terminadora,Spain - AEMPS,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2009-03-09
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,France - ANSM,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2009-03-17
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,UK - MHRA,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2009-04-09
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,Italy - Italian Medicines Agency,Completed,"PTC THERAPEUTICS, INC.",Commercial,United States,NA,2009-06-22
2008-003924-52,A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,Germany - BfArM,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2009-07-10
2008-005144-16,"Open-label, single-arm, multi-center validation study of the ROSA-Scale (Relevant Outcome Scale for Alzheimer Patients) in patients with dementia of Alzheimer’s type (DAT) treated with memantine over a 3 months period",Germany - BfArM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-10-20
2008-005144-16,"Open-label, single-arm, multi-center validation study of the ROSA-Scale (Relevant Outcome Scale for Alzheimer Patients) in patients with dementia of Alzheimer’s type (DAT) treated with memantine over a 3 months period",Austria - BASG,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-11-17
2008-001515-37,"A prospective angiogenic imaging study with DCE-MRI and DCE-USI in patients with colorectal cancer and liver metastases receiving sunitinib in addition to 5-FU, folinic acid and irinotecan (FOLFIRI) as 1st line therapy",Germany - BfArM,Completed,CESAR Central European Society for Anticancer Drug Research,Non-Commercial,Austria,NA,2008-11-12
2008-005903-25,"Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)",Germany - BfArM,Completed,4SC AG,Commercial,Germany,NA,2008-11-03
2008-005903-25,"Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)",Bulgarian Drug Agency,Completed,4SC AG,Commercial,Germany,NA,2010-04-14
2007-005916-15,"Low dose Urokinase therapy by patients with diabetic foot syndrom and critical limb ischemia versus conventionel standard therapy. A randomised, open, controlled Phase III-study.",Germany - BfArM,Prematurely Ended,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,NA,2008-02-11
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",Czech Republic - SUKL,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-08-13
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",Austria - BASG,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-09-10
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",Netherlands - Competent Authority,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-10-03
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",Germany - BfArM,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-10-14
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",UK - MHRA,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-10-14
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",Belgium - FPS Health-DGM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-10-30
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",France - ANSM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-10-31
2008-001432-13,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",Portugal - INFARMED,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2008-11-25
2008-001432-13,"Estudio abierto de tratamiento a largo plazo para evaluar la seguridad, la tolerabilidad y la eficacia a largo plazo de neramexano en pacientes con acúfenos subjetivos",Spain - AEMPS,Prematurely Ended,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2009-01-19
2008-006130-95,"Estudio abierto, prospectivo, de tres años de duración para evaluar la eficacia, la seguridad y la tolerabilidad clínicas de la atorvastatina en niños y adolescentes con hipercolesterolemia familiar heterocigótica ""A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA""",Spain - AEMPS,Completed,PFIZER,Commercial,Spain,NA,2009-02-18
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",Hungary - National Institute of Pharmacy,Completed,Pfizer Inc,Commercial,United States,NA,2009-03-02
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",Belgium - FPS Health-DGM,Completed,Pfizer Inc,Commercial,United States,NA,2009-03-04
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",Italy - Italian Medicines Agency,Completed,Pfizer Inc,Commercial,United States,NA,2009-08-11
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",Germany - BfArM,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA",Commercial,United States,Pfizer Inc,2009-09-15
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",Greece - EOF,Completed,Pfizer Inc,Commercial,United States,NA,2009-10-20
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",Slovakia - SIDC (Slovak),Completed,Pfizer Inc,Commercial,United States,NA,2010-02-10
2008-006130-95,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",NA,NA,Pfizer Inc,Commercial,United States,Pfizer Inc,2012-02-20
2008-004338-26,"Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la escala internacional de síntomas prostáticos (IPSS) en pacientes con síntomas del tracto urinario inferior (LUTS) asociados a cáncer de próstata localmente avanzado",Spain - AEMPS,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-09-18
2008-004338-26,"A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS), in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer",UK - MHRA,Prematurely Ended,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-10-03
2008-004338-26,"A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS), in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer",Germany - BfArM,Prematurely Ended,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-11-12
2007-004333-42,"Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (open) on the survival of patients with severe sepsis and septic shock.",Germany - BfArM,Completed,Friedrich-Schiller-University of Jena,Non-Commercial,Germany,biosyn Arzneimittel GmbH,2008-03-07
2006-003563-31,"Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM).",Denmark - DHMA,Ongoing,European Myeloma Network,Non-Commercial,Netherlands,NA,2007-02-28
2006-003563-31,"Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM).",Netherlands - Competent Authority,Ongoing,European Myeloma Network,Non-Commercial,Netherlands,NA,2007-05-10
2006-003563-31,"Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia)",Spain - AEMPS,Ongoing,Red Europea de Mieloma (European Myeloma Network),Non-Commercial,Netherlands,NA,2008-03-07
2006-003563-31,"Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network",France - ANSM,Ongoing,Centre Hospitalier de Lens,Non-Commercial,France,NA,2008-10-21
2006-003563-31,"Phase II Study of combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstroms Macroglobulinemia: A multicenter Trial of the European Myeloma Network",Italy - Italian Medicines Agency,Ongoing,E.M.N. - EUROPEAN MYELOMA NETWORK,Non-Commercial,Denmark,NA,2009-05-14
2008-005232-33,"A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)",Netherlands - Competent Authority,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-11-04
2008-005232-33,"A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)",Germany - BfArM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-11-25
2008-005232-33,"A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)",France - ANSM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-12-10
2008-005232-33,"Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción del tamaño de próstata en pacientes con cáncer de próstata de grado intermedio-alto, que requieren terapia hormonal neoadyuvante previa a radioterapia con intención curativa.",Spain - AEMPS,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2008-12-15
2008-005232-33,"A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)",UK - MHRA,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-01-20
2008-005232-33,"A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)",Greece - EOF,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-11-05
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Portugal - INFARMED,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-07-09
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Sweden - MPA,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-07-16
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Spain - AEMPS,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2008-10-17
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Austria - BASG,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-11-12
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis",Italy - Italian Medicines Agency,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-11-17
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Hungary - National Institute of Pharmacy,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-12-10
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Germany - BfArM,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2008-12-23
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",Greece - EOF,Prematurely Ended,Genzyme Europe BV,Commercial,Netherlands,NA,2009-02-18
2007-003885-16,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis",France - ANSM,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2009-03-16
2008-007786-23,ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO,Spain - AEMPS,Completed,"Pfizer, S.A.",Commercial,Spain,NA,2009-02-17
2008-007786-23,"RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA",Czech Republic - SUKL,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,NA,2009-03-02
2008-007786-23,"RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA",Germany - BfArM,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US",Commercial,United States,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US",2009-03-04
2008-000689-21,"Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant Population",UK - MHRA,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2008-06-17
2008-000689-21,"Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant Population",Germany - BfArM,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2008-07-10
2008-000689-21,"Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant Population",Sweden - MPA,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2008-08-01
2008-000689-21,"Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant Population",Netherlands - Competent Authority,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2008-08-13
2008-000689-21,"Plerixafor y G-SCF para la movilización de células madre de sangre periférica para el trasplante autólogo de células madre en pacientes con linfoma no Hodgkin (LNH), enfermedad de Hodgkin (EH) o mieloma múltiple (MM). Estudio de la seguridad del trasplante autólogo en la población general.",Spain - AEMPS,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2009-01-19
2008-000689-21,"Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkins Lymphoma (NHL), Hodgkins Disease (HD) or Multiple Myeloma (MM)  Safety Study in a General Autologous Transplant Population",Italy - Italian Medicines Agency,Completed,Genzyme Europe BV,Commercial,Netherlands,NA,2009-03-16
2006-005911-82,"A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with clinically relevant grass pollen sensitivity in comparison to a symptomatic standard treatment with add on placebo",Germany - PEI,Completed,Allergopharma GmbH & Co. KG,Commercial,Germany,Allergopharma GmbH & Co. KG,2006-12-21
2006-005911-82,"A multicenter, randomised, controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with clinically relevant grass pollen sensitivity in comparison to a symptomatic standard treatment with add on placebo",Poland - Office for Medicinal Products,Completed,Allergopharma Joachim Ganzer KG,Commercial,Germany,NA,2009-02-24
2008-004605-34,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic hepatitis C genotype 1 patients",Germany - BfArM,Completed,Debiopharm S.A.,Commercial,Switzerland,NA,2008-08-22
2008-004605-34,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic hepatitis C genotype 1 patients",France - ANSM,Completed,Debiopharm S.A.,Commercial,Switzerland,NA,2008-08-22
2008-004605-34,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic hepatitis C genotype 1 patients",Belgium - FPS Health-DGM,Completed,Debiopharm S.A.,Commercial,Switzerland,NA,2008-08-26
2008-004605-34,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic hepatitis C genotype 1 patients",Spain - AEMPS,Completed,Debiopharm S.A.,Commercial,Switzerland,NA,2008-09-24
2008-004605-34,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic hepatitis C genotype 1 patients",Poland - Office for Medicinal Products,Completed,Debiopharm S.A.,Commercial,Switzerland,NA,2008-10-06
2008-004605-34,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFN&#945;2a and ribavirin in treatment naïve chronic hepatitis C genotype 1 patients",Italy - Italian Medicines Agency,Completed,DEBIOPHARM S.A.,Commercial,Switzerland,NA,2008-10-10
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Denmark - DHMA,Completed,Spectrum Pharmaceuticals Inc.,Commercial,United States,Spectrum Pharmaceuticals Inc.,2008-10-07
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",France - ANSM,Completed,Topotarget A/S,Commercial,Denmark,NA,2008-11-14
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Italy - Italian Medicines Agency,Completed,TOPOTARGET A/S,Commercial,Denmark,NA,2008-12-24
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Netherlands - Competent Authority,Completed,Spectrum Pharmaceuticals Inc.,Commercial,United States,Spectrum Pharmaceuticals Inc.,2009-01-27
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Belgium - FPS Health-DGM,Completed,Spectrum Pharmaceuticals Inc.,Commercial,United States,NA,2009-02-02
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Germany - BfArM,Completed,Spectrum Pharmaceuticals Inc.,Commercial,United States,Spectrum Pharmaceuticals Inc.,2009-04-24
2008-005843-40,Estudio multicéntrico y abierto con Belinostat en pacientes con linfoma de células T periféricas (PTCL) reincidente o refractario.,Spain - AEMPS,Completed,Topotarget A/S,Commercial,Denmark,NA,2009-06-02
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Hungary - National Institute of Pharmacy,Completed,SPECTRUM Pharmaceuticals Inc.,Commercial,United States,Spectrum Pharmaceuticals Inc.,2009-07-30
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Slovakia - SIDC (Slovak),Completed,TopoTarget A/S,Commercial,Denmark,NA,2009-09-10
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",Poland - Office for Medicinal Products,Completed,"Spectrum Pharmaceuticals, Inc.",Commercial,United States,"Spectrum Pharmaceuticals, Inc",2010-03-03
2008-005843-40,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",UK - MHRA,Completed,Spectrum Pharmaceuticals Inc.,Commercial,United States,Spectrum Pharmaceuticals Inc.,2010-07-27
2008-001849-26,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus.",Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-07-29
2008-007320-25,"Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole",Germany - BfArM,Completed,TROPHOS SA,Commercial,France,NA,2009-02-18
2008-007320-25,"Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole",France - ANSM,Completed,TROPHOS SA,Commercial,France,NA,2009-03-16
2008-007320-25,"Phase II/III, multicenter, randomized, parallel group, double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole.",UK - MHRA,Completed,TROPHOS,Commercial,"France, Metropolitan",NA,2009-04-14
2008-007320-25,"Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole",Belgium - FPS Health-DGM,Completed,TROPHOS SA,Commercial,France,NA,2009-04-28
2008-007320-25,"Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole",Spain - AEMPS,Completed,TROPHOS SA,Commercial,France,NA,2009-07-16
2008-001371-30,Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia,Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2008-12-15
2008-006845-13,"Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit.",Denmark - DHMA,Completed,"McNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)",Commercial,Sweden,NA,2008-11-24
2008-006845-13,"Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit.",Germany - BfArM,Completed,"McNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)",Commercial,Sweden,NA,2008-11-28
2005-000771-18,"Prospective, doubleblind, randomized multicenter study to proof the clinical and bacteriological non-inferiority of amoxicillin versus moxifloxacin in hospitalized patients with non-severe community-acquired pneumonia",Germany - BfArM,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,NA,2006-05-17
2008-003174-18,"Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP)",Germany - PEI,Completed,Universitätsklinikum Heidelberg,Non-Commercial,Germany,NA,2008-12-09
2008-001361-29,Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation,France - ANSM,Completed,EBMT (European group for Blood and Marrow Transplantation),Non-Commercial,United Kingdom,NA,2009-06-09
2008-001361-29,Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation,UK - MHRA,Prematurely Ended,EBMT (European group for Blood and Marrow Transplantation),Non-Commercial,United Kingdom,NA,2009-06-11
2008-001361-29,Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation,Germany - BfArM,Completed,EBMT (European group for Blood and Marrow Transplantation),Non-Commercial,United Kingdom,NA,2009-08-20
2007-007869-21,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis",Lithuania - SMCA,Completed,Stallergenes S.A.,Commercial,France,NA,2008-06-19
2007-007869-21,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis",Germany - PEI,Completed,Stallergenes S.A.,Commercial,France,NA,2008-07-07
2007-007869-21,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis",France - ANSM,Completed,Stallergenes S.A.,Commercial,France,NA,2008-07-10
2007-007869-21,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis",Sweden - MPA,Completed,Stallergenes S.A.,Commercial,France,NA,2008-07-11
2007-007869-21,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis",Finland - Fimea,Completed,Stallergenes S.A.,Commercial,France,NA,2008-07-18
2007-007869-21,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis",Denmark - DHMA,Completed,Stallergenes S.A.,Commercial,France,NA,2008-08-12
2008-005085-30,Einfluss von Rasagilin auf das Riechvermögen von Patienten mit idiopathischem Parkinson-Syndrom (Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline),Germany - BfArM,Prematurely Ended,Technische Universität Dresden,Non-Commercial,Germany,TEVA Pharma GmbH,2009-03-04
2009-012820-97,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",UK - MHRA,Completed,"Astellas Pharma Global Development, Inc.",Commercial,United States,"Astellas Pharma Global Development, Inc.",2009-09-04
2009-012820-97,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",Germany - BfArM,Completed,"Astellas Pharma Global Development, Inc.",Commercial,United States,"Astellas Pharma Global Development, Inc.",2009-09-17
2009-012820-97,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",France - ANSM,Completed,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2009-09-22
2009-012820-97,"A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",Italy - Italian Medicines Agency,Completed,OSI PHARMACEUTICALS INC,Commercial,United Kingdom,NA,2010-03-23
2009-012820-97,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",Netherlands - Competent Authority,Completed,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2010-08-20
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",UK - MHRA,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,"Amicus Therapeutics, Inc.",2009-09-11
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",France - ANSM,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,NA,2009-10-01
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",Germany - BfArM,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,NA,2009-11-03
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",Netherlands - Competent Authority,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,NA,2009-11-20
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",Belgium - FPS Health-DGM,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,NA,2009-12-16
2009-013459-31,"ESTUDIO DOBLE CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA FARMACODINAMIA DE AT1001 EN PACIENTES CON ENFERMEDAD DE FABRY Y MUTACIONES EN GLA SENSIBLES A AT1001. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS.",Spain - AEMPS,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,NA,2009-12-22
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",Italy - Italian Medicines Agency,Completed,"AMICUS THERAPEUTICS, INC",Commercial,United States,NA,2010-01-15
2009-013459-31,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",Denmark - DHMA,Completed,"Amicus Therapeutics, Inc.",Commercial,United States,"Amicus Therapeutics, Inc.",2010-01-27
2006-007090-72,The role of the glutamatergic system in the extinction of conditioned reinforcement processes,Germany - BfArM,Ongoing,Central Institute of Mental Health,Non-Commercial,Germany,NA,2007-07-16
2008-002090-12,Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on perioperative morbidity and outcome in high risk cardiac surgical patients,Germany - BfArM,Completed,Hospital of the university of munich,Non-Commercial,Germany,Bayer Schering Pharma,2008-11-12
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Belgium - FPS Health-DGM,Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2009-02-13
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Germany - BfArM,Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2009-02-18
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Austria - BASG,Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2009-02-23
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Czech Republic - SUKL,Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2009-03-16
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Spain - AEMPS,Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2009-05-05
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Sweden - MPA,Prematurely Ended,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2009-05-08
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Poland - Office for Medicinal Products,Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2010-05-27
2008-006444-19,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",Slovakia - SIDC (Slovak),Completed,SYGNIS Bioscience GmbH & Co. KG,Commercial,Germany,NA,2010-10-28
2009-011679-65,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",Germany - BfArM,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NPS Pharmaceuticals,2009-12-23
2009-011679-65,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",Spain - AEMPS,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2010-02-19
2009-011679-65,"A Long Term, Open Labeled Study with Teduglutide for Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome who completed Study Cl0600020",Italy - Italian Medicines Agency,Completed,NPS PHARMACEUTICALS,Commercial,United Kingdom,NA,2010-03-11
2009-011679-65,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",UK - MHRA,Completed,NPS Pharmaceuticals,Commercial,United States,NPS Pharmaceuticals,2010-03-15
2009-011679-65,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",Denmark - DHMA,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2010-03-29
2009-011679-65,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",France - ANSM,Completed,"NPS Pharmaceuticals, Inc.",Commercial,United States,NA,2010-06-14
2008-005536-32,Phase II double-blind placebo-controlled trial of CY-503 in patients with chemotherapy-refractory metastatic colorectal cancer,Germany - BfArM,Prematurely Ended,Cytavis Biopharma GmbH,Commercial,Germany,NA,2008-12-29
2008-005536-32,Phase II double-blind placebo-controlled trial of CY-503 in patients with chemotherapy-refractory metastatic colorectal cancer,Austria - BASG,Prematurely Ended,Cytavis Biopharma GmbH,Commercial,Germany,NA,2010-06-17
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",UK - MHRA,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2009-10-20
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Netherlands - Competent Authority,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2009-10-22
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Germany - BfArM,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017 US",Commercial,United States,Pfizer Inc,2009-11-02
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Poland - Office for Medicinal Products,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2009-11-16
2009-012595-27,"Estudio en fase 3, aleatorizado y abierto, de la eficacia y seguridad de PF-02341066 frente a quimioterapia estándar (pemetrexed o docetaxel) en pacientes con cáncer de pulmón no microcítico (NSCLC) avanzado que presentan una translocación o inversión en el locus del gen de la quinasa de linfoma anaplásico (ALK)",Spain - AEMPS,Completed,"Pfizer, S.A.",Commercial,Spain,NA,2009-11-17
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Hungary - National Institute of Pharmacy,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2009-11-19
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",France - ANSM,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2009-12-08
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Greece - EOF,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2009-12-14
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Italy - Italian Medicines Agency,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2009-12-23
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Ireland - HPRA,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-01-13
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Bulgarian Drug Agency,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2010-02-23
2009-012595-27,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Sweden - MPA,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-09-03
2007-004309-90,Fahrtüchtigkeit bei Erwachsenen mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) vor und nach 10wöchiger Behandlung mit 40-80 mg Atomoxetin im Vgl. zu unbehandelten Erwachsenen mit ADHS,Germany - BfArM,Ongoing,Zentralinstitut für Seelische Gesundheit Mannheim,Non-Commercial,Germany,NA,2007-08-03
2008-006871-60,"Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",Germany - BfArM,Completed,"University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg",Non-Commercial,Germany,NA,2009-03-02
2008-006871-60,"Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",Austria - BASG,Completed,"University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg",Non-Commercial,Germany,NA,2009-03-31
2009-011277-33,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,Germany - BfArM,Completed,Charité - University Hospital of Berlin,Non-Commercial,Germany,NA,2009-05-26
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Hungary - National Institute of Pharmacy,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-05-27
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Netherlands - Competent Authority,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-06-11
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Germany - BfArM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-06-12
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Finland - Fimea,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-06-15
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Czech Republic - SUKL,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-06-17
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",UK - MHRA,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-06-18
2008-005276-27,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy",Belgium - FPS Health-DGM,Completed,Ferring Pharmaceuticals A/S,Commercial,Denmark,NA,2009-06-25
2007-007794-23,"Prospektive, doppelblinde, randomisierte, Plazebo-kontrollierte Cross-over Studie zur Wirkung von intravenösen Immunglobulinen bei komplex-regionalem Schmerzsyndrom Typ I (M. Sudeck)",Germany - PEI,Prematurely Ended,Justus-Liebig-University,Non-Commercial,Germany,NA,2009-01-23
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",France - ANSM,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,NA,2009-04-15
2008-007326-19,"Estudio de fase III, randomizado, abierto, para comparar la farmacocinética, eficacia y seguridad de trastuzumab por vía subcutánea (SC) con trastuzumab por vía intravenosa (IV) administrado a mujeres con cáncer de mama precoz (CMP) HER2 positivo.",Spain - AEMPS,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,NA,2009-04-20
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",Czech Republic - SUKL,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,F. Hoffmann-La Roche Ltd,2009-06-16
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",Estonia - SAM,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,F. Hoffmann-La Roche Ltd,2009-06-30
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",Germany - PEI,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,F. Hoffmann-La Roche Ltd,2009-07-23
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",UK - MHRA,Prematurely Ended,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,NA,2009-09-17
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",Sweden - MPA,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,F. Hoffmann-La Roche Ltd,2009-10-19
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC)",Italy - Italian Medicines Agency,Completed,F. Hoffmann - La Roche Ltd,Commercial,Switzerland,NA,2009-12-14
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",Slovakia - SIDC (Slovak),Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,NA,2010-05-18
2008-007326-19,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).",Hungary - National Institute of Pharmacy,Completed,F. Hoffmann-La Roche Ltd,Commercial,Switzerland,F. Hoffmann-La Roche Ltd,2011-01-14
2008-001770-33,"INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME",Germany - BfArM,Completed,"Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC",Non-Commercial,Germany,NA,2008-04-22
2007-006016-33,Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia,Germany - PEI,Prematurely Ended,Uniklinikum Tuebingen,Non-Commercial,Germany,NA,2008-03-12
2008-008198-73,"An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor.",Germany - PEI,Completed,Kiadis Pharma Netherlands B.V.,Commercial,Netherlands,PHARMACELL BV,2009-02-12
2008-008198-73,"An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor.",UK - MHRA,Prematurely Ended,Kiadis Pharma Netherlands B.V.,Commercial,Netherlands,PHARMACELL BV,2009-04-14
2008-008198-73,"An open label, uncontrolled, multicentre, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in atients receiving a CD34-selected peripheral blood stem cell graft from a related, halpoidentical donor.",Netherlands - Competent Authority,Prematurely Ended,Kiadis Pharma Netherlands B.V.,Commercial,Netherlands,NA,2009-07-01
2008-008198-73,"An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor.",Belgium - FPS Health-DGM,Prematurely Ended,Kiadis Pharma Netherlands B.V.,Commercial,Netherlands,PHARMACELL BV,2009-07-02
2008-007974-39,"Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimidine and bevacizumab vs. bevacizumab alone vs. no maintenance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer",Germany - PEI,Completed,AIO-Studien-gGmbH,Non-Commercial,Germany,NA,2009-03-26
2008-004675-22,Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD,Germany - PEI,Completed,University of Bonn,Non-Commercial,Germany,NA,2008-09-03
2009-010143-13,Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma,Germany - BfArM,Prematurely Ended,CESAR Central European Society for Anticancer Drug Research-EWIV,Non-Commercial,Austria,NA,2009-04-15
2008-006300-27,Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -,Netherlands - Competent Authority,Completed,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,NA,2009-02-17
2008-006300-27,Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -,Germany - BfArM,Completed,medac Gesellschaft für klinische Spezialpräparate mbH,Commercial,Germany,NA,2009-04-01
2009-010428-25,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability.",Czech Republic - SUKL,Completed,Grünenthal GmbH,Commercial,Germany,NA,2009-06-04
2009-010428-25,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability.",Netherlands - Competent Authority,Completed,Grünenthal GmbH,Commercial,Germany,NA,2009-06-18
2009-010428-25,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability.",Germany - BfArM,Completed,Grünenthal GmbH,Commercial,Germany,NA,2009-06-19
2009-010428-25,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability.",France - ANSM,Completed,Grünenthal GmbH,Commercial,Germany,NA,2009-07-02
2009-010428-25,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability.",Belgium - FPS Health-DGM,Completed,Grünenthal GmbH,Commercial,Germany,NA,2009-07-07
2009-010428-25,"Evaluación de la efectividad y la tolerabilidad de clorhidrato de tapentadol de liberación prolongada y de clorhidrato de tapentadol de liberación inmediata a demanda en pacientes con lumbalgia crónica severa de origen nociceptivo, neuropático o mixto en tratamiento con analgésicos del escalón III de la clasificación de la OMS y que presentan problemas de tolerabilidad",Spain - AEMPS,Completed,Grünenthal GmbH,Commercial,Germany,NA,2009-07-29
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Belgium - FPS Health-DGM,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-09-17
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Hungary - National Institute of Pharmacy,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-09-22
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Czech Republic - SUKL,Prematurely Ended,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-10-02
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Germany - BfArM,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-10-08
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,UK - MHRA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-10-19
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Austria - BASG,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-11-04
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Netherlands - Competent Authority,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-11-19
2008-007969-23,A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer (CRPC),Italy - Italian Medicines Agency,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2009-12-14
2008-007969-23,Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC). A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Spain - AEMPS,Completed,Celgene Corporation,Commercial,United States,NA,2010-01-14
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Denmark - DHMA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2010-02-01
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Sweden - MPA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2010-02-25
2008-007969-23,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,Greece - EOF,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2010-10-04
2009-014365-12,"Evaluación prospectiva en régimen abierto de la farmacocinética, la farmacodinamia y la seguridad de oseltamivir (Tamiflu®) en el tratamiento de lactantes de menos de 12 meses con infección gripal confirmada. An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants up to 12 months of age with laboratory confirmed influenza infection",Spain - AEMPS,Completed,F.Hoffmann-La Roche Ltd.,Commercial,Switzerland,NA,2009-10-14
2009-014365-12,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu®) in the treatment of infants 0 to <12 months of age with confirmed influenza infection",France - ANSM,Completed,F.Hoffmann-La Roche,Commercial,Switzerland,NA,2009-10-15
2009-014365-12,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with laboratory confirmed influenza infection",Germany - BfArM,Completed,F.Hoffmann-La Roche,Commercial,Switzerland,NA,2009-10-20
2009-014365-12,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to <12 months of age with laboratory confirmed influenza infection",UK - MHRA,Completed,F.Hoffmann-La Roche,Commercial,Switzerland,NA,2009-10-23
2009-014365-12,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with laboratory confirmed influenza infection",Belgium - FPS Health-DGM,Completed,F.Hoffmann-La Roche,Commercial,Switzerland,NA,2009-10-28
2009-014365-12,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants up to 12 months of age with laboratory confirmed influenza infection",Netherlands - Competent Authority,Completed,F.Hoffmann-La Roche,Commercial,Switzerland,NA,2009-10-29
2009-014365-12,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection.",Italy - Italian Medicines Agency,Completed,F.Hoffmann-La Roche,Commercial,Switzerland,NA,2010-01-13
2008-007645-31,Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie - PRIMAIN-Studie -,Germany - BfArM,Completed,University Medical Center Freiburg,Non-Commercial,Germany,NA,2009-03-16
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,UK - MHRA,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA",Commercial,United States,Pfizer Inc.,2009-09-24
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,Hungary - National Institute of Pharmacy,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,Commercial,United States,NA,2009-10-16
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,France - ANSM,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,Commercial,United States,NA,2009-10-23
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,Greece - EOF,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,Commercial,United States,NA,2009-12-14
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,Germany - BfArM,Completed,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA",Commercial,United States,Pfizer Inc.,2009-12-18
2008-004439-39,"Estudio abierto y aleatorizado, comparativo de dos estrategias diferentes en el tratamiento de sujetos con psoriasis en placas que han respondido a la administración de etanercept.",Spain - AEMPS,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,Commercial,United States,NA,2009-12-22
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,Portugal - INFARMED,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,Commercial,United States,NA,2009-12-29
2008-004439-39,Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment,Italy - Italian Medicines Agency,Completed,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,Commercial,United States,NA,2010-02-19
2008-008726-75,"A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers’ Diarrhea Vaccine System",Germany - PEI,Completed,"Intercell USA, Inc. (Intercell)",Commercial,United States,"Intercell USA, Inc.",2009-03-03
2008-008726-75,"A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers’ Diarrhea Vaccine System",UK - MHRA,Completed,"Intercell USA, Inc. (Intercell)",Commercial,United States,NA,2009-04-09
2008-000071-25,"Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema",Germany - BfArM,Completed,Jerini AG,Commercial,Germany,NA,2009-07-29
2008-000071-25,"Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema",Austria - BASG,Completed,Jerini AG,Commercial,Germany,NA,2009-08-05
2008-000071-25,"Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema",UK - MHRA,Completed,Jerini AG,Commercial,Germany,NA,2009-09-24
2008-000071-25,"Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema",France - ANSM,Completed,Jerini AG,Commercial,Germany,NA,2009-11-26
2008-000071-25,"""Estudio multicéntrico en abierto para evaluar la seguridad, la tolerabilidad local, la comodidad posológica y la eficacia de una formulación autoadministrada por vía subcutánea de icatibant en el tratamiento de los ataques agudos de angioedema hereditario."" Traducción: ""Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema""",Spain - AEMPS,Completed,Jerini AG,Commercial,Germany,NA,2009-11-30
2008-000071-25,"Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema. Short title: EASSI Evaluation of the Safety of Self-administration with Icatibant.",Italy - Italian Medicines Agency,Completed,JERINI AG,Commercial,Germany,NA,2010-06-08
2008-000071-25,"Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema",Denmark - DHMA,Completed,Jerini AG,Commercial,Germany,NA,2010-07-26
2008-007952-90,"A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis.",Germany - BfArM,Completed,Lipid Therapeutics GmbH,Commercial,Germany,NA,2009-08-04
2008-007952-90,"A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis.",Lithuania - SMCA,Completed,Lipid Therapeutics GmbH,Commercial,Germany,NA,2009-09-15
2009-012231-15,Pharmacokinetics of Mycophenolate Mofetil in de novo lung allograft recipients,Germany - BfArM,Completed,Roche Pharma AG,Commercial,Germany,NA,2009-09-01
2009-013669-25,An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen.,Germany - BfArM,Prematurely Ended,Aegera Therapeutics Inc.,Commercial,Canada,NA,2009-10-05
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Sweden - MPA,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-09-18
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Netherlands - Competent Authority,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-09-24
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Latvia - SAM,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-10-01
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Czech Republic - SUKL,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-10-05
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Finland - Fimea,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-10-05
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Ireland - HPRA,Completed,Ipsen Pharma,Commercial,France,NA,2009-10-20
2009-013222-16,"ESTUDIO EN FASE II ABIERTO, ADAPTATIVO, MULTICÉNTRICO, CON AUMENTO Y AJUSTE DE LA DOSIS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA ADMINISTRACIÓN SUBCUTÁNEA REPETIDA DE DISTINTAS DOSIS DE BIM 23A760 EN PACIENTES CON SÍNDROME CARCINOIDE.",Spain - AEMPS,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-10-26
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Belgium - FPS Health-DGM,Completed,Ipsen Pharma,Commercial,France,NA,2009-11-03
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Austria - BASG,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2009-11-09
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",France - ANSM,Completed,Ipsen Pharma,Commercial,France,NA,2009-11-19
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Germany - BfArM,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2010-03-18
2009-013222-16,"PHASE II, OPEN, ADAPTIVE, DOSE ESCALATING, MULTICENTRE TITRATION STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN PATIENTS WITH CARCINOID SYNDROME",Italy - Italian Medicines Agency,Prematurely Ended,IPSEN PHARMA SAS,Commercial,France,NA,2010-06-07
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",Slovakia - SIDC (Slovak),Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2010-06-10
2009-013222-16,"Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome",UK - MHRA,Prematurely Ended,Ipsen Pharma,Commercial,France,NA,2010-10-11
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Germany - BfArM,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",France - ANSM,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Netherlands - Competent Authority,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Belgium - FPS Health-DGM,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",UK - MHRA,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-06
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Austria - BASG,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-10
2008-003003-31,"Terapia de radiación y simultáneo (concurrente) más Temsirolimus coadyuvante (CCI-779) contra irradiación chimio con Temozolomide para glioblastoma recientemente diagnosticado sin methylation del promotor de gen MGMT - un multicentro randomizado, open-label, una fase II estudio",Spain - AEMPS,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-29
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study.",Italy - Italian Medicines Agency,Completed,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Non-Commercial,Belgium,NA,2009-11-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Germany - BfArM,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",France - ANSM,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Netherlands - Competent Authority,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Belgium - FPS Health-DGM,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-02
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",UK - MHRA,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-06
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study",Austria - BASG,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-10
2008-003003-31,"Terapia de radiación y simultáneo (concurrente) más Temsirolimus coadyuvante (CCI-779) contra irradiación chimio con Temozolomide para glioblastoma recientemente diagnosticado sin methylation del promotor de gen MGMT - un multicentro randomizado, open-label, una fase II estudio",Spain - AEMPS,Completed,EORTC Headquarters,Non-Commercial,Belgium,NA,2009-07-29
2008-003003-31,"Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study.",Italy - Italian Medicines Agency,Completed,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Non-Commercial,Belgium,NA,2009-11-02
2009-013792-22,"A Phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g), LEO 29102 cream vehicle, and Elidel (Pimecrolimus) cream 10 mg/g, after cutaneous administration twice daily for 4 weeks. An international, multi-centre, prospective, randomised, double-blind, 7 arm, vehicle-controlled, parallel group study",Germany - BfArM,Completed,LEO Pharma A/S,Commercial,Denmark,NA,2009-10-06
2009-013792-22,"A Phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g), LEO 29102 cream vehicle, and Elidel (Pimecrolimus) cream 10 mg/g, after cutaneous administration twice daily for 4 weeks. An international, multi-centre, prospective, randomised, double-blind, 7 arm, vehicle-controlled, parallel group study",Finland - Fimea,Completed,LEO Pharma A/S,Commercial,Denmark,NA,2009-10-08
2009-012439-14,"A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer",Ireland - HPRA,Completed,"Astellas Pharma Global Development, Inc. (APGD)",Commercial,United States,"Astellas Pharma Global Development, Inc. (APGD)",2009-10-22
2009-012439-14,"A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer",Czech Republic - SUKL,Completed,"Astellas Pharma Global Development, Inc. (APGD)",Commercial,United States,"Astellas Pharma Global Development, Inc. (APGD)",2009-11-11
2009-012439-14,"A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer",Belgium - FPS Health-DGM,Completed,"Astellas Pharma Global Development, Inc. (APGD)",Commercial,United States,"Astellas Pharma Global Development, Inc. (APGD)",2010-01-26
2009-012439-14,"A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer",UK - MHRA,Completed,"Astellas Pharma Global Development, Inc. (APGD)",Commercial,United States,"Astellas Pharma Global Development, Inc. (APGD)",2010-03-15
2009-012439-14,"A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer",Germany - BfArM,Completed,"Astellas Pharma Global Development, Inc. (APGD)",Commercial,United States,"Astellas Pharma Global Development, Inc. (APGD)",2010-04-23
2009-013884-21,"A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)",Germany - BfArM,Prematurely Ended,Enceladus Pharmaceuticals BV,Commercial,Netherlands,Enceladus Pharmaceuticals BV,2009-09-09
2009-013884-21,"A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)",Belgium - FPS Health-DGM,Prematurely Ended,Enceladus Pharmaceuticals BV,Commercial,Netherlands,Enceladus Pharmaceuticals BV,2009-09-10
2009-013884-21,"A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)",Poland - Office for Medicinal Products,Prematurely Ended,Enceladus Pharmaceuticals BV,Commercial,Netherlands,Enceladus Pharmaceuticals BV,2010-01-13
2007-003003-12,Die Bedeutung der Inflammationslast („inflammatory/pathogen burden“) für das kardiale Altern,Germany - BfArM,Prematurely Ended,Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg,Non-Commercial,Germany,NA,2008-08-28
2006-004290-97,"A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",Germany - PEI,Completed,"Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy",Non-Commercial,Germany,NA,2006-10-17
2008-005976-28,Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study Version 1.2 2008-09-11 Amendment 2 2009-07-07,Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,NA,2009-04-07
2009-012607-26,MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers,Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,NA,2009-09-08
2009-012607-26,MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers,Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,NA,2009-09-08
2007-005352-17,"A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia",Germany - BfArM,Completed,University Bonn,Non-Commercial,Germany,Federal Ministry of Education and Research,2009-08-05
2007-000460-24,Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status,Germany - PEI,Completed,University of Duisburg-Essen,Non-Commercial,Germany,NA,2008-11-21
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Italy - Italian Medicines Agency,Prematurely Ended,PHILOGEN S.P.A.,Commercial,Italy,NA,2007-12-17
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Germany - PEI,Prematurely Ended,Philogen S.p.A.,Commercial,Italy,NA,2008-02-04
2007-005737-11,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,Austria - BASG,Prematurely Ended,Philogen S.p.A.,Commercial,Italy,NA,2011-03-03
2009-014728-44,A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory metastatic colorectal cancer and k-ras wild-type tumours,Germany - BfArM,Temporarily Halted,Martin Luther Universität Halle-Wittenberg,Non-Commercial,Germany,Biocompatibles UK Limited,2009-11-04
2008-007031-41,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",Germany - BfArM,Prematurely Ended,Center for Stroke Research Berlin - Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-09-14
2009-014076-22,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03)",Germany - PEI,Completed,Fresenius Biotech GmbH,Commercial,Germany,Fresenius Biotech GmbH,2009-08-04
2009-014076-22,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03)",France - ANSM,Ongoing,Fresenius Biotech GmbH,Commercial,Germany,NA,2009-11-19
2009-014076-22,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03). Estudio abierto de fase II para evaluar la seguridad de un segundo ciclo de infusión i.p. de catumaxomab en pacientes con ascitis maligna causada por un carcinoma que precisan la primera punción terapéutica tras el tratamiento del estudio CASIMAS (IP-CAT-AC-03).",Spain - AEMPS,Ongoing,Fresenius Biotech GmbH,Commercial,Germany,NA,2009-12-17
2009-014076-22,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03)",Italy - Italian Medicines Agency,Completed,FRESENIUS BIOTECH GMBH,Commercial,Germany,NA,2010-02-04
2009-014076-22,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03)",Belgium - FPS Health-DGM,Completed,Fresenius Biotech GmbH,Commercial,Germany,NA,2010-04-09
2009-014076-22,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03)",Sweden - MPA,Completed,Fresenius Biotech GmbH,Commercial,Germany,NA,2010-05-31
2009-013886-24,"A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease",Germany - BfArM,Completed,BIOPROJET,Commercial,France,NA,2009-10-29
2009-013886-24,"A Randomized, Multicenter, 12-Week, Double-blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson Disease, followed by a 9-months Open-Label Extension Phase",Czech Republic - SUKL,Completed,BIOPROJET,Commercial,France,NA,2009-11-18
2009-013886-24,"A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease",Sweden - MPA,Completed,BIOPROJET,Commercial,France,BIOPROJET,2009-12-21
2009-015113-44,"Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: darunavir/r + tenofovir/emtricitabina vs darunavir/r + raltegravir",Spain - AEMPS,Completed,ANSR,Non-Commercial,France,NA,2010-02-12
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,France - ANSM,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-02-15
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Sweden - MPA,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-02-16
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Ireland - HPRA,Completed,Agence nationale de recherches sur le sida et les hépatites virales (National Agency for AIDS-ANRS),Non-Commercial,France,NA,2010-02-16
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Denmark - DHMA,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-02-17
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Portugal - INFARMED,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-02-18
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Austria - BASG,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-02-23
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Germany - BfArM,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-03-05
2009-015113-44,An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,UK - MHRA,Completed,INSERM-ANRS,Non-Commercial,France,NA,2010-03-17
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Poland - Office for Medicinal Products,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-05-10
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral na�ve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir.,Italy - Italian Medicines Agency,Completed,Agence nationale de recherches sur le sida et les h�patites virales ANRS,Non-Commercial,France,NA,2010-05-13
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Belgium - FPS Health-DGM,Completed,Inserm- ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-06-02
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Netherlands - Competent Authority,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-06-10
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Hungary - National Institute of Pharmacy,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-06-14
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Greece - EOF,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-06-30
2009-015113-44,"Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: darunavir/r + tenofovir/emtricitabina vs darunavir/r + raltegravir",Spain - AEMPS,Completed,ANSR,Non-Commercial,France,NA,2010-02-12
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,France - ANSM,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-02-15
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Sweden - MPA,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-02-16
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Ireland - HPRA,Completed,Agence nationale de recherches sur le sida et les hépatites virales (National Agency for AIDS-ANRS),Non-Commercial,France,NA,2010-02-16
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Denmark - DHMA,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-02-17
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Portugal - INFARMED,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-02-18
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Austria - BASG,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-02-23
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Germany - BfArM,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-03-05
2009-015113-44,An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,UK - MHRA,Completed,INSERM-ANRS,Non-Commercial,France,NA,2010-03-17
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Poland - Office for Medicinal Products,Completed,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-05-10
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral na�ve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir.,Italy - Italian Medicines Agency,Completed,Agence nationale de recherches sur le sida et les h�patites virales ANRS,Non-Commercial,France,NA,2010-05-13
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Belgium - FPS Health-DGM,Completed,Inserm- ANRS (Agence nationale de recherches sur le sida et les hépatites virales),Non-Commercial,France,NA,2010-06-02
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Netherlands - Competent Authority,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-06-10
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Hungary - National Institute of Pharmacy,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-06-14
2009-015113-44,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,Greece - EOF,Completed,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Non-Commercial,France,NA,2010-06-30
2009-017052-27,"A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",Germany - PEI,Completed,Medizinische Hochschule Hannover,Non-Commercial,Germany,NA,2009-12-01
2009-013328-21,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess the Safety and Efficacy of BGP-15 when Administered Orally Once or Twice Daily as Add-on Therapy to the Combination of Metformin and Sulfonylurea Treatment or Metformin Alone in Patients with Type 2 Diabetes Mellitus",Hungary - National Institute of Pharmacy,Prematurely Ended,"N-GENE Research Laboratories, Inc.",Commercial,United States,NA,2011-01-11
2009-015537-67,"Untersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase II Studie",Germany - BfArM,Prematurely Ended,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,Non-Commercial,Germany,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,2009-10-26
2009-014691-21,"GAND-emesis: A multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of palonosetron and dexamethasone plus the neurokinin1-receptor antagonist, fosaprepitant dimeglumine or placebo in patients receiving radiotherapy and concomitant weekly cisplatin.",Denmark - DHMA,Completed,Odense University Hospital,Non-Commercial,Denmark,Odense University Hospital,2010-01-06
2009-014691-21,"GAND-emesis A multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of palonosetron and dexamethasone plus the neurokinin1-receptor antagonist, fosaprepitant dimeglumine or placebo in patients receiving radiotherapy and concomitant weekly cisplatin",Germany - BfArM,Completed,Odense University Hospital,Non-Commercial,Denmark,Odense University Hospital,2011-12-06
2007-004611-61,"Prospektive, randomisierte, monozentrische 2-armige Studie zum Einsatz von Daptomycin in der antibiotischen Prophylaxe von sternalen Wundinfektionen nach medianer Sternotomie",Germany - BfArM,Completed,Medizinische Hochschule Hannover (MHH),Non-Commercial,Germany,NA,2007-10-31
2009-012013-22,"A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children from 2 to <12 Years of age with Allergic Rhinoconjunctivitis or Chronic Urticaria",Germany - BfArM,Completed,FAES FARMA S.A.,Commercial,Spain,NA,2009-08-05
2009-012013-22,"A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children from 2 to <12 Years of Age with Allergic Rhinoconjunctivitis or Chronic Urticaria Estudio farmacocinético multicéntrico, internacional, adaptativo, abierto, de administración repetida de bilastina en niños de 2 a <12 años con rinoconjuntivitis alérgica o urticaria crónica",Spain - AEMPS,Completed,FAES FARMA S.A.,Commercial,Spain,NA,2009-08-24
2009-012013-22,"A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children from 2 to <12 Years of age with Allergic Rhinoconjunctivitis or Chronic Urticaria",Sweden - MPA,Completed,FAES FARMA S.A.,Commercial,Spain,FAES Farma S.A.,2009-08-24
2009-015496-27,Wirksamkeit von Etoricoxib bei Patienten mit neuropathischen Schmerzen mit und ohne peripherer Hyperalgesie (Efficacy of etoricoxibe in patients with neuropathic pain with and without peripheral hyperalgesia),Germany - BfArM,Ongoing,BG university hospital Bergmannsheil GmbH,Non-Commercial,Germany,NA,2009-12-28
2009-014677-41,"CHAMP – An open-label, randomised, multicentre, phase II clinical study of panitumumab plus pemetrexed and cisplatin (PemCisP) versus PemCis in the first-line treatment of patients with stage IIIB or IV primary nonsquamous non-small cell lung cancer, with particular regard to the KRAS status",Germany - PEI,Prematurely Ended,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,Non-Commercial,Germany,AMGEN GmbH,2009-11-02
2009-014918-99,"Intra-articular treatment with MEN16132 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multi-centre, double blind, placebo controlled, five parallel group, dose finding study",Germany - BfArM,Completed,"Menarini Ricerche, S.p.A",Commercial,Italy,NA,2009-10-22
2009-014918-99,"Intra-articular treatment with MEN16132 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multicentre, double blind, placebo controlled, five parallel group, dose finding study",Italy - Italian Medicines Agency,Completed,MENARINI RICERCHE S.P.A.,Commercial,Italy,NA,2009-11-17
2009-014918-99,"TRATAMIENTO INTRAARTICULAR CON MEN 16132 EN PACIENTES AFECTOS DE OSTEOARTRITIS PRIMARIA DE RODILLA EN FASE SINTOMÁTICA: ESTUDIO ALEATORIZADO MULTICÉNTRICO DE BÚSQUEDA DE DOSIS, DOBLE CIEGO Y CONTROLADO CON PLACEBO EN 5 GRUPOS PARALELOS Intra-articular treatment with MEN16132 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multi-centre, double blind, placebo controlled, five parallel group, dose finding study",Spain - AEMPS,Completed,"Menarini Ricerche, S.p.A",Commercial,Italy,NA,2009-11-24
2011-000369-11,"Open-label, single-dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of Cinryze® [C1 Inhibitor (human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema (Protocol 0624-203).",Hungary - National Institute of Pharmacy,Completed,ViroPharma Incorporated,Commercial,United States,ViroPharma Incorporated,2011-03-19
2011-000369-11,Open-label single-dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of Cinryze® [C1 Inhibitor (human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema (Protocol 0624-203).,Germany - PEI,Completed,ViroPharma Incorporated,Commercial,United States,ViroPharma Incorporated,2011-08-30
2009-011020-65,A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.,Germany - BfArM,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2010-01-18
2009-011020-65,A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.,France - ANSM,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2010-01-19
2009-011020-65,A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.,Austria - BASG,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2010-01-19
2009-011020-65,A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.,Finland - Fimea,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2010-01-21
2009-011020-65,A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.,Denmark - DHMA,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,EORTC,2010-01-25
2009-011020-65,Un estudio en fase III sobre lenalidomida como mantenimiento tras citorreducción con gemcitabina o doxorrubicina liposómica +/- radioterapia en pacientes con linfoma cutáneo de células T avanzado no tratado previamente con quimioterapia intravenosa. (A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.),Spain - AEMPS,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2010-02-08
2009-011020-65,A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.,UK - MHRA,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2010-03-15
2009-011020-65,A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.,Netherlands - Competent Authority,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2010-03-17
2009-011020-65,A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.,Belgium - FPS Health-DGM,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2011-04-11
2010-018739-17,"A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with Sorafenib",Belgium - FPS Health-DGM,Prematurely Ended,"Astellas Pharma Global Development, Inc.",Commercial,United States,"Astellas Pharma Global Development, Inc.",2010-06-22
2010-018739-17,"A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with Sorafenib",Spain - AEMPS,Prematurely Ended,"OSI Pharmaceuticals, Inc.",Commercial,United States,NA,2010-08-12
2010-018739-17,"A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with Sorafenib",Germany - BfArM,Completed,"Astellas Pharma Global Development, Inc.",Commercial,United States,NA,2010-09-21
2010-018739-17,"A randomized, placebo-controlled, double-blind, phase 2 study of second-line treatment with OSI-906 in patients with advanced hepatocellular carcinoma (HCC) after failure of first-line treatment with sorafenib",Italy - Italian Medicines Agency,Prematurely Ended,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.",Commercial,United States,"Astellas Pharma Global Development, Inc.",2012-01-05
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",UK - MHRA,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2009-07-06
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",Germany - BfArM,Completed,Shire Pharmaceutical Development Ltd.,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2009-08-14
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",Sweden - MPA,Completed,Shire Pharmaceutical Development Ltd.,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2009-08-28
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",France - ANSM,,Shire Pharmaceutical Development Ltd.,Commercial,United Kingdom,NA,2009-09-07
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy. Estudio de fase IIIb, doble ciego, aleatorizado, controlado con fármaco activo y en grupos paralelos para evaluar el tiempo hasta la respuesta a lisdexanfetamina dimesilato y atomoxetina clorhidrato en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con Hiperactividad (TDAH) que han presentado respuesta inadecuada al tratamiento con metilfenidato",Spain - AEMPS,Completed,Shire Pharmaceutical Development Ltd.,Commercial,United Kingdom,NA,2009-10-01
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",Belgium - FPS Health-DGM,Completed,Shire Pharmaceutical Development Ltd.,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2009-10-29
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",Poland - Office for Medicinal Products,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2011-04-21
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.",Hungary - National Institute of Pharmacy,Completed,Shire Pharmaceutical Development Limited,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2011-05-31
2009-011745-94,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy",Italy - Italian Medicines Agency,Completed,Shire Pharmaceutical Development LtD,Commercial,United Kingdom,Shire Pharmaceutical Development Ltd,2012-05-28
2009-011902-41,Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer,Germany - BfArM,Completed,"Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena",Non-Commercial,Germany,NA,2009-06-22
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Germany - BfArM,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Inc.,2010-04-01
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Belgium - FPS Health-DGM,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Inc,2010-04-07
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Netherlands - Competent Authority,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2010-04-08
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",France - ANSM,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2010-04-09
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Portugal - INFARMED,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2010-04-12
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",UK - MHRA,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Inc.,2010-04-16
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Austria - BASG,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Inc.,2010-04-19
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.",Spain - AEMPS,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2010-04-22
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Denmark - DHMA,Completed,Gilead Sciences Incorporated,Commercial,United States,Gilead Sciences Inc.,2010-05-07
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Na�ve Adults",Italy - Italian Medicines Agency,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2010-05-10
2009-016759-22,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",Sweden - MPA,Completed,Gilead Sciences Incorporated,Commercial,United States,NA,2010-06-03
2009-016504-22,"A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE AD02 administered repeatedly to patients with early Alzheimer’s disease.",Austria - BASG,Completed,AFFiRiS AG,Commercial,Austria,AFFiRiS AG,2010-02-08
2009-016504-22,"A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE AD02 administered repeatedly to patients with early Alzheimer’s disease.",Germany - PEI,Completed,AFFiRiS AG,Commercial,Austria,AFFiRiS AG,2010-02-12
2009-016504-22,"A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE® AD02 administered repeatedly to patients with early Alzheimer’s disease.",Slovakia - SIDC (Slovak),Completed,AFFiRiS AG,Commercial,Austria,AFFiRiS AG,2010-03-24
2009-016504-22,"A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE® AD02 administered repeatedly to patients with early Alzheimer’s disease.",Czech Republic - SUKL,Completed,AFFiRiS AG,Commercial,Austria,AFFiRiS AG,2010-04-02
2009-016504-22,"A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE AD02 administered repeatedly to patients with mild Alzheimer’s disease.",France - ANSM,Ongoing,AFFiRiS AG,Commercial,Austria,NA,2010-04-13
2009-016992-31,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,Netherlands - Competent Authority,Ongoing,Democritus Universityof Thrace Medical School,Non-Commercial,Greece,NA,2009-12-14
2009-016994-13,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,Netherlands - Competent Authority,Completed,University Utrecht,Non-Commercial,Netherlands,NA,2009-12-16
2009-016994-13,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,Germany - BfArM,Completed,University Utrecht,Non-Commercial,Netherlands,NA,2012-07-30
2009-016994-13,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,Austria - BASG,Completed,University Utrecht,Non-Commercial,Netherlands,NA,2012-08-08
2010-019287-37,A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy adn safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment,Germany - BfArM,Completed,Finox AG,Commercial,Switzerland,NA,2010-04-22
2010-019287-37,A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy adn safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment,Austria - BASG,Completed,Finox AG,Commercial,Switzerland,NA,2010-05-03
2010-019287-37,Un estudio multicéntrico de fase III realizado con un grupo paralelo aleatorizado y enmascaramiento para los evaluadores para comparar la eficacia y seguridad de dos formulaciones r-hFSH (AFOLIA frente a Gonal-f®) en mujeres para el tratamiento de reproducción asistida.,Spain - AEMPS,Completed,Finox AG,Commercial,Switzerland,NA,2010-05-17
2010-019287-37,A Phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy and safety of two r-hFSH formulations (AFOLIA vs Gonal-f®) in women for assisted reproductive treatment,UK - MHRA,Prematurely Ended,Finox AG,Commercial,Switzerland,NA,2010-06-21
2010-019287-37,A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy adn safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment,Denmark - DHMA,Completed,Finox AG,Commercial,Switzerland,NA,2010-07-12
2009-011580-36,Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) according to HER2 and EGFR status: a randomized phase II trial,Belgium - FPS Health-DGM,Prematurely Ended,EORTC - European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,GSK,2010-08-09
2009-011580-36,Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) according to HER2 and EGFR status: a randomized phase II trial,Germany - BfArM,Completed,EORTC - European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,GSK,2010-08-23
2009-011580-36,Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) according to HER2 and EGFR status: a randomized phase II trial,Hungary - National Institute of Pharmacy,Prematurely Ended,EORTC - European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2010-09-30
2009-011580-36,Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) according to HER2 and EGFR status: a randomized phase II trial,Portugal - INFARMED,Prematurely Ended,EORTC - European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,NA,2010-10-25
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",UK - MHRA,Completed,Shire Development LLC,Commercial,United States,Shire Development LLC,2010-03-17
2009-017044-13,"Estudio en fase 3b/4, abierto, multicéntrico y prospectivo para evaluar el efecto del estado de la remisión sobre la capacidad para mantener o alcanzar la remisión clínica y endoscópica durante una fase de mantenimiento a largo plazo de 12 meses con 2,4 g/día de MMX&#61650; mesalamina/mesalazina una vez al día en pacientes adultos con colitis ulcerosa A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",Spain - AEMPS,Completed,Shire Development Inc.,Commercial,United States,NA,2010-04-19
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",Ireland - HPRA,Completed,Shire Development LLC,Commercial,United States,Shire Development LLC,2010-04-20
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",Hungary - National Institute of Pharmacy,Completed,Shire Development LLC,Commercial,United States,Shire Development LLC,2010-04-26
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",Belgium - FPS Health-DGM,Completed,Shire Development LLC,Commercial,United States,Shire Development LLC,2010-05-06
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",Czech Republic - SUKL,Completed,Shire Development LLC,Commercial,United States,Shire Development LLC,2010-05-28
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",Germany - BfArM,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2010-06-16
2009-017044-13,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX® Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis",France - ANSM,Completed,Shire Development Inc,Commercial,United States,NA,2010-06-22
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,Belgium - FPS Health-DGM,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2010-05-25
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,France - ANSM,Completed,"PTC Therapeutics, Inc",Commercial,United States,NA,2010-06-17
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,Netherlands - Competent Authority,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2010-06-24
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,Sweden - MPA,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2010-10-11
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,Italy - Italian Medicines Agency,Completed,"PTC THERAPEUTICS, INC.",Commercial,United States,NA,2010-11-02
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,Germany - BfArM,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2011-04-13
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,Spain - AEMPS,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2011-07-29
2010-019692-30,A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,UK - MHRA,Completed,"PTC Therapeutics, Inc",Commercial,United States,"PTC Therapeutics, Inc",2011-08-23
2009-017374-20,"Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea – randomised, double-blind, placebo-controlled trial",Germany - BfArM,Prematurely Ended,Bernhard-Nocht-Institute for Tropical Medicine,Non-Commercial,Germany,BMBF,2010-03-11
2008-008448-26,"Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Birch) in patients with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma",Germany - PEI,Completed,LETI Pharma GmbH,Commercial,Germany,NA,2009-06-10
2008-008448-26,"Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Birch) in patients with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma",Lithuania - SMCA,Completed,LETI Pharma GmbH,Commercial,Germany,NA,2009-06-12
2010-021018-49,Fish OIL optimal dosE Determination Study,Germany - BfArM,Prematurely Ended,GWT-TUD GmbH,Non-Commercial,Germany,Fresenius- Kabi,2012-01-18
2010-018371-18,"A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2010/2011 when administered to adult and elderly subjects",Germany - PEI,Completed,Novartis Vaccines and Diagnostics GmbH,Commercial,Germany,NA,2010-03-05
2010-018665-30,COMFORT-study Comparison of Olanzapin and Metoclopramide For treatment Of bReakThrough emesis,Germany - BfArM,Prematurely Ended,Martin-Luther University Halle-Wittenberg,Non-Commercial,Germany,NA,2010-04-06
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Germany - BfArM,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US",Commercial,United States,Pfizer Inc,2010-08-31
2010-021336-33,"Estudio en Fase 3, aleatorizado y abierto de la eficacia y seguridad de crizotinib frente a pemetrexed /cisplatino o pemetrexed /carboplatino en pacientes no tratados previamente con carcinoma de pulmón no escamoso que entrañe una situación de translocación o inversión con implicación del locus del gen quinasa del linfoma anaplásico (ALK)",Spain - AEMPS,Completed,"Pfizer, S.A.",Commercial,Spain,NA,2010-09-22
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Finland - Fimea,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-11-04
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Ireland - HPRA,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-11-12
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Austria - BASG,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-11-17
2010-021336-33,"Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus.",Italy - Italian Medicines Agency,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY10017",Commercial,United States,NA,2010-11-19
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",UK - MHRA,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-12-23
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Belgium - FPS Health-DGM,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2011-06-09
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Netherlands - Competent Authority,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2011-06-16
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Denmark - DHMA,Prematurely Ended,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2011-06-22
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Portugal - INFARMED,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2011-07-13
2010-021336-33,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",Norway - NOMA,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2011-08-08
2008-007546-56,A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach,Germany - BfArM,Completed,"Klinikum der Universität München, Campus Großhadern",Non-Commercial,Germany,NA,2009-08-21
2010-019427-58,"A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery",Germany - PEI,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,NA,2010-03-26
2010-019427-58,"A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery",UK - MHRA,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,Omrix Biopharmaceutical Ltd.,2010-06-22
2010-019427-58,"A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery",Netherlands - Competent Authority,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,NA,2010-07-01
2009-016501-41,"A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair",Germany - PEI,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,NA,2009-12-30
2009-016501-41,"A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair",Belgium - FPS Health-DGM,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,"Ethicon, Inc.",2010-02-17
2009-016501-41,"A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair",Netherlands - Competent Authority,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,NA,2010-02-24
2009-016501-41,"A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair",Finland - Fimea,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,"Ethicon, Inc.",2010-02-25
2009-016501-41,"A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair",UK - MHRA,Completed,Omrix Biopharmaceuticals Ltd,Commercial,Israel,NA,2010-03-17
2010-019844-38,"A double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of early the treatment with Eplerenone in patients with acute myocardial infarction.",Spain - AEMPS,Completed,"Pfizer, S.A",Commercial,Spain,NA,2010-06-17
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",Slovakia - SIDC (Slovak),Completed,Pfizer Inc.,Commercial,United States,NA,2010-06-28
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",Czech Republic - SUKL,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-06-30
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",Hungary - National Institute of Pharmacy,Completed,Pfizer Inc.,Commercial,United States,NA,2010-07-16
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",UK - MHRA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-08-17
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",Germany - BfArM,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA",Commercial,United States,Pfizer Inc,2010-09-13
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",Netherlands - Competent Authority,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-12-08
2010-019844-38,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",Greece - EOF,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2011-01-11
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-04-20
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-04-20
2008-005609-21,Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors.,Germany - BfArM,Completed,"Faculty For Medicine, Otto-von-Guericke University Magdeburg",Non-Commercial,Germany,NA,2009-06-03
2010-020916-12,"A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC",Germany - BfArM,Completed,"Astellas Pharma Global Development, Inc.",Commercial,United States,"Astellas Pharma Global Development, Inc",2010-10-20
2010-020916-12,"A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC",UK - MHRA,Completed,"Astellas Pharma Global Development, Inc.",Commercial,United States,"Astellas Pharma Global Development, Inc.",2010-10-28
2008-007520-26,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)",Germany - BfArM,Prematurely Ended,Klinikum der Universität München,Non-Commercial,Germany,NA,2009-11-13
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,UK - MHRA,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,NA,2011-03-10
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Germany - BfArM,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,PharmaMar S.A.,2011-03-15
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Belgium - FPS Health-DGM,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,NA,2011-03-17
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Hungary - National Institute of Pharmacy,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,PharmaMar S.A.,2011-03-19
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Denmark - DHMA,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,NA,2011-03-21
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Austria - BASG,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,PharmaMar S.A.,2011-03-31
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Netherlands - Competent Authority,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,Pharma Mar S.A,2011-05-11
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Slovakia - SIDC (Slovak),Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,PharmaMar S.A.,2011-07-15
2009-014889-26,Un estudio multicéntrico de fase IIb/III que compara la eficacia de trabectedin administrado como una infusión de 3 horas o de 24 horas con doxorubicin en pacientes con sarcoma de tejidos blandos no tratado avanzado o metastático. A phase IIb/III multicenter study comparing the efficacy of trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma.,Spain - AEMPS,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,NA,2012-01-25
2009-014889-26,TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma,Poland - Office for Medicinal Products,Completed,EORTC (European Organisation for Research and Treatment of Cancer),Non-Commercial,Belgium,PharmaMar S.A.,2012-07-11
2009-017365-36,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus",Germany - PEI,Completed,GANYMED Pharmaceuticals AG,Commercial,Germany,NA,2010-02-19
2009-017365-36,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus",Latvia - SAM,Completed,GANYMED Pharmaceuticals AG,Commercial,Germany,NA,2010-04-28
2009-017365-36,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus",Czech Republic - SUKL,Completed,GANYMED Pharmaceuticals AG,Commercial,Germany,NA,2010-05-21
2009-017365-36,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus",Lithuania - SMCA,Prematurely Ended,GANYMED Pharmaceuticals AG,Commercial,Germany,NA,2010-05-31
2009-017365-36,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus",Austria - BASG,Completed,GANYMED Pharmaceuticals AG,Commercial,Germany,NA,2010-06-14
2009-017365-36,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus",Bulgarian Drug Agency,Completed,GANYMED Pharmaceuticals AG,Commercial,Germany,NA,2011-01-20
2009-011999-30,"A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis",Ireland - HPRA,Prematurely Ended,Stallergenes S.A.,Commercial,France,Stallergenes S.A,2009-06-09
2009-011999-30,"""A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis"". ""Estudio aleatorizado, doble ciego, controlado con placebo, multinacional, de fase III para evaluar la eficacia y la seguridad de la inmunoterapia sublingual (SLIT) con 300 IR administrada en comprimidos con alergenos una vez al día a adolescentes y niños de más de 5 años con rinitis alérgica a los ácaros del polvo doméstico"".",Spain - AEMPS,Prematurely Ended,Stallergenes S.A.,Commercial,France,NA,2009-06-29
2009-011999-30,"A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis",Hungary - National Institute of Pharmacy,Completed,Stallergenes S.A.,Commercial,France,NA,2009-07-01
2009-011999-30,"A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis",Germany - PEI,Prematurely Ended,Stallergenes S.A.,Commercial,France,Stallergenes S.A,2009-07-06
2009-011999-30,"A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis",France - ANSM,Completed,Stallergenes S.A.,Commercial,France,NA,2009-08-06
2009-011999-30,"A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis",Denmark - DHMA,Prematurely Ended,Stallergenes S.A.,Commercial,France,Stallergenes S.A,2009-08-24
2009-011999-30,"A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis",Slovakia - SIDC (Slovak),Prematurely Ended,Stallergenes S.A.,Commercial,France,NA,2009-09-10
2010-019057-17,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection",Netherlands - Competent Authority,Completed,Santaris Pharma A/S,Commercial,Denmark,NA,2010-03-24
2010-019057-17,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection",Germany - BfArM,Completed,Santaris Pharma A/S,Commercial,Denmark,NA,2010-05-11
2010-019057-17,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection",Slovakia - SIDC (Slovak),Completed,Santaris Pharma A/S,Commercial,Denmark,NA,2010-05-20
2010-019057-17,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection",Poland - Office for Medicinal Products,Completed,Santaris Pharma A/S,Commercial,Denmark,NA,2010-06-07
2008-005365-61,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",Germany - BfArM,Completed,Med. Fakultaet der Friedrich-Alexander Universitaet Erlangen-Nuernberg,Non-Commercial,Germany,Celgene GmbH,2009-12-03
2005-002011-24,Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study,Finland - Fimea,Completed,European Group for Blood and Marrow Transplantation (EBMT),Non-Commercial,Germany,NA,2008-04-08
2005-002011-24,Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study (RICMAC),Belgium - FPS Health-DGM,Completed,European Group for Blood and Marrow Transplantation,Non-Commercial,United Kingdom,NA,2009-03-10
2005-002011-24,Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study (RICMAC),UK - MHRA,Completed,European Group for Blood and Marrow Transplantation,Non-Commercial,United Kingdom,NA,2009-04-16
2009-010727-91,Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten),Germany - BfArM,Prematurely Ended,"LMU München, Campus Großhadern",Non-Commercial,Germany,NA,2012-06-05
2009-017432-40,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)",Germany - PEI,Completed,MOLOGEN AG,Commercial,Germany,Mologen AG,2009-12-08
2009-017432-40,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)",Austria - BASG,Prematurely Ended,MOLOGEN AG,Commercial,Germany,Mologen AG,2010-02-02
2009-017432-40,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)",UK - MHRA,Completed,MOLOGEN AG,Commercial,Germany,Mologen AG,2010-06-16
2009-017432-40,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)",Czech Republic - SUKL,Prematurely Ended,MOLOGEN AG,Commercial,Germany,Mologen AG,2010-12-01
2005-006098-29,"Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin plus Cisplatin und Plazebo in der Therapie des lokal fortgeschrittenen bzw. metastasierten Urothelkarzinoms",Germany - BfArM,Ongoing,Universitätsklinikum Essen,Non-Commercial,Germany,NA,2006-09-01
2010-022229-13,"A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy naїve Subjects with Stage IV Adenocarcinoma of the Lung with Wild Type EGFR",Germany - PEI,Completed,Morphotek Inc.,Commercial,United States,NA,2010-12-13
2010-022229-13,"Estudio aleatorizado, doble ciego, controlado con placebo, de la seguridad y la eficacia de farletuzumab en combinación con carboplatino y paclitaxel o docetaxel seguidos de pemetrexed en sujetos con adenocarcinoma de pulmón en estadío IV y EGFR de tipo salvaje que nunca han recibido quimioterapia",Spain - AEMPS,Prematurely Ended,Morphotek Inc.,Commercial,United States,NA,2010-12-17
2010-022229-13,"A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy naїve Subjects with Stage IV Adenocarcinoma of the Lung with Wild Type EGFR",Italy - Italian Medicines Agency,Prematurely Ended,MORPHOTEK INC,Commercial,United States,NA,2010-12-24
2010-019424-31,"A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following islet transplantation in patients with type 1 diabetes mellitus",Germany - BfArM,Completed,Dompé s.p.a.,Commercial,Italy,Dompé s.p.a.,2010-05-04
2010-019424-31,"A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type 1 diabetes mellitus.",Italy - Italian Medicines Agency,Completed,DOMPE` s.p.a.,Commercial,Italy,NA,2010-05-11
2010-019424-31,"A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following islet transplantation in patients with type 1 diabetes mellitus",Germany - BfArM,Completed,Dompé s.p.a.,Commercial,Italy,Dompé s.p.a.,2010-05-04
2010-019424-31,"A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type 1 diabetes mellitus.",Italy - Italian Medicines Agency,Completed,DOMPE` s.p.a.,Commercial,Italy,NA,2010-05-11
2010-019411-37,"A Prospective, Open Label, Randomised, Parallel Group Trial Comparing the Effects of Highly Purified Menotrophin and Recombinant Follicle Stimulating Hormone (rFSH, Follitropin alpha) Administered Subcutaneoulsy to Subfertile Female Patients Undergoing IVF Using Antagonist Down-Regulation on Progesterone Serum Levels During the Follicular Phase and their Possible Use as Predictors for the Success Rate of Ongoing Pregnancies (PREDICT)",Germany - BfArM,Completed,FERRING Arzneimittel GmbH,Commercial,Germany,NA,2010-07-02
2010-019975-30,"Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma patients",Germany - BfArM,Completed,"University Medical Center, Johannes Gutenberg-University Mainz",Non-Commercial,Germany,NA,2010-06-25
2009-017520-88,Ciclosporin vs. Alitretinoin for severe atopic hand dermatitis. A randomized controlled investigator-initiated double-blind trial.,Germany - BfArM,Prematurely Ended,"Medical Faculty, TU Dresden",Non-Commercial,Germany,NA,2010-08-17
2010-019954-42,Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia,Germany - BfArM,Prematurely Ended,"Med. Klinik II, Klinikum der Universität München Grosshadern",Non-Commercial,Germany,NA,2010-07-07
2009-014383-18,"A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer",Germany - BfArM,Completed,Medizinische Hochschule Hannover,Non-Commercial,Germany,Novartis,2010-07-13
2009-015950-39,Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis,Germany - PEI,Completed,Johann Wolfgang Goethe-Universität Frankfurt/M.,Non-Commercial,Germany,"University Hospital Goethe-University, Department of rheumatology",2009-12-28
2010-023178-37,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients",UK - MHRA,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc",2010-11-02
2010-023178-37,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients",Germany - BfArM,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2010-11-03
2010-023178-37,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients.",Spain - AEMPS,Completed,"Gilead Sciences, Inc.",Commercial,United States,NA,2010-11-19
2010-023178-37,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients",Belgium - FPS Health-DGM,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2010-11-26
2010-023178-37,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients",Italy - Italian Medicines Agency,Completed,Gilead Sciences Inc.,Commercial,United States,NA,2010-12-27
2010-023178-37,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients",Austria - BASG,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-03-03
2009-016782-28,Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III),Germany - PEI,Ongoing,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,Non-Commercial,Germany,AMGEN GmbH,2010-06-11
2010-022871-78,"A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",Germany - PEI,Completed,Medizinische Hochschule Hannover,Non-Commercial,Germany,NA,2010-09-30
2010-020077-16,"Estudio de 12 semanas de duración, multicéntrico, doble ciego, controlado con placebo, aleatorizado de etanercept con un AINE de base en el tratamiento de sujetos adultos con espondiloartritis axial sin signos radiográficos con una extensión abierta de 92 semanas. A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Spain - AEMPS,Completed,"Pfizer, S.A",Commercial,Spain,NA,2010-10-22
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Hungary - National Institute of Pharmacy,Completed,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-11-17
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Germany - BfArM,Completed,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2010-11-24
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Belgium - FPS Health-DGM,Completed,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-01-17
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",UK - MHRA,Completed,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-02-04
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Denmark - DHMA,Prematurely Ended,"Pfizer Ltd., Ramsgate Road, Sandwich, kent, CT13 9NJ, United Kingdom",Commercial,,NA,2011-05-04
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Netherlands - Competent Authority,Completed,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-05-23
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Finland - Fimea,Completed,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-08-11
2010-020077-16,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION",Czech Republic - SUKL,Completed,Pfizer Inc,Commercial,United States,Pfizer Inc,2012-02-02
2010-020737-50,"Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia",UK - MHRA,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2010-08-09
2010-020737-50,"Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia",Germany - BfArM,Completed,Merz Pharmaceuticals GmbH,Commercial,Germany,NA,2010-08-24
2010-019035-35,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A0081194",Czech Republic - SUKL,Completed,Pfizer Inc.,Commercial,United States,Pfizer Inc.,2010-11-09
2010-019035-35,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A0081194",Hungary - National Institute of Pharmacy,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,NA,2011-01-31
2010-019035-35,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A0081194",Germany - BfArM,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017 USA",Commercial,United States,Pfizer Inc.,2011-02-07
2010-019035-35,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A0081194",Bulgarian Drug Agency,Completed,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-02-24
2010-022679-71,Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation,Germany - BfArM,Prematurely Ended,"Clinical Trials Center Aachen, University of Aachen",Non-Commercial,Germany,"University Hospital RWTH Aachen, Department of Anesthesiology",2010-12-15
2010-021370-11,"An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy.",Germany - BfArM,Completed,iOMEDICO AG,Non-Commercial,Germany,Novartis,2010-10-28
2010-019634-26,"A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients",Germany - BfArM,Completed,"Mpex Pharmaceuticals, Inc.",Commercial,United States,"Mpex Pharmaceuticals, Inc.",2011-01-25
2010-019634-26,"A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients",UK - MHRA,Completed,"Mpex Pharmaceuticals, Inc.",Commercial,United States,"Mpex Pharmaceuticals, Inc.",2011-02-07
2010-019634-26,"A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients",France - ANSM,,"Mpex Pharmaceuticals, Inc.",Commercial,United States,NA,2011-02-08
2010-019634-26,"A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients",Ireland - HPRA,Completed,"Mpex Pharmaceuticals, Inc.",Commercial,United States,"Mpex Pharmaceuticals, Inc",2011-02-15
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",UK - MHRA,Completed,Biogen Idec Limited,Commercial,United Kingdom,Biogen Idec Limited,2011-01-10
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",Belgium - FPS Health-DGM,Completed,Biogen Idec Limited,Commercial,United Kingdom,Biogen Idec Limited,2011-01-24
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",Sweden - MPA,Completed,Biogen Idec Limited,Commercial,United Kingdom,Biogen Idec Limited,2011-02-09
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",Ireland - HPRA,Completed,Biogen Idec Limited,Commercial,United Kingdom,Biogen Idec Limited,2011-02-15
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de la seguridad y eficacia de Dexpramipexol en sujetos con Esclerosis Lateral Amiotrófica",Spain - AEMPS,Completed,Biogen Idec Limited,Commercial,United Kingdom,NA,2011-02-21
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",Germany - BfArM,Completed,Biogen Idec Limited,Commercial,United Kingdom,Biogen Idec Limited,2011-02-21
2010-022818-19,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",Netherlands - Competent Authority,Completed,Biogen Idec Limited,Commercial,United Kingdom,Biogen Idec Limited,2011-05-11
2010-023762-49,"ESTUDIO EN FASE 2A, ALEATORIZADO, DOBLE CIEGO, SIN ENMASCARAMIENTO PARA EL PROMOTOR, CONTROLADO CON PLACEBO, DE DOSIS MÚLTIPLES PARA EVALUAR LA FARMACODINÁMICA, LA FARMACOCINÉTICA Y LA SEGURIDAD DE ANRUKINZUMAB EN PACIENTES CON COLITIS ULCEROSA ACTIVA A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS",Spain - AEMPS,Completed,"Pfizer, S.L.U.",Commercial,Spain,NA,2011-02-11
2010-023762-49,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS",Austria - BASG,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-04-26
2010-023762-49,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS",Bulgarian Drug Agency,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-05-31
2010-023762-49,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS",Poland - Office for Medicinal Products,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-07-05
2010-023762-49,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS",Germany - PEI,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA",Commercial,United States,Pfizer Inc,2011-08-17
2010-023762-49,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS",Belgium - FPS Health-DGM,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-11-21
2005-000295-41,"Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s disease.",Germany - BfArM,Completed,Universität zu Köln,Non-Commercial,Germany,NA,2005-12-20
2010-022584-35,Clofarabine salvage therapy in patients with relapsed or refractory AML The BRIDGE Trial,Germany - BfArM,Completed,Dresden Universtity of Technology,Non-Commercial,Germany,Penn Pharmaceutical Services (Penn),2010-09-28
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years",Sweden - MPA,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-06-08
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years",Czech Republic - SUKL,Completed,Pfizer Inc.,Commercial,United States,Pfizer Inc,2010-06-21
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged more or equal 11 to <19 Years",Spain - AEMPS,Completed,PFIZER S.L.U.,Commercial,Spain,Pfizer Inc.,2010-06-25
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years",Poland - Office for Medicinal Products,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-07-01
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years",Germany - PEI,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US",Commercial,United States,Pfizer Inc,2010-07-13
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years",Finland - Fimea,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-08-02
2009-014493-18,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years",Denmark - DHMA,Completed,"Pfizer Inc 235 East 42nd Street, New York, NY10017",Commercial,United States,Pfizer Inc,2010-08-13
2010-018300-85,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",Czech Republic - SUKL,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-05-24
2010-018300-85,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",Germany - BfArM,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-05-26
2010-018300-85,"ESTUDIO DE FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR EL EFECTO DE IBODUTANT ORAL EN EL SÍNDROME DEL INTESTINO IRRITABLE CON DIARREA (SII-D) - Estudio IRIS-2",Spain - AEMPS,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-05-31
2010-018300-85,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",Sweden - MPA,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-06-11
2010-018300-85,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D).",Italy - Italian Medicines Agency,Completed,MENARINI RICERCHE S.P.A.,Commercial,Italy,NA,2010-06-14
2010-018300-85,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",Denmark - DHMA,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-06-25
2010-018300-85,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",Bulgarian Drug Agency,Completed,Menarini Ricerche S.p.A.,Commercial,Italy,NA,2010-08-11
2009-017595-25,Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery,Germany - BfArM,Prematurely Ended,University Hospital Muenster,Non-Commercial,Germany,Fresenius Kabi Deutschland GmbH,2011-01-17
2009-015159-26,"UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.",Germany - BfArM,Ongoing,Universitaetsklinikum Wuerzburg,Non-Commercial,Germany,NA,2010-11-18
2010-018850-11,Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study,Germany - PEI,Completed,Medizinische Hochschule Hannover (MHH),Non-Commercial,Germany,AMGEN GmbH,2010-12-22
2010-022449-38,"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REPEVAX AND BIVALENT rLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY SUBJECTS AGED ≥11 TO <19 YEARS",Germany - PEI,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc.,2010-12-08
2010-022449-38,"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REPEVAX AND BIVALENT rLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY SUBJECTS AGED ≥11 TO <19 YEARS",Finland - Fimea,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc.,2010-12-27
2010-023688-16,"An Open-Label, Randomized, Parallel Group Study of Patients Treated with Paclitaxel with Standard Dosing versus Pharmacokinetic Guided Dose Adjustment in Patients with Advanced NSCLC",Germany - BfArM,Completed,CESAR Central European Society for Anticancer Drug Research-EWIV,Non-Commercial,Austria,SALADAX Biomedical,2011-01-12
2010-021994-35,"A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis C and/or Hepatitis B Virus",Hungary - National Institute of Pharmacy,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-05-02
2010-021994-35,"A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis C and/or Hepatitis B Virus",Czech Republic - SUKL,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-05-10
2010-021994-35,"A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis C and/or Hepatitis B Virus",Germany - BfArM,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-05-11
2010-021994-35,"A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis C and/or Hepatitis B Virus",UK - MHRA,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-05-24
2010-021994-35,"""Estudio multicéntrico, aleatorizado, enmascarado y controlado con placebo para evaluar la seguridad de maraviroc en combinación con otros antirretrovirales en sujetos infectados por el VIH-1 y por el virus de la hepatitis C y/o B""",Spain - AEMPS,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,NA,2011-06-06
2010-019267-11,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE THE SAFETY AND EFFICACY OF PANZYTRAT® 25 000 TO KREON® 25 000 IN THE CONTROL OF STEATORRHEA IN SUBJECTS AGED 7 YEARS AND OLDER WITH CYSTIC FIBROSIS (CF) AND EXOCRINE PANCREATIC INSUFFICIENCY (EPI)",Germany - BfArM,Completed,Axcan Pharma Inc.,Commercial,Canada,Axcan Pharma SAS,2010-10-19
2010-020538-24,White spot lesion development in post-orthodontic patients following weekly application of a 1.25% fluoride gel compared to placebo over 6 months,Germany - BfArM,Completed,GABA International AG,Commercial,Switzerland,GABA International AG,2010-11-10
2010-019085-82,"A PHASE II, DOUBLE BLIND, RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF THREE DOSES OF DYSPORT RU (20 U, 50 U AND 75 U) ADMINISTERED AS A SINGLE TREATMENT CYCLE TO IMPROVE THE APPEARANCE OF MODERATE TO SEVERE GLABELLAR LINES",Germany - BfArM,Completed,Ipsen Innovation,Commercial,France,Ipsen Innovation,2010-12-27
2009-014441-93,"Clinical trial to assess the efficacy of the fixed combination product Tepilta® in the treatment of radiation-induced oesophagitis compared to its active ingredients oxetacaine and antacids, and to placebo",Germany - BfArM,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,MEDA Pharma GmbH & Co. KG,2010-05-17
2009-014441-93,"Clinical trial to assess the efficacy of the fixed combination product Tepilta® in the treatment of radiation-induced oesophagitis compared to its active ingredients oxetacaine and antacids, and to placebo",Austria - BASG,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,MEDA Pharma GmbH & Co. KG,2010-12-07
2010-020219-35,Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI,UK - MHRA,Prematurely Ended,Royal Brompton & Harefield NHS Foundation Trust,Non-Commercial,United Kingdom,NA,2011-03-30
2010-020219-35,Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI,Germany - BfArM,Completed,Royal Brompton & Harefield NHS Foundation Trust,Non-Commercial,United Kingdom,DAIICHI SANKYO EUROPE GmbH,2011-04-05
2011-000503-40,DABI-ADP-1:,Germany - BfArM,Completed,"Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen",Non-Commercial,Germany,NA,2011-02-18
2010-019884-12,Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection,Germany - BfArM,Prematurely Ended,Universitätsklinikum Aachen,Non-Commercial,Germany,Bristol-Myers Squibb,2010-10-14
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Germany - BfArM,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-09-16
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Hungary - National Institute of Pharmacy,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-09-16
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Sweden - MPA,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-09-19
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Finland - Fimea,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-09-22
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Belgium - FPS Health-DGM,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-09-27
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Spain - AEMPS,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,"Pfizer, S.L.U.",2011-09-28
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",UK - MHRA,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-10-18
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Austria - BASG,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-10-24
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Denmark - DHMA,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-11-03
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Netherlands - Competent Authority,Completed,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-11-07
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Portugal - INFARMED,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2011-11-18
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",Poland - Office for Medicinal Products,Prematurely Ended,ViiV Healthcare UK Limited,Commercial,United Kingdom,ViiV Healthcare Limited,2012-01-10
2010-021785-30,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS WITH CCR5-TROPIC HIV-1",Italy - Italian Medicines Agency,Prematurely Ended,VIIV HEALTHCARE UK LIMITED,Commercial,United Kingdom,ViiV Healthcare Limited,2012-03-29
2009-014589-24,"Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia",Germany - PEI,Prematurely Ended,Octapharma AG,Commercial,Switzerland,Octapharma AG,2011-04-12
2009-014589-24,"Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia",Czech Republic - SUKL,Prematurely Ended,Octapharma AG,Commercial,Switzerland,Octapharma AG,2011-04-26
2009-014589-24,"Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia",Bulgarian Drug Agency,Prematurely Ended,Octapharma AG,Commercial,Switzerland,Octapharma AG,2011-09-13
2009-014589-24,"Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia",France - ANSM,Completed,Octapharma AG,Commercial,Switzerland,Octapharma AG,2011-09-27
2011-000504-18,DABI-ADP-2:,Germany - BfArM,Completed,"Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen",Non-Commercial,Germany,NA,2011-02-21
2010-019998-14,"Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component",Netherlands - Competent Authority,Completed,Grünenthal GmbH,Commercial,Germany,NA,2010-12-02
2010-019998-14,"Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component",Germany - BfArM,Completed,Grünenthal GmbH,Commercial,Germany,NA,2010-12-06
2010-019998-14,"Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component",Austria - BASG,Completed,Grünenthal GmbH,Commercial,Germany,Grünenthal GmbH,2010-12-22
2010-019998-14,"Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component",Belgium - FPS Health-DGM,Completed,Grünenthal GmbH,Commercial,Germany,NA,2011-01-06
2010-019998-14,"Evaluación de la efectividad, seguridad y tolerabilidad de tapentadol de liberación prolongada frente a una combinación de tapentadol de liberación prolongada y pregabalina en pacientes con lumbalgia crónica severa con un componente de dolor neuropático. Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component.",Spain - AEMPS,Completed,Grünenthal GmbH,Commercial,Germany,NA,2011-01-20
2010-019998-14,"Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component",Denmark - DHMA,Completed,Grünenthal GmbH,Commercial,Germany,Grünenthal GmbH,2011-02-04
2010-023941-31,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Universitätsmedizin Berlin,2011-03-17
2010-023210-31,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS",Germany - BfArM,Completed,Ipsen Innovation,Commercial,France,Ipsen Innovation,2011-11-09
2010-023210-31,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS",Austria - BASG,Completed,Ipsen Innovation,Commercial,France,Ipsen Innovation,2012-01-18
2010-023210-31,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS",Italy - Italian Medicines Agency,Completed,IPSEN INNOVATION,Commercial,France,IPSEN Innovation,2012-03-12
2010-023210-31,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS",Lithuania - SMCA,Completed,Ipsen Innovation,Commercial,France,Ipsen Innovation,2012-05-29
2010-023210-31,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS",Czech Republic - SUKL,Completed,Ipsen Innovation,Commercial,France,Ipsen Innovation,2012-06-13
2010-022656-22,"A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy.",Spain - AEMPS,Completed,"Pfizer, S.L.U.",Commercial,Spain,Pfizer Inc,2011-06-16
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Sweden - MPA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-06-23
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Slovakia - SIDC (Slovak),Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-06-24
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Poland - Office for Medicinal Products,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-07-11
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Hungary - National Institute of Pharmacy,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-07-29
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Ireland - HPRA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-08-05
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Finland - Fimea,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-08-11
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Belgium - FPS Health-DGM,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-08-18
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",UK - MHRA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-09-07
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Germany - BfArM,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA",Commercial,United States,Pfizer Inc,2011-09-15
2010-022656-22,"ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 (DACOMITINIB) VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Austria - BASG,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-10-03
2010-022656-22,"A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Denmark - DHMA,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-10-26
2010-022656-22,"A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY",Greece - EOF,Completed,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",Commercial,United States,Pfizer Inc,2011-11-02
2010-023050-37,"A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)",Germany - BfArM,Ongoing,Martin-Luther-Universität Halle-Wittenberg,Non-Commercial,Germany,Martin-Luther-Universität Hallen-Wittenberg,2011-03-21
2010-023050-37,"A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)",Germany - BfArM,Ongoing,Martin-Luther-Universität Halle-Wittenberg,Non-Commercial,Germany,Martin-Luther-Universität Hallen-Wittenberg,2011-03-21
2010-021397-12,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux disease and with persistent symptoms despite taking a stable dose of proton pump inhibitors.",Belgium - FPS Health-DGM,Completed,Shire-Movetis NV,Commercial,Belgium,NA,2010-09-02
2010-021397-12,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux disease and with persistent symptoms despite taking a stable dose of proton pump inhibitors.",France - ANSM,Completed,Movetis NV,Commercial,Belgium,NA,2010-09-13
2010-021397-12,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux disease and with persistent symptoms despite taking a stable dose of proton pump inhibitors.",Germany - BfArM,Prematurely Ended,Shire-Movetis NV,Commercial,Belgium,NA,2010-09-14
2010-021397-12,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux disease and with persistent symptoms despite taking a stable dose of proton pump inhibitors.",UK - MHRA,Completed,Shire-Movetis NV,Commercial,Belgium,NA,2010-10-08
2010-021397-12,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux disease and with persistent symptoms despite taking a stable dose of proton pump inhibitors.",Netherlands - Competent Authority,Completed,Movetis NV,Commercial,Belgium,NA,2010-10-12
2009-015119-42,"An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS",Germany - PEI,Completed,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,Non-Commercial,Germany,NA,2010-02-11
2010-022687-12,"A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma (Sorafenib Treatment of Metastatic Uveal Melanoma)",Germany - BfArM,Completed,Universitätsklinikum Essen,Non-Commercial,Germany,NA,2010-12-14
2007-003103-12,"A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia",Germany - BfArM,Completed,Hospital of the University of Munich,Non-Commercial,Germany,NA,2008-08-20
2006-005906-30,"The effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg plus 10 mg Ezetimibe on LDL-Subfractions in patients with Type 2 Diabetes (Die Wirkung einer Monotherapie mit Ezetimib 10 mg vs. Monotherapie mit Simvastatin 20 mg vs. Kombinationsbehandlung mit Ezetimib 10 mg und Simvastatin 20 mg auf die LDL-Subfraktionen bei Patienten mit Typ II Diabetes)",Germany - BfArM,Completed,"Universitätsklinikum Freiburg, Abteilung klinische Chemie",Non-Commercial,Germany,NA,2007-04-23
2011-000152-42,An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females,Germany - BfArM,Completed,"Medical Faculty, University Magdeburg",,Germany,NA,2011-06-20
2010-024652-28,"Estudio para evaluar la actividad y la tolerabilidad de la biterapia con lopinavir/ritonavir y 3TC en sustitución de una triple terapia que incluya lopinavir/ritonavir y 3TC ó FTC en pacientes con infección por VIH y supresión virológica: ensayo clínico controlado, abierto, con asignación aleatoria, de 48 semanas de duración",Spain - AEMPS,Completed,Fundació Clínic per a la Recerca Biomèdica,Non-Commercial,Spain,NA,2011-09-15
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS",Germany - BfArM,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,Astellas Pharma Europe B.V.,2011-03-21
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS",Czech Republic - SUKL,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,Astellas Pharma Europe B.V.,2011-03-22
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS",Lithuania - SMCA,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,Astellas Pharma Europe B.V.,2011-03-23
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS",Latvia - SAM,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,Astellas Pharma Europe B.V.,2011-03-23
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS",Poland - Office for Medicinal Products,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,Astellas Pharma Europe B.V.,2011-04-26
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, en grupos paralelos, con un diseño adaptativo combinando prueba de concepto y búsqueda de dosis para evaluar la eficacia, seguridad, farmacodinámica y farmacocinética de ASP3652 en el tratamiento de la prostatitis crónica/síndrome de dolor pélvico crónico",Spain - AEMPS,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,NA,2011-06-13
2010-023775-25,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS",UK - MHRA,Completed,Astellas Pharma Europe B.V.,Commercial,Netherlands,Astellas Pharma Europe B.V.,2012-10-19
2007-003099-20,"A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine. - CLL2O Protocol of the German CLL Study Group (GCLLSG) -",Germany - PEI,Ongoing,Universitätsklinikum Ulm,Non-Commercial,Germany,NA,2007-08-23
2007-003099-20,"A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine. - CLL2O Protocol of the German CLL Study Group (GCLLSG) -",France - ANSM,Ongoing,Universitätsklinikum Ulm,Non-Commercial,Germany,NA,2007-12-17
2007-003099-20,"A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine. - CLL2O Protocol of the German CLL Study Group (GCLLSG) -",Austria - BASG,Ongoing,Universitätsklinikum Ulm,Non-Commercial,Germany,NA,2008-04-09
2010-023022-20,"A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy",Germany - BfArM,Prematurely Ended,Universitätsklinikum Ulm,Non-Commercial,Germany,GlaxoSmithKline GmbH & Co KG,2011-04-26
2010-023022-20,"A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy",Austria - BASG,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,GlaxoSmithKline GmbH & Co KG,2012-06-01
2011-003473-29,Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea,Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,University of Cologne,2012-07-11
2010-024094-39,"Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten.",Germany - BfArM,Completed,"University of Ulm, University Hospital Ulm",Non-Commercial,Germany,NA,2011-06-10
2011-000902-24,"An open-label, single arm, phase II trial to investigate the safety and efficacy of Sym004 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have failed anti-EGFR monoclonal antibody-based therapy",Belgium - FPS Health-DGM,Completed,Symphogen A/S,Commercial,Denmark,Symphogen A/S,2011-04-26
2011-000902-24,"An open-label, single arm, phase II trial to investigate the safety and efficacy of Sym004 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have failed anti-EGFR monoclonal antibody-based therapy",Germany - PEI,Completed,Symphogen A/S,Commercial,Denmark,Symphogen A/S,2011-05-13
2010-022413-26,Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study),Germany - BfArM,Prematurely Ended,University Medical Center Hamburg-Eppendorf,Non-Commercial,Germany,University Medical Center Hamburg-Eppendorf,2011-04-20
2009-012587-14,SEGURIDAD Y EFICACIA DEL ACETATO DE ESLICARBAZEPINA (ESL) COMO TERAPIA ADYUVANTE PARA CRISIS PARCIALES EN PACIENTES MAYORES/ SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,Spain - AEMPS,Completed,"BIAL - Portela & Ca, S.A.",Commercial,Portugal,NA,2009-10-23
2009-012587-14,SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,Czech Republic - SUKL,Completed,"BIAL - Portela & Ca, S.A.",Commercial,Portugal,"BIAL - Portela & Ca, S.A.",2009-11-12
2009-012587-14,SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,Austria - BASG,Completed,"BIAL - Portela & Ca, S.A.",Commercial,Portugal,"BIAL - Portela & Ca, S.A.",2009-12-14
2009-012587-14,SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,Portugal - INFARMED,Completed,"BIAL - Portela & Ca, S.A.",Commercial,Portugal,"BIAL - Portela & Ca, S.A.",2009-12-30
2009-012587-14,SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,Germany - BfArM,Completed,"BIAL - Portela & Ca, S.A.",Commercial,Portugal,"BIAL - Portela & Ca, S.A.",2010-02-12
2009-012587-14,SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,Bulgarian Drug Agency,Completed,"BIAL - Portela & Ca, S.A.",Commercial,Portugal,"BIAL - Portela & Ca, S.A.",2011-01-17
2011-000553-23,A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer,Germany - BfArM,Completed,German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP),Non-Commercial,Germany,GBG Forschungs GmbH,2011-05-03
2011-003006-25,"The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Hungary - National Institute of Pharmacy,Completed,Shire Development Inc.,Commercial,United States,Shire Development Inc.,2011-11-22
2011-003006-25,"The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Poland - Office for Medicinal Products,Completed,Shire Development Inc.,Commercial,United States,Shire Development Inc.,2011-11-22
2011-003006-25,"The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Czech Republic - SUKL,Completed,Shire Development LLC.,Commercial,United States,Shire Development Inc.,2011-11-24
2011-003006-25,"The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Belgium - FPS Health-DGM,Completed,Shire Development LLC,Commercial,United States,Shire Development Inc,2012-07-10
2011-003006-25,"The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Estonia - SAM,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2012-07-17
2011-003006-25,"The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Finland - Fimea,Completed,Shire Development Inc,Commercial,United States,Shire Development Inc,2012-10-26
2011-003006-25,"Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.",Italy - Italian Medicines Agency,Prematurely Ended,SHIRE PHARMACEUTICALS LTD,Commercial,United Kingdom,Shire Development Inc.,2013-01-15
2011-004304-38,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,Germany - BfArM,Prematurely Ended,PARI Pharma GmbH,Commercial,Germany,PARI Pharma GmbH,2011-11-28
2011-004304-38,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,UK - MHRA,Prematurely Ended,PARI Pharma GmbH,Commercial,Germany,PARI Pharma GmbH,2011-12-09
2011-004304-38,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,Belgium - FPS Health-DGM,Prematurely Ended,PARI Pharma GmbH,Commercial,Germany,PARI Pharma GmbH,2011-12-15
2011-004304-38,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,Denmark - DHMA,Completed,PARI Pharma GmbH,Commercial,Germany,PARI Pharma GmbH,2011-12-19
2011-004304-38,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,Austria - BASG,Prematurely Ended,PARI Pharma GmbH,Commercial,Germany,PARI Pharma GmbH,2011-12-20
2011-004304-38,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,Spain - AEMPS,Prematurely Ended,PARI Pharma GmbH,Commercial,Germany,PARI Pharma GmbH,2012-06-22
2010-022054-16,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carcinoma (LEIDA 2),Germany - BfArM,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,MEDA Pharma GmbH & Co. KG,2011-05-26
2010-022054-16,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carcinoma (LEIDA 2),Austria - BASG,Completed,MEDA Pharma GmbH & Co. KG,Commercial,Germany,MEDA Pharma GmbH & Co. KG,2011-06-06
2011-002257-61,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)",Germany - PEI,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2011-08-01
2011-002257-61,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)",UK - MHRA,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2011-08-24
2011-002257-61,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)",Spain - AEMPS,Completed,Micromet AG,Commercial,Germany,Micromet AG,2011-10-03
2011-002257-61,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)",Italy - Italian Medicines Agency,Completed,MICROMET AG,Commercial,Germany,MICROMET AG,2012-03-01
2011-000475-14,"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults",Germany - PEI,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,Novartis Vaccines and Diagnostics S.r.l,2011-06-08
2011-000475-14,"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults",Czech Republic - SUKL,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,Novartis Vaccines and Diagnostics S.r.l,2011-10-04
2010-021775-80,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,Germany - PEI,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-09-14
2010-024264-18,"A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",Germany - PEI,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2011-08-01
2010-024264-18,"A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",Austria - BASG,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2011-08-16
2010-024264-18,"A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",Netherlands - Competent Authority,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2012-01-10
2010-024264-18,"A Single-Arm Multicenter Phase II Study preceded by Dose Evalua-tion to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",Italy - Italian Medicines Agency,Completed,MICROMET GMBH,Commercial,Germany,Micromet GmbH,2012-03-12
2010-024264-18,"A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",UK - MHRA,Completed,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2013-07-08
2010-024264-18,"A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",NA,NA,Amgen Research (Munich) GmbH,Commercial,Germany,Amgen Research (Munich) GmbH,2014-10-28
2011-001507-13,"Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable adenocarcinoma of the gastroesophageal junction or stomach (HerFLOT)",Germany - PEI,Completed,AIO-Studien-gGmbH,Non-Commercial,Germany,AIO-Studien-gGmbH,2011-07-05
2011-004388-62,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation With or Without Heartburn.",Poland - Office for Medicinal Products,Completed,Shire-Movetis NV,Commercial,Switzerland,Shire-Movetis NV,2012-04-03
2011-004388-62,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation With or Without Heartburn.",Hungary - National Institute of Pharmacy,Completed,Shire-Movetis NV,Commercial,Belgium,Shire-Movetis NV,2012-04-11
2011-004388-62,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation With or Without Heartburn.",Germany - BfArM,Completed,Shire-Movetis NV,Commercial,Belgium,Shire-Movetis NV,2012-04-16
2011-004388-62,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation With or Without Heartburn.",Belgium - FPS Health-DGM,Completed,Shire-Movetis NV,Commercial,Belgium,Shire-Movetis NV,2012-04-17
2011-004388-62,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation With or Without Heartburn.",Latvia - SAM,Completed,Shire-Movetis NV,Commercial,Switzerland,Shire-Movetis NV,2012-04-23
2011-004388-62,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) with Persistent Regurgitation With or Without Heartburn.",Czech Republic - SUKL,Completed,Shire-Movetis NV,Commercial,Belgium,Shire-Movetis NV,2012-05-24
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",Belgium - FPS Health-DGM,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-11-17
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",Germany - BfArM,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-11-18
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",Spain - AEMPS,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-11-22
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",Austria - BASG,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-11-29
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",Portugal - INFARMED,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-11-29
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",UK - MHRA,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2012-01-30
2011-004483-30,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV-1 Infected Patients.",Italy - Italian Medicines Agency,Completed,GILEAD SCIENCE INC.,Commercial,United States,Gilead Sciences Inc,2012-03-02
2011-004963-56,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients",UK - MHRA,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-11-21
2011-004963-56,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients",Germany - BfArM,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-12-16
2011-004963-56,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients",Belgium - FPS Health-DGM,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2011-12-16
2011-004963-56,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients",Austria - BASG,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2012-02-08
2011-004963-56,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients",Spain - AEMPS,Completed,"Gilead Sciences, Inc.",Commercial,United States,"Gilead Sciences, Inc.",2012-02-17
2011-004963-56,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Eviltegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients.",Italy - Italian Medicines Agency,Completed,GILEAD SCIENCE INC.,Commercial,United States,Gilead Sciences Inc.,2012-03-02
2010-024379-15,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2011-07-20
2010-024111-13,Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy,Germany - PEI,Completed,AIO-Studien-gGmbH,Non-Commercial,Germany,Fresenius Biotech GmbH,2011-02-01
2010-023384-18,"Randomized, double-blind, phase I/II clinical study to investigate the safety and immunogenicity of a multivalent recombinant OspA Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects aged 18 to 70 years.",Germany - PEI,Completed,Baxter Innovations GmbH,Commercial,Austria,Baxter Innovations GmbH,2010-12-08
2010-023384-18,"Randomized, double-blind, phase I/II clinical study to investigate the safety and immunogenicity of a multivalent recombinant OspA Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects aged 18 to 70 years.",Austria - BASG,Completed,Baxter Innovations GmbH,Commercial,Austria,Baxter Innovations GmbH,2010-12-14
2009-011898-33,Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study,Germany - BfArM,Completed,Martin-Luther-Universität Halle-Wittenberg,Non-Commercial,Germany,Merck KGaA Darmstadt,2011-06-10
2011-001138-40,First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma,Germany - BfArM,Completed,iOMEDICO AG,Non-Commercial,Germany,Novartis AG,2011-09-08
2011-002947-83,Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.,Germany - PEI,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2012-11-14
2011-002947-83,Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.,Belgium - FPS Health-DGM,Completed,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2012-11-19
2011-002947-83,Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.,Spain - AEMPS,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2013-03-21
2011-002947-83,Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.,UK - MHRA,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2013-08-08
2011-002947-83,Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.,Italy - Italian Medicines Agency,Prematurely Ended,European Organisation for Research and Treatment of Cancer,Non-Commercial,Belgium,European Organisation for Research and Treatment of Cancer,2013-08-19
2010-023237-37,A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer,Germany - BfArM,Prematurely Ended,GBG Forschungs GmbH (German Breast Group),Non-Commercial,Germany,NA,2011-10-05
2010-021719-18,Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,Genzyme Europe BV,2011-10-05
2011-005180-24,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia",UK - MHRA,Completed,"Gilead Sciences, Inc.",Commercial,United States,Gilead Sciences Inc.,2012-03-12
2011-005180-24,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia",Germany - BfArM,Completed,"Gilead Sciences, Inc.",Commercial,United States,Gilead Sciences Inc.,2012-10-15
2006-002516-10,"A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures.",Germany - BfArM,Prematurely Ended,Eisai Ltd,Commercial,United Kingdom,NA,2008-07-09
2006-002516-10,"A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures.",Netherlands - Competent Authority,Prematurely Ended,Eisai Ltd,Commercial,United Kingdom,NA,2008-07-11
2006-002516-10,"A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures.",Hungary - National Institute of Pharmacy,Completed,Eisai Ltd,Commercial,United Kingdom,NA,2008-07-21
2006-002516-10,"A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures.",Belgium - FPS Health-DGM,Completed,Eisai Ltd,Commercial,United Kingdom,NA,2008-08-06
2006-002516-10,"A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures.",UK - MHRA,Prematurely Ended,Eisai Ltd,Commercial,United Kingdom,NA,2008-10-13
2006-002516-10,"A randomised, double blind, placebo-controlled study to evaluate the safety and tolerability and to explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures",Italy - Italian Medicines Agency,Prematurely Ended,EISAI LTD UK,Commercial,United Kingdom,NA,2009-04-22
2009-017485-23,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",Belgium - FPS Health-DGM,Completed,EORTC,Non-Commercial,Belgium,Roche,2013-01-15
2009-017485-23,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",France - ANSM,Completed,EORTC,Non-Commercial,Belgium,Roche,2013-04-22
2009-017485-23,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",UK - MHRA,Completed,EORTC,Non-Commercial,Belgium,Roche,2013-06-05
2009-017485-23,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",Germany - PEI,Completed,EORTC,Non-Commercial,Belgium,Roche,2013-06-13
2009-017485-23,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",Greece - EOF,Completed,EORTC,Non-Commercial,Belgium,Roche,2013-07-15
2009-017485-23,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",Austria - BASG,Completed,EORTC,Non-Commercial,Belgium,Roche,2013-09-12
2011-002472-16,"Open, prospective, diagnostic, multicentre study in healthy subjects, patients with urea cycle disorders (UCD), and carriers of UCD mutations, to evaluate in vivo ureagenesis measured after a single application of Sodium [1,2-13C]-Acetate",Germany - BfArM,Completed,Cytonet GmbH & Co KG,Commercial,Germany,NA,2011-08-22
2007-000479-40,Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology,Germany - BfArM,Ongoing,"Department of Psychiatry, RWTH Aachen",Non-Commercial,Germany,NA,2009-02-26
2010-019748-38,Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®,Germany - PEI,Completed,University of Heidelberg,Non-Commercial,Germany,NA,2010-09-29
2009-012957-39,"A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia",Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,NA,2010-08-10
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment.",Spain - AEMPS,Completed,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-01-11
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine hydrochloride (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment.",Hungary - National Institute of Pharmacy,Prematurely Ended,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-01-23
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter, International Study to investigate the safety and efficacy of ST261 (Propionyl-L-Carnitine Hydrochloride) modified release tablets in Patients Affected by mild Ulcerative Colitis under Oral Stable Treatment",Latvia - SAM,Prematurely Ended,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-01-24
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment.",Germany - BfArM,Completed,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-02-09
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter, International Study to investigate the safety and efficacy of ST261 (Propionyl-L-Carnitine Hydrochloride) modified release tablets in Patients Affected by mild Ulcerative Colitis under Oral Stable Treatment",Lithuania - SMCA,Prematurely Ended,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-02-15
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment.",Austria - BASG,Prematurely Ended,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-02-15
2011-004770-28,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter, International Study to investigate the safety and efficacy of ST261 (Propionyl-L-Carnitine Hydrochloride) modified release tablets in Patients Affected by mild Ulcerative Colitis under Oral Stable Treatment",Poland - Office for Medicinal Products,Prematurely Ended,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Commercial,Italy,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,2012-02-16
2011-000756-42,"A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.",Germany - BfArM,Prematurely Ended,Dompé s.p.a.,Commercial,Italy,Dompé s.p.a.,2011-06-08
2011-000756-42,"A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.",Italy - Italian Medicines Agency,Prematurely Ended,DOMPE' s.p.a.,Commercial,Italy,Dompe' spa,2012-03-20
2011-002192-41,"Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with fludarabine and treosulfan",Germany - BfArM,Completed,University Hospital Tübingen,Non-Commercial,Germany,Medac GmbH,2011-12-27
2011-003412-23,EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.,France - ANSM,Completed,Pierre Fabre Médicament - IRPF,Commercial,France,Pierre Fabre Medicament,2011-11-24
2011-003412-23,EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.,Czech Republic - SUKL,Completed,Pierre Fabre Médicament - IRPF,Commercial,France,Pierre Fabre Medicament,2011-12-09
2011-003412-23,EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.,Spain - AEMPS,Completed,Pierre Fabre Médicament - IRPF,Commercial,France,Pierre Fabre Medicament,2011-12-23
2011-003412-23,EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.,Germany - BfArM,Completed,Pierre Fabre Médicament - IRPF,Commercial,France,Pierre Fabre Medicament,2011-12-29
2011-003412-23,EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.,Hungary - National Institute of Pharmacy,Completed,Pierre Fabre Médicament - IRPF,Commercial,France,Pierre Fabre Medicament,2012-06-29
2011-005018-13,"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp",UK - MHRA,Completed,LEO Pharma A/S,Commercial,Denmark,LEO Pharma A/S,2012-04-03
2011-005018-13,"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp",Germany - BfArM,Completed,LEO Pharma A/S,Commercial,Denmark,LEO Pharma A/S,2012-04-19
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",Sweden - MPA,Prematurely Ended,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-04-19
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",Ireland - HPRA,Prematurely Ended,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-06-07
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",Spain - AEMPS,Prematurely Ended,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-06-11
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",Belgium - FPS Health-DGM,Prematurely Ended,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-06-14
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",Netherlands - Competent Authority,Prematurely Ended,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-06-14
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",UK - MHRA,Prematurely Ended,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-06-18
2011-006119-70,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",Germany - BfArM,Completed,Biogen Idec Research Limited,Commercial,United Kingdom,Biogen Idec Research Limited,2012-06-20
2012-000416-28,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma",Germany - PEI,Completed,LETI Pharma GmbH,Commercial,Germany,LETI Pharma GmbH,2012-04-02
2012-000416-28,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma",Spain - AEMPS,Completed,LETI Pharma GmbH,Commercial,Germany,LETI Pharma GmbH,2012-04-17
2012-000416-28,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma",Czech Republic - SUKL,Completed,LETI Pharma GmbH,Commercial,Germany,LETI Pharma GmbH,2012-05-15
2012-000416-28,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma",Poland - Office for Medicinal Products,Completed,LETI Pharma GmbH,Commercial,Germany,LETI Pharma GmbH,2012-05-28
2010-023426-20,"Low dose Urokinase therapy in patients with diabetic foot syndrome, critical limb ischemia as well as rest ischemia or missing of option revascularisation in comparison to the standard therapy - randomized, open, controlled phase III",Germany - BfArM,Prematurely Ended,GWT-TUD GmbH,Non-Commercial,Germany,medac GmbH,2010-12-03
2010-022467-36,A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy,Germany - BfArM,Completed,Freistaat Bayern,Non-Commercial,Germany,Klinikum der Universität Regensburg,2011-06-22
2011-006271-18,"A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Fluvirin®), Flirmulation 2012/2013, when Administered to Adult and Elderly Subjects.",Germany - PEI,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Italy,Novartis Vaccines and Diagnostics S.r.l.,2012-04-24
2012-000632-26,Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3,UK - MHRA,Completed,The Medicines Company,Commercial,Switzerland,The Medicines Company,2012-05-10
2012-000632-26,Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3,Germany - BfArM,Completed,The Medicines Company,Commercial,Switzerland,The Medicines Company,2012-06-04
2012-000632-26,Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3,Netherlands - Competent Authority,Completed,The Medicines Company,Commercial,Switzerland,The Medicines Company,2012-06-21
2012-000632-26,Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3),Italy - Italian Medicines Agency,Completed,THE MEDICINES COMPANY UK,Commercial,United Kingdom,The Medicines Company,2012-10-16
2011-004301-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,Germany - BfArM,Completed,"Free State of Bavaria, represented by the University of Regensburg, represented by Prof. Edward K. Geissler",Non-Commercial,Germany,European Commission,2011-12-07
2011-004301-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,France - ANSM,Completed,"Free State of Bavaria, represented by the University of Regensburg, represented by the University Hospital Regensburg",Non-Commercial,Germany,European Commission,2013-04-19
2011-004301-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,Italy - Italian Medicines Agency,Completed,"Free State of Bavaria, represented by the University of Regensburg, represented by Prof. Edward K. Gessler",Non-Commercial,Germany,European Commission,2013-08-14
2011-004301-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial,Germany - PEI,Prematurely Ended,University Hospital Regensburg,Non-Commercial,Germany,European Commission,2013-06-06
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Germany - BfArM,Completed,Birken AG,Commercial,Germany,Birken AG,2012-04-11
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Czech Republic - SUKL,Completed,Birken AG,Commercial,Germany,Birken AG,2012-06-06
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Finland - Fimea,Completed,Birken AG,Commercial,Germany,Birken AG,2012-06-26
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Austria - BASG,Completed,Birken AG,Commercial,Germany,Birken AG,2013-03-26
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Bulgarian Drug Agency,Completed,Birken AG,Commercial,Germany,Birken AG,2013-04-16
2012-000777-23,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites",Poland - Office for Medicinal Products,Completed,Birken AG,Commercial,Germany,Birken AG,2013-04-30
2010-022938-85,Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer,Germany - BfArM,Completed,AIO-Studien-gGmbH,Non-Commercial,Germany,NA,2011-04-28
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Estonia - SAM,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-07-10
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Austria - BASG,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-07-31
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Netherlands - Competent Authority,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-08-01
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Germany - BfArM,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-08-03
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",UK - MHRA,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-08-03
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Sweden - MPA,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-08-08
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Spain - AEMPS,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-08-23
2012-001942-16,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection.",Poland - Office for Medicinal Products,Completed,Gilead Sciences Inc.,Commercial,United States,Gilead Sciences Inc.,2012-09-20
2011-004405-25,Study for prevention of peritoneal carcinomatosis in patients with stomach cancer,Germany - BfArM,Prematurely Ended,University Hospital Tübingen,Non-Commercial,Germany,University Hospital Tübingen,2012-01-06
2012-000295-42,"A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).",Belgium - FPS Health-DGM,Completed,GENFIT,Commercial,France,GENFIT,2012-08-16
2012-000295-42,"A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH)",Germany - BfArM,Completed,GENFIT,Commercial,France,GENFIT,2012-09-05
2012-000295-42,"A Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH). A Multicentre, Randomized, Double Blind, Placebo-Controlled study, with an adaptive design to allow for initial GFT505 80mg dosing versus placebo, followed by a second phase including GFT505 120mg dose, after review of 6-month safety analysis of the 80mg data on at least 50% of patients.",Spain - AEMPS,Completed,GENFIT,Commercial,France,GENFIT,2012-09-07
2012-000295-42,"A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).",UK - MHRA,Completed,GENFIT,Commercial,France,GENFIT,2012-09-19
2012-000295-42,"A Multicentre, Randomized, Double Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).",Netherlands - Competent Authority,Completed,GENFIT,Commercial,France,GENFIT,2012-10-03
2012-000295-42,"A Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH). A Multicentre, Randomized, Double Blind, Placebo-Controlled study, with an adaptive design to allow for initial GFT505 80mg dosing versus placebo, followed by a second phase including GFT505 120mg dose, after review of 6-month safety analysis of the 80mg data on at least 50% of patients.",Italy - Italian Medicines Agency,Completed,GENFIT SA,Commercial,France,GENFIT,2012-10-11
2009-018077-31,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,Austria - BASG,Ongoing,St. Anna Kinderkrebsforschung/CCRI,Non-Commercial,Austria,FWF-KLIF,2010-09-24
2009-018077-31,ESTUDIO EN FASE I/II DE BÚSQUEDA DE DOSIS DE CH14.18/CHO EN INFUSIÓN CONTÍNUA COMBINADO CON ALDESLEUKINA (IL-2) SUBCUTÁNEA EN PACIENTES CON NEUROBLASTOMA PRIMARIO REFRACTARIO O EN RECAÍDA,Spain - AEMPS,Ongoing,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE DE VALENCIA,Non-Commercial,Spain,NA,2011-02-03
2009-018077-31,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,Germany - PEI,Ongoing,Universitätsmedizin Greifswald,Non-Commercial,Germany,Apeiron Biologics AG,2011-09-19
2009-018077-31,A PHASE I/II DOSE SCHEDULE FINDING STUDY OF CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA A SIOPEN Study,Italy - Italian Medicines Agency,Ongoing,St. Anna Kinderkrebsforchung Children's Cancer Research Institute,Non-Commercial,Austria,St. Anna Kinderkrebsforchung Children's Cancer,2012-03-20
2009-018077-31,A phase I/II dose schedule finding study of ch14.18/CHO continuous infusion combined with subcutaneous Aldesleukin (IL-2) in patients with primary refractory or relapsed Neuroblastoma,UK - MHRA,GB - no longer in EU/EEA,St. Anna Kinderkrebsforschung,Non-Commercial,Austria,CRUK (CTAAC),2012-05-10
2009-018077-31,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,Ireland - HPRA,Ongoing,St. Anna Kinderkrebsforschung/CCRI,Non-Commercial,Austria,FWF-KLIF,2012-10-11
2009-018077-31,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,Poland - Office for Medicinal Products,Completed,Jagiellonian University Medical College,Non-Commercial,Poland,Jagiellonian University Medical College in Krakow,2016-01-20
2009-018077-31,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,Belgium - FPS Health-DGM,Ongoing,St. Anna Kinderkrebsforschung/CCRI,Non-Commercial,Austria,University Hospital Ghent,2016-05-19
2012-002359-40,"NEUPRO OL, Efficacy profile of Neurexan® in an experimental acute stress setting – an explorative open-label study in healthy probands",Germany - BfArM,Completed,Biologische Heilmittel Heel GmbH,Commercial,Germany,Biologische Heilmittel Heel GmbH,2012-06-15
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Sweden - MPA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-03-13
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Czech Republic - SUKL,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-03-15
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Finland - Fimea,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-03
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Austria - BASG,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-11
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Slovakia - SIDC (Slovak),Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-12
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Spain - AEMPS,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-12
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Belgium - FPS Health-DGM,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-13
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Slovenia - JAZMP,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-17
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",UK - MHRA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-18
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Germany - BfArM,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-19
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Greece - EOF,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-04-30
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Portugal - INFARMED,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-06-12
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, non-inferiority efficacy and tolerability study.",Italy - Italian Medicines Agency,Completed,ASTELLAS PHARMA,Commercial,Italy,Astellas Pharma Europe Ltd,2012-08-03
2011-005872-41,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",Bulgarian Drug Agency,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-08-21
2010-022854-18,OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL),Germany - BfArM,Prematurely Ended,"Dekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator",Non-Commercial,Germany,Bristol-Myers Squibb GmbH & CoKGaA (BMS),2011-01-25
2011-005939-78,"A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study)",Germany - BfArM,Prematurely Ended,CESAR Central European Society for Anticancer Drug Research-EWIV,Non-Commercial,Austria,Roche Pharma AG,2012-03-01
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis.",Sweden - MPA,Completed,Stallergenes S.A.,Commercial,France,Stallergenes,2010-08-16
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Germany - PEI,Completed,Stallergenes S.A.,Commercial,France,Stallergene,2010-08-16
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Slovakia - SIDC (Slovak),Completed,Stallergenes SA,Commercial,France,NA,2010-08-17
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Latvia - SAM,Completed,Stallergenes S.A.,Commercial,France,NA,2010-08-26
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Finland - Fimea,Completed,Stallergenes S.A.,Commercial,France,Stallergene,2010-08-26
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Czech Republic - SUKL,Completed,Stallergenes S.A.,Commercial,France,Stallergenes,2010-09-10
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Estonia - SAM,Completed,Stallergenes S.A.,Commercial,France,Stallergenes,2010-09-15
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Lithuania - SMCA,Completed,Stallergenes S.A.,Commercial,France,Stallergene,2010-09-17
2010-020693-42,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis",Denmark - DHMA,Completed,Stallergenes S.A.,Commercial,France,Stallergenes,2010-09-21
2011-001963-37,Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC),Germany - BfArM,Completed,Universitätsklinikum Essen,Non-Commercial,Germany,Lilly Deutschland GmbH,2012-06-01
2012-003570-77,"Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild allergic asthma – A randomised, double-blind, parallel, multicentre, phase-IIa study –",Germany - BfArM,Completed,sterna biologicals GmbH & Co. KG,Commercial,Germany,sterna biologicals GmbH & Co. KG Biomedizinisches Forschungszentrum (BMFZ),2012-09-13
2012-001815-21,"A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa",Spain - AEMPS,Prematurely Ended,"Shire Regenerative Medicine, Inc.",Commercial,United States,"Shire Regenerative Medicine, Inc.",2012-09-26
2012-001815-21,"A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa",Germany - PEI,Prematurely Ended,"Shire Regenerative Medicine, Inc.",Commercial,United States,"Shire Regenerative Medicine, Inc.",2012-11-01
2012-001815-21,"A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa",Austria - BASG,Completed,"Shire Regenerative Medicine, Inc.",Commercial,United States,"Shire Regenerative Medicine, Inc.",2013-01-25
2012-001815-21,"A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa",Portugal - INFARMED,Prematurely Ended,"Shire Regenerative Medicine, Inc.",Commercial,United States,"Shire Regenerative Medicine, Inc.",2013-03-28
2012-002529-30,"Three-armed, randomized, double-blind dose-finding trial on efficiency and safety of Ibuprofen 5% gel, Ibuprofen 7,5% gel und Ibuprofen 10% gel in patients with actinic keratosis Olsen grade I/II",Germany - BfArM,Completed,Dolorgiet GmbH & Co. KG,Commercial,Germany,Dolorgiet GmbH & Co. KG,2012-09-04
2011-005296-16,Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial),Germany - PEI,Prematurely Ended,University Medical Center Hamburg-Eppendorf,Non-Commercial,Germany,Roche Pharma AG,2012-06-21
2011-004777-89,Efficacy and safety of Euminz® (10% ethanolic solution of peppermint oil for topical use) compared to placebo in patients with episodic tension-type headache (ETTH),Germany - BfArM,Completed,Cassella-med GmbH & Co. KG,Commercial,Germany,Cassella-med GmbH & Co.KG,2011-12-05
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Sweden - MPA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-07-09
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Denmark - DHMA,Prematurely Ended,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-07-18
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Austria - BASG,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-07-18
2012-000531-88,"A phase IIIb/IV randomized, controlled, double-blind, double- dummy, parallel group study to compare the efficacy of fidaxomicin to vancomycin in the sustained clinical cure of Clostridium difficile Infection in adults receiving immunosuppressive therapy.",Italy - Italian Medicines Agency,Prematurely Ended,ASTELLAS PHARMA,Commercial,Italy,ASTELLAS PHARMA EUROPE LTD.,2012-07-25
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Finland - Fimea,Prematurely Ended,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-07-25
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",UK - MHRA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-07-26
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Germany - BfArM,Prematurely Ended,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-08-09
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Hungary - National Institute of Pharmacy,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-08-27
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Greece - EOF,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-09-20
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Belgium - FPS Health-DGM,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2012-12-19
2012-000531-88,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy.",Spain - AEMPS,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,Astellas Pharma Europe Ltd.,2013-01-23
2012-003954-95,"Prospective, randomized, double-blind, placebo-controlled, clinical trial to explore the anti-pruritic effect, the safety and local tolerability of a topical Sertaconazol cream 2% in patients with atopic dermatitis.",Germany - BfArM,Completed,Spirig Pharma AG,Commercial,Switzerland,Spirig Pharma AG,2012-10-04
2012-001947-31,Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial,Germany - PEI,Prematurely Ended,Technische Universität Dresen,Non-Commercial,Germany,GlaxoSmithKline GmbH & Co KG,2012-07-17
2012-002278-30,Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.,Germany - BfArM,Completed,University Hospital Erlangen,Non-Commercial,Germany,Boehringer Ingelheim International GmbH,2012-06-14
2012-001134-33,"Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure",Germany - BfArM,Prematurely Ended,Universitätsklinikum Ulm,Non-Commercial,Germany,Vifor Pharma,2012-08-28
2012-003217-33,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,HEYL Chem.-pharm. Fabrik GmbH & Co. KG,2012-08-13
2012-003286-18,A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU),Hungary - National Institute of Pharmacy,Prematurely Ended,Smith & Nephew Inc.,Commercial,United States,Smith & Nephew Inc.,2013-06-07
2012-003286-18,A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU),Poland - Office for Medicinal Products,Prematurely Ended,Smith & Nephew Inc.,Commercial,United States,Smith & Nephew Inc.,2013-07-22
2012-003286-18,A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU),Germany - PEI,Prematurely Ended,Smith & Nephew Inc.,Commercial,United States,Smith & Nephew Inc.,2013-09-16
2012-003286-18,A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU),Belgium - FPS Health-DGM,Completed,Smith & Nephew Inc.,Commercial,United States,Smith & Nephew Inc.,2013-09-17
2012-003286-18,A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU),Czech Republic - SUKL,Prematurely Ended,Smith & Nephew Inc.,Commercial,United States,Smith & Nephew Inc.,2013-09-26
2011-004482-32,"Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)",Germany - BfArM,Completed,Universitätsklinikum Ulm,Non-Commercial,Germany,TEVA,2012-12-21
2013-000621-30,"A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell Culture (Optaflu®) in Healthy Adults",Germany - PEI,Completed,Novartis Vaccines and Diagnostics GmbH,Commercial,Netherlands,Novartis Vaccines and Diagnostics Srl,2013-03-19
2012-002699-14,"A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years",UK - MHRA,Completed,Pharmaxis Ltd.,Commercial,Australia,NA,2012-07-03
2012-002699-14,"A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years",France - ANSM,Completed,Pharmaxis Ltd.,Commercial,Australia,Pharmaxis Ltd.,2012-09-20
2012-002699-14,"A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years",Belgium - FPS Health-DGM,Completed,Pharmaxis Ltd.,Commercial,Australia,Pharmaxis Ltd.,2013-02-15
2012-002699-14,"A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years",Netherlands - Competent Authority,Completed,Pharmaxis Ltd.,Commercial,Australia,Pharmaxis Ltd.,2013-10-02
2012-002699-14,"A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years",Italy - Italian Medicines Agency,Completed,Pharmaxis Ltd.,Commercial,Australia,Pharmaxis Ltd.,2014-02-20
2012-005686-12,Patient-reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea,UK - MHRA,Completed,Galderma R&D,Commercial,France,Galderma R&D,2013-04-05
2012-005686-12,Patient-Reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea,Sweden - MPA,Completed,Galderma R&D,Commercial,France,Galderma R&D,2013-04-10
2012-005686-12,Patient-Reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea,Germany - BfArM,Completed,Galderma R&D,Commercial,France,Galderma R&D,2013-04-11
2013-000601-23,"A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin®) in Healthy Adults",Germany - PEI,Completed,Novartis Vaccines and Diagnostics S.r.l.,Commercial,Netherlands,Novartis Vaccines and Diagnostics S.r.l.,2013-03-19
2012-003858-81,Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus,Germany - BfArM,Prematurely Ended,"RWTH Aachen, Medizinische Fakultät",Non-Commercial,Germany,"University Hospital Aachen, Department of Internal Medicine I",2013-04-22
2011-006041-14,"A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation",Poland - Office for Medicinal Products,Completed,MerLion Pharmaceuticals GmbH,Commercial,Germany,MerLion Pharmaceuticals GmbH,2012-07-17
2013-001113-32,"A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the Post-anesthesia Care Unit / Intensive Care Unit",Germany - BfArM,Completed,PAION UK Limited,Commercial,United Kingdom,PAION UK Limited,2013-04-26
2012-005439-10,Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion,Germany - PEI,Completed,"University of Leipzig Ritterstr. 26, 04109 Leipzig",Non-Commercial,Germany,Novartis,2013-07-23
2013-001632-21,"A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis",Lithuania - SMCA,Completed,Maruho Europe Limited,Commercial,United Kingdom,Maruho Europe Limited,2013-07-17
2013-001632-21,"A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis",Hungary - National Institute of Pharmacy,Completed,Maruho Europe Limited,Commercial,United Kingdom,Maruho Europe Limited,2013-07-17
2013-001632-21,"A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis",Poland - Office for Medicinal Products,Completed,Maruho Europe Limited,Commercial,United Kingdom,Maruho Europe Limited,2013-08-07
2013-001632-21,"A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis",Bulgarian Drug Agency,Completed,Maruho Europe Limited,Commercial,United Kingdom,Maruho Europe Limited,2013-09-25
2013-001632-21,"A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis",Austria - BASG,Completed,Maruho Europe Limited,Commercial,United Kingdom,Maruho Europe Limited,2013-11-18
2013-000068-27,A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease.,Netherlands - Competent Authority,Completed,Xenikos BV,Commercial,Netherlands,Xenikos,2013-11-20
2013-000068-27,A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease.,Germany - PEI,Completed,Xenikos BV,Commercial,Netherlands,Xenikos,2013-11-25
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Norway - NOMA,Ongoing,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2013-09-09
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Spain - AEMPS,Ongoing,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2013-09-16
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Italy - Italian Medicines Agency,Prematurely Ended,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2014-04-18
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Belgium - FPS Health-DGM,Prematurely Ended,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2014-04-22
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Germany - PEI,Prematurely Ended,Fundacio Clinic per a la Recerca Biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2014-04-25
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Austria - BASG,Prematurely Ended,"Medical University of Graz, Department of Internal Medicine, Division of Gastroenterology and Hepatology",Non-Commercial,Austria,"Medical University of Graz, Department of Internal Medicine, Division of Gastroenterology and Hepatology",2014-07-14
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Denmark - DHMA,Prematurely Ended,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2014-07-22
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Ireland - HPRA,Prematurely Ended,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2014-07-25
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",UK - MHRA,Prematurely Ended,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2014-07-30
2013-002416-27,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.",Netherlands - Competent Authority,Ongoing,Fundacio Clinic per a la recerca biomedica,Non-Commercial,Spain,Fundacio Clinic per a la recerca biomedica,2015-10-27
2013-000931-28,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma",Italy - Italian Medicines Agency,Completed,Glycotope GmbH,Commercial,Germany,Glycotope GmbH,2013-04-08
2013-000931-28,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma",Germany - PEI,Prematurely Ended,Glycotope GmbH,Commercial,Germany,Glycotope GmbH,2013-04-17
2013-000931-28,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma",Hungary - National Institute of Pharmacy,Prematurely Ended,Glycotope GmbH,Commercial,Germany,Glycotope GmbH,2013-05-02
2013-000931-28,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX TM After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma",Spain - AEMPS,Completed,Glycotope GmbH,Commercial,Germany,Glycotope GmbH,2013-05-16
2013-000931-28,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma",UK - MHRA,Prematurely Ended,Glycotope GmbH,Commercial,Germany,Glycotope GmbH,2013-06-28
2013-000931-28,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma",Poland - Office for Medicinal Products,Prematurely Ended,Glycotope GmbH,Commercial,Germany,Glycotope GmbH,2013-09-19
2013-002755-15,A first-in-human dose escalation and dose finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer,Belgium - FPS Health-DGM,Completed,Ganymed Pharmaceuticals AG,Commercial,Germany,Ganymed Pharmaceuticals AG,2013-11-27
2012-003882-17,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",Germany - BfArM,Completed,Charité Universitaetsmedizin Berlin,Non-Commercial,Germany,Volkswagen Foundation,2013-04-08
2012-003859-12,Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus,Germany - BfArM,Prematurely Ended,"RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A)",Non-Commercial,Germany,"University Hospital Aachen , Internal Medicine I",2013-04-22
2008-008474-31,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,Germany - BfArM,Completed,Charité Berlin,Non-Commercial,Germany,NA,2009-06-26
2005-005714-20,"A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN",Finland - Fimea,Completed,Astellas Pharma Europe Ltd,Commercial,United Kingdom,NA,2006-04-06
2005-005714-20,"A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN",Hungary - National Institute of Pharmacy,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-06-06
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Germany - BfArM,Completed,Astellas Pharma Europe Limited,Commercial,United Kingdom,NA,2006-06-07
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Ireland - HPRA,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-06-09
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Spain - AEMPS,Completed,Astellas Pharma GmbH,Non-Commercial,Germany,NA,2006-07-31
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",France - ANSM,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-08-22
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Czech Republic - SUKL,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-12-01
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",UK - MHRA,Completed,Astellas Pharma Europe Ltd,Commercial,United Kingdom,NA,2007-07-31
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Germany - BfArM,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-06-07
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Netherlands - Competent Authority,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-06-28
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",Spain - AEMPS,Completed,Astellas Pharma GmbH,Commercial,Germany,NA,2006-08-07
2005-005714-20,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN",UK - MHRA,Completed,Astellas Pharma Europe Ltd,Commercial,United Kingdom,NA,2006-09-20
2013-004489-32,An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer,Germany - PEI,Prematurely Ended,CureVac AG,Commercial,Germany,CureVac AG,2013-12-05
2013-004604-19,Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheumatoid arthritis (RA) patients,Germany - PEI,Prematurely Ended,Heinrich-Heine-Universität Düsseldorf,Non-Commercial,Germany,AbbVie Deutschland GmbH&Co.KG,2014-06-03
2014-000477-39,Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML),Germany - BfArM,Prematurely Ended,University Hospital Ulm,Non-Commercial,Germany,Boehringer Ingelheim,2015-11-17
2013-000522-58,"A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia",Germany - BfArM,Prematurely Ended,Klinikum der Universität München,Non-Commercial,Germany,GlaxoSmithKline GmbH & Co. KG,2014-06-18
2014-002442-45,Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,Germany - BfArM,Completed,Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)],Non-Commercial,Germany,Bristol-Myers Squibb,2014-09-11
2014-002442-45,Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,Belgium - FPS Health-DGM,Completed,The Kompetenznetz Vorhofflimmern e.V. [German Atrial Fibrillation Competence Network association (AFNET e.V.)],Non-Commercial,Germany,Bristol-Myers Squibb,2014-10-28
2014-002442-45,Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,Denmark - DHMA,Completed,Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)],Non-Commercial,Germany,Brystol-Myers Sqibb,2014-11-10
2014-002442-45,AXAFA - AFNET 5 Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,UK - MHRA,Completed,Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)],Non-Commercial,Germany,Bristol-Myers Squibb,2015-02-18
2014-002442-45,Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,Netherlands - Competent Authority,Completed,Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)],Non-Commercial,Germany,Brystol-Myers Sqibb,2015-03-05
2014-002442-45,Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,Spain - AEMPS,Completed,The Kompetenznetz Vorhofflimmern e.V. [German Atrial Fibrillation Competence Network association (AFNET e.V.)],Non-Commercial,Germany,Bristol-Myers Squibb,2015-06-15
2014-002442-45,Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,Austria - BASG,Completed,Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork],Non-Commercial,Germany,Bristol-Myers Squibb,2016-02-24
2012-004240-30,"Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-specific peptide-stimulated T-cells (CD3+) for the prevention or treatment of reactivation of 'CMV and/or EBV in patients after allogeneic HLA-identical stem cell transplantation",Germany - PEI,Prematurely Ended,Universitätsklinikum Erlangen,Non-Commercial,Germany,"Bayerisches Staatsministerium für Bildung und Kultus, Wissenschaft und Kunst",2013-12-02
2013-001037-40,"A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29",Germany - PEI,Completed,InflaRx GmbH,Commercial,Germany,InflaRx GmbH,2013-08-13
2009-015936-14,PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,Austria - BASG,Completed,"University Children´s Hospital Tübingen,",Non-Commercial,Germany,Universitätsklinikum Tübingen,2010-02-02
2009-015936-14,PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,Germany - PEI,Completed,"University Children´s Hospital Tübingen,",Non-Commercial,Germany,University of Tuebingen,2010-02-04
2014-000816-32,"A Phase 3b, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps™ (Raplixa™) and Tachosil® in Surgical Hemostasis during Hepatic Resection",Germany - PEI,Completed,"ProFibrix, A wholly owned subsidary of the Medicines Company",Commercial,Netherlands,"ProFibrix, A wholly owned subsidary of the Medicines Company",2014-05-14
2014-000816-32,"A Phase 3b, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps™ (Raplixa™) and Tachosil® in Surgical Hemostasis during Hepatic Resection",Austria - BASG,Completed,"ProFibrix, A wholly owned subsidary of the Medicines Company",Commercial,Netherlands,"ProFibrix, A wholly owned subsidary of the Medicines Company",2014-06-11
2013-000338-37,"Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial",Germany - BfArM,Completed,"Technische Universität München, vertreten durch das Klinikum rechts der Isar",Non-Commercial,Germany,Deutsche Forschungsgemeinschaft (DFG),2014-09-23
2013-001081-42,Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,Gilead Sciences Europe Ltd,2014-07-29
2013-004616-21,"A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod)",Germany - BfArM,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,Novartis Pharma GmbH,2014-02-04
2014-002363-15,"EVITA Trial: Effect of VItamin D as add-on Therapy for vitamin D insufficient patients with severe Asthma: a randomized, double-blind, placebo-controlled trial.",Germany - BfArM,Prematurely Ended,University Medical Center of the Johannes Gutenberg University Mainz,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung (BMBF),2014-11-04
2014-005306-37,"A randomized, double-blind, multiple dosing (14 days), placebo-controlled, incomplete block crossover, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild to moderate asthma",Germany - BfArM,Completed,AstraZeneca AB,Commercial,,AstraZeneca AB,2015-03-25
2014-005306-37,"A randomized, double-blind, multiple dosing (14 days), placebo-controlled, incomplete block crossover, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild to moderate asthma",Bulgarian Drug Agency,Completed,AstraZeneca AB,Commercial,,AstraZeneca AB,2015-04-22
2015-001868-19,"A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study",Germany - PEI,Prematurely Ended,University medical center of Johannes Gutenberg University Mainz,Non-Commercial,Germany,GlaxoSmithKline,2015-07-06
2014-001983-36,"Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patients with EGFR mutated, metastatic non-small-cell lung cancer progressing after treatment with afatinib as first EGFR-targeting agent.",Germany - BfArM,Prematurely Ended,AIO-Studien-gGmbH,Non-Commercial,Germany,Boehringer Ingelheim,2015-03-02
2015-003036-12,"A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing complex cardiac surgery (CARDIAC)",Germany - PEI,Completed,InflaRx GmbH,Commercial,Germany,InflaRx GmbH,2015-10-16
2016-003962-24,"A multi-centre, randomized, placebo-controlled, double-blind, parallel-group study investigating safety and efficacy of a sore throat lozenge in the symptomatic treatment of patients with acute pharyngitis.",Germany - BfArM,Completed,Medice Arzneimittel Pütter GmbH & Co. KG,Commercial,Germany,Medice Arzneimittel Pütter GmbH & Co. KG,2016-11-15
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",France - ANSM,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-02-04
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Germany - BfArM,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-02-12
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Czech Republic - SUKL,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-02-18
2007-005376-13,"Estudio clínico multicéntrico, aleatorizado y abierto, con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))",Spain - AEMPS,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-02-19
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Hungary - National Institute of Pharmacy,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-04
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Ireland - HPRA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-07
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",UK - MHRA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-07
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Sweden - MPA,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-13
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Netherlands - Competent Authority,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-19
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Austria - BASG,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-25
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Greece - EOF,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-03-28
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Slovakia - SIDC (Slovak),Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-04-09
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Portugal - INFARMED,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-05-05
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))",Belgium - FPS Health-DGM,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-05-06
2007-005376-13,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF-/ ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf (FK506E (MR4))",Italy - Italian Medicines Agency,Completed,Astellas Pharma Europe Ltd.,Commercial,United Kingdom,NA,2008-06-18
2006-007021-32,"Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen",Germany - BfArM,Completed,Novartis Pharma GmbH,Commercial,Germany,NA,2007-04-17
2008-001833-87,"Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malign lymphoma, phase IV study",Germany - BfArM,Prematurely Ended,University Medical Center Freiburg,Non-Commercial,Germany,NA,2008-05-26
2009-009871-36,Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy,Germany - BfArM,Completed,Friedrich- Alexander- Universität Erlangen Nürnberg,Non-Commercial,Germany,Universitätsklinikum Erlangen,2009-08-06
2010-020403-75,ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial,Germany - BfArM,Completed,Universität Leipzig,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2011-06-16
2008-003064-19,"Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma",Germany - BfArM,Completed,Universität Leipzig,Non-Commercial,Germany,Sanofi-Aventis,2008-10-23
2009-013956-62,"Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.",Germany - BfArM,Prematurely Ended,University Medical Center of the University Ulm,Non-Commercial,Germany,NA,2010-03-25
2010-018892-20,Pathophysiologie der Cheyne-Stokes Atmung: Senkung des pulmonalkapillären Wedge-Drucks als kausaler Therapieansatz,Germany - BfArM,Completed,Herz- & Diabeteszentrum NRW,Non-Commercial,Germany,NA,2010-03-26
2010-019715-38,"Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla Creme, Polidocanolhaltige Creme)",Germany - BfArM,Completed,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,Non-Commercial,Germany,NA,2010-06-01
2009-017347-33,A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy,Germany - BfArM,Prematurely Ended,University of Leipzig,Non-Commercial,Germany,NA,2010-06-09
2008-007645-31,Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie - PRIMAIN-Studie -,Germany - BfArM,Completed,University Medical Center Freiburg,Non-Commercial,Germany,NA,2009-03-16
2009-015749-22,"A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds",Germany - PEI,Completed,University of Leipzig,Non-Commercial,Germany,Abott Germany,2010-09-20
2009-016907-41,"Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",Germany - BfArM,Completed,"Charité, Universitätsmedizin Berlin",Non-Commercial,Germany,Deutsche Forschungsgemeinschaft,2012-08-13
2010-022057-42,Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors,Germany - BfArM,Completed,Universität Leipzig,Non-Commercial,Germany,Deutsche Forschungsgemeinschaft,2011-02-25
2008-000782-35,"Dose-escalating study to determine the maximum tolerated dose (MTD) of the mistletoe extract WEME 200 mg for intravesical instillation in patients with completely resected (R0) superficial bladder carcinoma (pTa low grade [multilocular or recurrence], pT1 low grade)",Germany - BfArM,Prematurely Ended,Verein fuer Krebsfoschung (Society for Cancer Research),Commercial,Switzerland,NA,2009-01-27
2008-008555-41,Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA),Germany - BfArM,Prematurely Ended,Universitätsklinikum Essen,Non-Commercial,Germany,"BMBF, Fördernummer 01G10817",2010-08-10
2009-017261-32,Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma,Germany - BfArM,Completed,Martin-Luther-Universität Halle-Wittenberg,Non-Commercial,Germany,GlaxoSmithKline GmbH & Co.KG,2011-05-16
2011-000152-42,An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females,Germany - BfArM,Completed,"Medical Faculty, University Magdeburg",,Germany,NA,2011-06-20
2010-021782-70,"Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation, intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolarised helium-3 gas; a comparison with pulmonary function tests und H-MRI (long-term observation)",Germany - BfArM,Prematurely Ended,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,Non-Commercial,Germany,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,2010-11-25
2010-022864-12,Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab therapy of patients with chronic urticaria (OTTO-Study),Germany - PEI,Completed,"Medical Faculty, Otto-von-Guericke-University Magdeburg",Non-Commercial,Germany,NA,2011-02-24
2011-001819-30,Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy (Hypericin PDD),Germany - BfArM,Completed,Sanochemia Pharmazeutika AG,Commercial,Austria,Sanochemia Pharmazeutika AG,2011-07-18
2011-001819-30,Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy (Hypericin PDD),Austria - BASG,Completed,Sanochemia Pharmazeutika AG,Commercial,Austria,Sanochemia Pharmazeutika AG,2011-07-22
2011-005628-16,FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients,Germany - BfArM,Completed,University of Cologne,Non-Commercial,Germany,Leibniz-Preis DFG-Projektnummer BR1492/7-1,2012-05-08
2011-000624-16,Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome Male infertility with infection and inflammation -MIBIE-,Germany - BfArM,Prematurely Ended,Justus Liebig Universität Gießen,Non-Commercial,Germany,Justus Liebig Universität Gießen,2011-09-05
2010-023414-31,Ketamine in treatment resistant major depression (TRD),Germany - BfArM,Completed,Medizinische Fakultät. Otto von Guericke Universität,,Germany,DFG,2012-03-08
2011-001765-41,"Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines",Germany - BfArM,Prematurely Ended,Medizinische Fakultät der Otto-von-Guericke Universität Magdeburg Universitätsklinikum Magdeburg A.ö.R.,Non-Commercial,Germany,Boehringer Ingelheim Pharma GmbH & Co. KG,2011-10-25
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",UK - MHRA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-02-23
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",Sweden - MPA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-03-08
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",Germany - BfArM,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-03-10
2005-000454-73,"A multicenter, randomized, double-blind, placebo-controlled, 3-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk myelodyplastic syndromes (MDS) associated with a deletion (del) 5q[31] cytogenetic abnormality.",Spain - AEMPS,Completed,Celgene Europe Limited,Commercial,United Kingdom,NA,2005-09-08
2005-000454-73,"A multicenter, randomized, double-blind, placebo-controlled, 3-arm study of the efficacy and safety of 2 doses of Lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion (DEL) 5q[31] cytogenetic abnormality",Italy - Italian Medicines Agency,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-10-24
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",Belgium - FPS Health-DGM,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2006-02-20
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",UK - MHRA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-02-23
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",Sweden - MPA,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-03-08
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",Germany - BfArM,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-03-10
2005-000454-73,"A multicenter, randomized, double-blind, placebo-controlled, 3-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk myelodyplastic syndromes (MDS) associated with a deletion (del) 5q[31] cytogenetic abnormality.",Spain - AEMPS,Completed,Celgene Europe Limited,Commercial,United Kingdom,NA,2005-09-08
2005-000454-73,"A multicenter, randomized, double-blind, placebo-controlled, 3-arm study of the efficacy and safety of 2 doses of Lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion (DEL) 5q[31] cytogenetic abnormality",Italy - Italian Medicines Agency,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2005-10-24
2005-000454-73,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY",Belgium - FPS Health-DGM,Completed,Celgene Corporation,Commercial,United States,Celgene Corporation,2006-02-20
2006-005970-26,"A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer",Germany - BfArM,Prematurely Ended,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2007-01-11
2006-005970-26,"A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer",Germany - BfArM,Prematurely Ended,Universitätsklinikum Münster,Non-Commercial,Germany,NA,2007-01-11
2005-001347-37,Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreated AML: a randomized phase III trial (AML- 17) of the EORTC-LG and the GIMEMA-ALWP.,Italy - Italian Medicines Agency,Completed,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,Non-Commercial,Italy,NA,2006-08-31
2011-004361-32,Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid,Germany - BfArM,Prematurely Ended,Philipps-Universität Marburg,Non-Commercial,Germany,Universitätsklinikum Marburg-Klinik für Dermatologie,2012-05-22
2007-004528-19,Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®,Germany - BfArM,Ongoing,University of Wuerzburg,Non-Commercial,Germany,NA,2007-11-19
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Germany - PEI,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-03-01
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Slovakia - SIDC (Slovak),Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-04-03
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",UK - MHRA,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-05-15
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Austria - BASG,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-05-24
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Hungary - National Institute of Pharmacy,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-06-20
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.",Spain - AEMPS,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-08-24
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Bulgarian Drug Agency,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-02-12
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Germany - PEI,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-03-01
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Slovakia - SIDC (Slovak),Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-04-03
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",UK - MHRA,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-05-15
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Austria - BASG,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-05-24
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Hungary - National Institute of Pharmacy,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-06-20
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.",Spain - AEMPS,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2007-08-24
2006-006370-25,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease",Bulgarian Drug Agency,Completed,immatics biotechnologies GmbH,Commercial,Germany,NA,2008-02-12
2005-002716-16,A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS,Italy - Italian Medicines Agency,Completed,PHILOGEN S.P.A.,Non-Commercial,Italy,NA,2006-02-07
2005-002716-16,A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS,Italy - Italian Medicines Agency,Completed,PHILOGEN S.P.A.,Non-Commercial,Italy,NA,2006-02-07
2004-001307-35,"A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered subcutaneously to subfertile female patients undergoing IVF using antagonist downregulation.",UK - MHRA,Completed,Ferring Arzneimittel GmbH,Commercial,Germany,NA,2005-09-22
2004-001307-35,"A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered subcutaneously to subfertile female patients undergoing IVF using antagonist downregulation.",UK - MHRA,Completed,Ferring Arzneimittel GmbH,Commercial,Germany,NA,2005-09-22
2012-003281-40,"Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy: a randomized, placebo controlled cross over study",Germany - BfArM,Ongoing,Universitätsklinikum Freiburg,Non-Commercial,Germany,None (no funding),2012-08-27
2011-006250-90,"Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).",Germany - BfArM,Ongoing,EANM Forschungs GmbH / EANM Research Ltd.,Non-Commercial,Austria,EANM Forschungs GmbH / EANM Research Ltd.,2012-03-16
2011-006250-90,"Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).",Austria - BASG,Prematurely Ended,EANM Forschungs GmbH / EANM Research Ltd.,Non-Commercial,Austria,EANM Forschungs GmbH / EANM Research Ltd.,2012-04-10
2007-000579-40,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-10-02
2013-001599-40,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,DFG (BMBF),2013-11-14
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Karl und Veronika Carstens Stiftung Essen,2011-12-09
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Karl und Veronika Carstens Stiftung Essen,2011-12-09
2009-013702-14,"Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",Germany - BfArM,Completed,Hospital of the University of Munich,Non-Commercial,Germany,Deutsches Zentrum für Luft- und Raumfahrt (DLR),2010-05-05
2009-013702-14,"Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",Germany - BfArM,Completed,Hospital of the University of Munich,Non-Commercial,Germany,Deutsches Zentrum für Luft- und Raumfahrt (DLR),2010-05-05
2013-000107-17,Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM),Germany - BfArM,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Bundesministerium für Bildung und Forschung (BMBF),2013-04-05
2013-000107-17,Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM),Germany - BfArM,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Bundesministerium für Bildung und Forschung (BMBF),2013-04-05
2012-005312-26,Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder,Germany - BfArM,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Biogen Idec GmbH,2013-01-11
2012-005312-26,Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder,Germany - BfArM,Completed,"Hospital of the University of Munich, Grosshadern",Non-Commercial,Germany,Biogen Idec GmbH,2013-01-11
2012-004585-18,"Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. Randomized, controlled study to compare the analgesic therapy with tapentadol compared to pure opioid receptor agonists",Germany - BfArM,Completed,Philipps-Universität Marburg,Non-Commercial,Germany,Grünenthal,2012-12-07
2012-004442-15,"High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety",Germany - BfArM,Completed,University Leipzig,Non-Commercial,Germany,Janssen Pharmaceutica NV,2013-09-17
2012-004442-15,"High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety",Germany - BfArM,Completed,University Leipzig,Non-Commercial,Germany,Janssen Pharmaceutica NV,2013-09-17
2013-001601-85,"Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial",Germany - BfArM,Completed,University Hospital Münster,Non-Commercial,Germany,Federal Ministry of Education and Research (BMBF),2013-11-14
2014-001148-40,Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting,Germany - BfArM,Ongoing,Heart Center Freiburg - Bad Krozingen,Non-Commercial,Germany,"Heart Center Freiburg - Bad Krozingen, Department of Cardiology and Angiology II",2014-04-23
2013-004353-24,Wound Management in Post-Bariatric Surgery Investigation for the reduction of the mean drainage volume in patients after abdominoplasty / lower body lift using Artiss Fibrin Sealant in comparison to the standard procedure,Germany - PEI,Prematurely Ended,Universität Leipzig,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2014-01-23
2013-004353-24,Wound Management in Post-Bariatric Surgery Investigation for the reduction of the mean drainage volume in patients after abdominoplasty / lower body lift using Artiss Fibrin Sealant in comparison to the standard procedure,Germany - PEI,Prematurely Ended,Universität Leipzig,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2014-01-23
2013-001081-42,Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,Germany - BfArM,Completed,Hannover Medical School,Non-Commercial,Germany,Gilead Sciences Europe Ltd,2014-07-29
2014-003022-40,Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin,Germany - PEI,Completed,Universitätsklinikum Münster,Non-Commercial,Germany,Janssen-Cilag GmbH,2014-10-30
2015-002365-34,"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS",Latvia - SAM,Completed,Polichem S.A.,Commercial,Switzerland,Polichem S.A.,2015-08-11
2015-002365-34,"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS",Germany - BfArM,Completed,Polichem S.A.,Commercial,Switzerland,Polichem S.A.,2015-08-18
2015-002365-34,"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS",Czech Republic - SUKL,Completed,Polichem S.A.,Commercial,Switzerland,Polichem S.A.,2015-09-11
2015-002365-34,"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS",Poland - Office for Medicinal Products,Completed,Polichem S.A.,Commercial,Switzerland,Polichem S.A.,2015-10-14
2015-002365-34,"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS",Bulgarian Drug Agency,Completed,Polichem S.A.,Commercial,Switzerland,Polichem S.A.,2015-11-17
2015-002365-34,"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS",Greece - EOF,Completed,Polichem S.A.,Commercial,Switzerland,Polichem S.A.,2015-12-07
2015-000460-34,"Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)",Germany - BfArM,Completed,Hospital of the University of Munich,Non-Commercial,Germany,Bundesministerium fuer Forschung und Bildung (BMBF),2015-10-12
2015-000460-34,"Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)",Austria - BASG,Completed,Hospital of the University of Munich,Non-Commercial,Germany,Bundesministerium fuer Forschung und Bildung (BMBF),2015-11-11
2015-005071-25,Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting,Germany - BfArM,Ongoing,University Heart Center Freiburg - Bad Krozingen,Non-Commercial,Germany,"University Heart Center Freiburg - Bad Krozingen, Department of Cardiology and Angiology II",2015-11-27
2012-001582-33,Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease,Germany - BfArM,Completed,University Hospital Erlangen,Non-Commercial,Germany,University of Erlangen; Bayer Healthcare,2012-07-03
2012-001583-29,"Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a non contrast arterial spin labeling perfusion MRI (ASL-MRP) in subjects with minor cognitive impairment or minor Alzheimer's disease compared to age matched mentally healthy subjects",Germany - BfArM,Completed,University Hospital Erlangen,Non-Commercial,Germany,"University of Erlangen, Bayer Healthcare",2012-07-12
